

ISBN 978-82-4714888-4 (printed version) ISBN 978-82-471-4889-1 (electronic version) ISSN 1503-8181

**NTNU – Trondheim** Norwegian University of Science and Technology



**NTNU – Trondheim** Norwegian University of Science and Technology

Bjarne Martens Nes

# Peak oxygen uptake and habitual exercise as a basis for primary prevention

Thesis for the degree of Philosophiae Doctor

Trondheim, December 2013

Norwegian University of Science and Technology Faculty of Medicine Department of Circulation and Medical Imaging



NTNU – Trondheim Norwegian University of Science and Technology



# NTNU

Norwegian University of Science and Technology

Thesis for the degree of Philosophiae Doctor

Faculty of Medicine Department of Circulation and Medical Imaging

© Bjarne Martens Nes

ISBN 978-82-4714888-4 (printed version) ISBN 978-82-471-4889-1 (electronic version) ISSN 1503-8181

Doctoral theses at NTNU, 2013:368



Printed by Skipnes Kommunikasjon as

#### SAMANDRAG

Maksimalt oksygenopptak (VO<sub>2peak</sub>) er rekna som ein av dei viktigaste prognostiske markørane for framtidig hjarte-/karsjukdom og tidleg død. Ettersom direkte måling av VO<sub>2peak</sub> er tidkrevjande og kostbart har implementeringa i førebyggjande helsearbeid og klinisk praksis vore begrensa. Både VO<sub>2peak</sub> og ei rekkje andre sentrale helseparameter, kan betrast ved ei viss mengd fysisk aktivitet i kvardagen, og dagens globale anbefalingar er at alle vaksne bør utføre minst 150 minutt med moderat intensitet eller minst 75 minutt med høg intensitet per veke. Utforminga av anbefalingane inneber at det totale energiforbruket, og dermed helsegevinstane, kan oppnås ved ulike tilnærmingar der kortare varigheit kan kompenserast med høgare intensitet og vice versa. I dette prosjektet nytta me data på direkte målt VO<sub>2peak</sub> frå 4631 deltakarar i den siste Helseundersøkelsen i Nord-Trøndelag (HUNT 3, 2006-08) til først å utvikle ein prediksjonsmodell for å kunne estimere VO<sub>2peak</sub> og vidare undersøke om denne modellen kunne predikere framtidig hjerte-/kardødeligheit og død uansett årsak i ein stor befolkning. Me såg vidare på korleis ulike tilnærmingar til dagens anbefalingar for fysisk aktivitet var assosiert med direkte målt VO<sub>2peak</sub> i utvalet frå HUNT. Hovedfunna i avhandlinga er at VO<sub>2peak</sub> kan estimerast relativt nøyaktig ved ein regresjonsmodell med lett tilgjengelige variablar som alder, kroppssamansetning, fysisk aktivitetsnivå og kvilepuls og at modellen kan nyttast til å kategorisere personar med låg eller høg direkte målt VO<sub>2peak</sub>. Denne modellen vart nytta til å estimere VO<sub>2peak</sub> i eit stort utval friske deltakarar frå HUNT 1 (1984-86) som vart fulgt fram til registrert dødsdato eller slutten av 2010. For kvar 3,5 mL·kg<sup>-1</sup>·min<sup>-1</sup> høgare estimert VO<sub>2peak</sub> var risikoen for død av hjarte-/karsjukdom 21 % lågare for personar av begge kjønn som var under 60 år ved undersøkelsen, medan risikoen uansett dødsårsak var henholdsvis 15 % og 8 % lågare for menn og kvinner. Vidare viser me at grupper som rapporterer fysisk aktivitetsvanar i tråd med dagens anbefalingar, anten ved moderat relativ intensitet over lengre tid eller høg intensitet over kortare tid, i gjennomsnitt hadde tilfredsstillande høg og tilnærma lik VO<sub>2peak</sub>. Samtidig viser me at eit relativt begrensa antal personar som rapporterte ein tidsbruk under minimum anbefaling, men med svært høg relativ intensitet, også hadde tilsvarande høg VO<sub>2peak</sub>. Også når tidsbruken eller det samla energiforbruket var konstant fann me at dei som rapporterte høg intensitet hadde høgare VO2peak enn dei som rapporterte låg eller moderate intensitet.

#### Bjarne M. Nes

K.G. Jebsen Senter for hjertetrening Institutt for sirkulasjon og bildediagnostikk, Det medisinske fakultet, NTNU Hovedveileder: Professor Ulrik Wisløff. Bi-veileder: Forskar Imre Janszky Hovedfinansiering: Nasjonalforeningen for folkehelsen

#### SUMMARY

Directly measured peak oxygen uptake (VO<sub>2peak</sub>) is established as an important prognostic marker of cardiovascular disease and premature mortality, but is rarely evaluated for prevention purposes or in primary care settings due to costly and time-consuming procedures. Both VO<sub>2peak</sub> and several other health parameters can, however, be improved and maintained by regular exercise, and today's recommendations suggest that all adults should do at least 150 minutes of moderate intensity or 75 minutes or vigorous intensity exercise per week. Hence, the total recommended volume or energy expenditure may be reached by strictly different approaches. In the current thesis, data on directly measured VO<sub>2peak</sub> in 4631 individuals from the third wave of the Nord-Trøndelag Health Study (HUNT 3, 2006-08), were used to first derive a simple prediction model for VO<sub>2peak</sub> that potentially could supplement direct measurements in healthcare settings and for research purposes. Next, the clinical utility of this model was examined by its ability to predict all-cause and cardiovascular mortality in a large sample of healthy men and women from the HUNT 1 (1984-86) cohort. Furthermore, we examined how different combinations of intensity and total time spent at habitual exercise were associated with VO<sub>2peak</sub> in apparently healthy, community dwelling individuals from HUNT 3. The findings in this thesis indicate that VO<sub>2peak</sub> can be predicted with reasonable accuracy by using easily available clinical and selfreported variables such as age, body composition, self-reported physical activity and resting heart rate, and that the model can be used to correctly classify subjects in the correct tail of the VO<sub>2peak</sub> distribution. For each metabolic equivalent (i.e. MET, ~3.5 mL·kg<sup>-1</sup>·min<sup>-1</sup>) higher CRF, the risk of CVD mortality was 21% lower in both men and women who were below 60 years at baseline, while the corresponding risk of all-cause mortality was 15% and 8% lower in men and women, respectively, for each MET higher CRF. Furthermore, we demonstrate that habitual exercise patterns of moderate intensity for a long total duration or vigorous intensity for a relatively short duration, adding up to the total volume as recommended by the health authorities, both were associated with a beneficial VO<sub>2peak</sub> –level. However, a higher VO<sub>2peak</sub> was observed among those reporting vigorous intensity compared to low and moderate intensity for a similar time spent, and energy expenditure used during exercise.

> Bjarne M. Nes K.G. Jebsen Center for Exercise in Medicine Department of Circulation and Medical Imaging, Faculty of Medicine, NTNU Supervisor: Professor Ulrik Wisløff. Co-supervisor: Researcher Imre Janszky Funding source: Norwegian Council on Cardiovascular Disease

# ACKNOWLEDGEMENTS

The present PhD project was carried out during the years 2009-2013 at the Department of Circulation and Medical Imaging, Faculty of Medicine, Norwegian University of Science and Technology (NTNU). The work was financed by grants from the Norwegian Council on Cardiovascular Disease.

First and foremost I will express my gratitude to my main supervisor Professor Ulrik Wisløff. You opened the door into the scientific world for me as a fresh master student, and have literally kept it open since then. Your never-ending optimism and enthusiasm, along with creative ideas and wide scientific knowledge, have provided me the self-confidence to do independent research. A huge thank you also to co-supervisor Professor Imre Janszky, your expertise in epidemiology and statistics are beyond remarkable and your thoughtful comments on study design and interpretation have been invaluable. The collaboration with you and Professor Lars Vatten has been of utmost importance for our research group in general and me in particular. I also want to thank Javaid Nauman and Stian Aspenes for fruitful discussions and your important contributions to the studies.

All other colleagues and friends in the Cardiac Exercise Research Group; the working environment you are making, both scientifically and socially, is simply outstanding!

Finally, I want to thank my parents for your encouragement and support throughout these years and life itself.

Bjarne M. Nes, Trondheim, 2013

# LIST OF PAPERS

The thesis is based on the following original papers and is referred to by their roman numbers throughout the text.

# Paper I

Nes, BM, Janszky, I, Vatten, LJ, Nilsen, TIL, Aspenes, ST & Wisløff, U. (2011) Estimating VO<sub>2peak</sub> from a nonexercise prediction model: The HUNT Study, Norway. *Medicine & Science in Sports & Exercise*. **43**(11):2024-2030

# Paper II

Nes, BM, Janszky, I, Bertheussen, GF, Aspenes, ST, Vatten, LJ, & Wisløff, U. (2012) Exercise patterns and peak oxygen uptake in a healthy population: The HUNT Study. *Medicine & Science in Sports & Exercise*. **44**(10):1881-1889

# Paper III

Nes, BM, Vatten, LJ, Nauman, J, Janszky, I & Wisløff, U. (2013) Estimated cardiorespiratory fitness as a predictor of long-term all-cause and cardiovascular disease mortality: The HUNT Study in Norway. *Medicine & Science in Sports & Exercise. Accepted for publication.* 

# ABBREVIATIONS

ACLS	Aerobics Center Longitudinal Study
ACSM	American College of Sports Medicine
BMI	Body mass index
CI	Confidence interval
CRF	Cardiorespiratory fitness
GLM	General linear model
HUNT	Nord-Trøndelag Health Study
MET	Metabolic equivalent
PA	Physical activity
$R^2$	Coefficient of determination (variance explained)
RHR	Resting heart rate
SD	Standard deviation
SEE	Standard error of the estimate
VO <sub>2max</sub>	Maximal oxygen uptake
VO <sub>2peak</sub>	Peak oxygen uptake
WC	Waist circumference
WHO	World Health Organization

# DEFINITIONS

# **Cardiorespiratory fitness:**

The ability to perform large-muscle dynamic moderate-to-high intensity exercise for prolonged periods<sup>1</sup>.

# **Exercise:**

Physical activity that is planned, structured and repetitive and has as a final or intermediate objective the improvement or maintenance of physical fitness<sup>2,3</sup>.

# Maximal/peak oxygen uptake (VO<sub>2max/peak</sub>):

The highest rate at which oxygen can be taken up and utilized by the body during strenuous, dynamic exercise with a large muscle mass<sup>4</sup>.

# Metabolic equivalent (MET):

METs is the ratio of the rate of energy expended during an activity to the rate of energy expended at rest<sup>2</sup>. 1 MET is the rate of energy expenditure while sitting at rest and is, by convention, defined as  $3.5 \text{ mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1.5}$ .

# Non-exercise model:

A multiple regression model derived to estimate the level of cardiorespiratory fitness without exercise testing

# **Physical activity:**

Any voluntary movement produced by skeletal muscles that result in energy expenditure above resting levels<sup>2,3</sup>.

# **Physical fitness:**

A set of attributes that people have or achieve that relates to the ability to perform physical activity<sup>3</sup>.

# TABLE OF CONTENTS

SAMANDRAG	I
SUMMARY	II
ACKNOWLEDGEMENTS	III
LIST OF PAPERS	IV
ABBREVIATIONS	V
DEFINITIONS	VI
TABLE OF CONTENTS	VII
BACKGROUND	1
Physical activity and cardiorespiratory fitness as separate risk factors	2
Maximal/peak oxygen uptake (VO <sub>2max/peak</sub> )	
Non-exercise models of peak oxygen uptake	4
Associations between physical activity and peak oxygen uptake (VO <sub>2peak</sub> )	5
Current physical activity recommendations for apparently healthy adults	6
AIMS AND HYPOTHESES	9
MATERIAL AND METHODS	
The Nord-Trøndelag Health Study (HUNT)	
The HUNT Fitness Study	
Clinical measurements	
Peak oxygen uptake (VO <sub>2peak</sub> ) measurements	
Self-reported information	
Other register data	14
Ethics	14
METHODOLOGICAL CONSIDERATIONS	
Selection bias	
Information bias	
Assessment of physical activity (PA)	
Confounding	
External validity (generalizability)	
Statistical analyses	
RESULTS AND DISCUSSION	
Non-exercise models of peak oxygen uptake (VO <sub>2peak</sub> )	
Cross-validity of the model	
Cross-classification	
Intensity and volume of physical activity in relation to health outcomes	

	Intensity and volume of exercise in relation to peak oxygen uptake (VO <sub>2peak</sub> )	37
	Practical application of the results	40
	Future research	41
	Conclusions	42
R	EFERENCES	43

# PAPERS

APPENDIX

## BACKGROUND

The past century represented a dramatic epidemiological transition in the burden of disease worldwide. While communicable diseases have been the leading cause of deaths for many decades, recent reports states that preventable, non-communicable diseases (i.e. cardiovascular disease, cancer, chronic pulmonary diseases and type 2 diabetes) now account for at least 60% of all deaths globally<sup>6</sup>. The majority of these diseases share a number of common modifiable risk factors, where the most prominent are unhealthy diet, high blood pressure, high cholesterol, tobacco smoking, obesity and physical inactivity<sup>7</sup>. The Global Burden of Disease Study conservatively estimated that lack of physical activity (PA) alone accounted for  $\sim 3.2$  million deaths worldwide in 2010<sup>7</sup>. In comparison  $\sim 5.7$  million deaths were attributed to smoking and  $\sim$ 1.4 million to child and maternal under-nutrition. Similarly important is that inactivity may be causally related to several other high ranked risk factors, and combined with an increasing prevalence worldwide, inactivity might now be regarded as one of the leading global health problems<sup>8,9</sup>. Additionally, a certain amount of regular PA is a prerequisite for maintaining or improving several aspects of physical fitness, and in particular cardiorespiratory fitness (CRF), which is suggested to be an even stronger predictor of morbidity and premature mortality than inactivity<sup>10,11</sup>.

Against this backdrop, the public health attention to PA levels has evolved rapidly over the last 20 years. Several national governments, as well as global organizations such as World Health Organization (WHO) and the United Nations, have placed increased PA higher on the agenda and launched strategies and action plans aiming to combat the growing burden of inactivity related disease<sup>12-16</sup>. Individual patient counseling in primary care, however, are commonly restricted to assessment of more traditional health indicators (commonly referred to as `vital signs`) such as pulse rate, blood pressure, respiratory rate and body temperature $^{17}$ . Established cardiovascular risk factors such as overweight, dyslipidemia, smoking and family history of disease have also gained recognition and are commonly evaluated collectively through so-called risk-score models such as the Framingham Risk Score, Q-Risk or the European Score prediction chart<sup>18-20</sup>. Physical inactivity, and in particular low CRF, has received less attention despite a growing body of evidence supporting its important prognostic utility<sup>21-25</sup>. However, through the *Exercise is Medicine*<sup>®</sup> initiative, the American College of Sports Medicine (ACSM) in partnership with the American Medical Association, now encourages that measurement of PA status should be included as a vital sign at every clinical visit. A large healthcare system, Kaiser Permanente in California (USA), comprising more

1

than 3.4 million residents and 4000 physicians, has served as a role model and pioneered the inclusion of the PA vital sign<sup>26</sup>. At every visit, for every patient, two questions on frequency and duration of moderate-to-vigorous PA are used to calculate minutes per week of exercise which is automatically recorded in the electronic medical journals.

An individuals` CRF, however, is not routinely examined in healthcare settings despite that CRF appears to be strongly associated with overall health status and future risk of chronic disease in both high-risk and apparently healthy persons<sup>24,27-29</sup>. Indeed, some studies suggest that the CRF level is a better predictor than traditional health parameters such as hypertension, smoking, overweight, dyslipidemia and type 2 diabetes<sup>24,30</sup>. Nevertheless, regular measurement of CRF is presently limited to prognostic evaluation in heart disease patients or as the cardinal performance measure in endurance athletes<sup>31,32</sup>.

# Physical activity and cardiorespiratory fitness as separate risk factors

Although closely related and often used interchangeably, PA and CRF have strictly different meanings. PA is a behavior which is commonly quantified by the total volume performed i.e. by multiplying the number of bouts or sessions (*frequency*), the time of participation of each single session (*duration*) and the physiological effort associated with the PA (*intensity*), respectively<sup>2</sup>. On the other hand, CRF is a physiological attribute related to the ability to do strenuous exercise and is highly dependent on the upper limit of the cardiovascular system to supply and extract oxygen<sup>3</sup>. Both PA and CRF are inversely related to cardiovascular disease, its risk factors, and premature cardiovascular and all-cause mortality<sup>33-37</sup>. Some studies report that PA and CRF are related to these health outcomes independent of each other and it has also been suggested that the health-promoting effect goes through different mechanisms<sup>38,39</sup>. A meta-analysis from 2001 proposed that PA and CRF certainly have different relationships to cardiovascular risk<sup>39</sup>. While a relatively linear risk reduction was observed across strata of self-reported PA, a considerably greater benefit was found in the lower end of the CRF spectrum (until approximately the 20<sup>th</sup> percentile). The finding that the greatest risk improvement is observed between the least fit and the next least fit groups are consistent among several large population based studies, although specific cut-off values associated with increased risk are vet to be established  $^{28,40,41}$ . Nevertheless, few studies have examined the combined effect of PA and CRF in order to elucidate what is more important for future health outcomes. Recently, Lee et al. examined the combined associations and relative contributions of PA and CRF with all-cause mortality in ~42,000 healthy men and women from the

Aerobics Center Longitudinal Study (ACLS) cohort<sup>10</sup>. They reported that men and women who did not meet the recommended level of PA, but were among the 40% most fit for their age group, had lowered risk of premature mortality. On the contrary, those who met the recommended level of PA, but were among the 20% with lowest CRF, did not have significantly lower relative risks compared to those who were both inactive and unfit. Similarly, Sassen et al. reported that the relation between PA and cardiovascular risk factors disappeared when the level of CRF was adjusted for, while adjustment for PA volume did not attenuate the relationship between CRF and cardiovascular risk<sup>42</sup>. Moreover, high intensity PA was the main characteristic of PA in determining the risk factor prevalence. Consequently, one may propose that a low level of CRF warrants consideration as a risk factor independent of overall PA level. Also, it may be speculated that the association between PA and health and longevity are largely mediated by CRF.

# Maximal/peak oxygen uptake (VO<sub>2max/peak</sub>)

Maximal oxygen uptake (VO<sub>2max</sub>) is recognized as the gold standard measurement of  $CRF^{32}$ . VO<sub>2max</sub> is defined as the highest rate of oxygen uptake obtained during strenuous, dynamical work involving large muscle groups<sup>3</sup>. The oxygen uptake  $(VO_2)$  is set by the Fick equation  $(VO_2 = heart rate \times cardiac stroke volume \times arteriovenous O_2-difference)$  and  $VO_{2max}$  is therefore equal to the maximal ability of the cardiopulmonary system to supply, and skeletal muscles and the heart muscle cells to extract, oxygen during dynamical muscle work. The measurement of VO<sub>2max</sub> is generally performed by ventilatory gas analysis during an incremental treadmill or bicycle protocol to exhaustion<sup>43</sup>. In principle, the term VO<sub>2max</sub> implies that a maximal physiologic limit is achieved and objective criteria are suggested to consolidate that the rate of oxygen transport are maximized<sup>44</sup>. The plateau criterion implies that no further increase in oxygen uptake is seen despite increase in workload. As a secondary criterion of VO<sub>2max</sub>, the respiratory exchange ratio (RER) should generally exceed a prespecified level, typically  $\geq 1.05 - 1.10$ , in order to certify that a near maximum effort is obtained. However, both the ability to reach a plateau, and the corresponding RER, vary considerably among individuals, despite maximal exercise, and in most clinical settings the term  $VO_{2peak}$  seems more appropriate<sup>44</sup>.

Lack of established reference values of  $VO_{2peak}$  and consensus on clinically relevant cut-off values that defines increased risk for different populations may have limited the implementation of CRF measurement in healthcare settings<sup>32</sup>. Other reasons may be that the

procedure for direct measurement is time-consuming, expensive, requires extra facilities, trained personnel and a high degree of motivation and effort from the individual with possible accompanying risks. Some of these constraints have been overcome by the development of exercise protocols that estimates  $VO_{2peak}$  from surrogate measures such as total treadmill time, heart rate at sub-maximal levels, perceived exertion or maximal watt production<sup>45-47</sup>. Although these protocols may be more cost-effective and applicable for mass testing, the feasibility in most time-limited healthcare settings seems questionable. Recently, a group of leading experts in the field, on behalf of the American Heart Association, have claimed for a national registry for CRF in the United States with the possibility of international expansion<sup>32</sup>. The expert group specifically emphasized the need for establishment of normative data for the population using directly measured  $VO_2$  by maximal exercise testing and the potential to derive prediction formulas for CRF from other variables in the registry.

## Non-exercise models of peak oxygen uptake

The strong statistical association between  $VO_{2peak}$  and certain health indicators such as age, PA, body composition, smoking status, resting heart rate, nutritional status and occupation have facilitated the development of multivariable regression models that combined explains a substantial proportion of the variance in  $VO_{2peak}$ . Such prediction models, commonly referred to in the literature as *non-exercise models*, predict  $VO_{2peak}$  reasonably well and are therefore suggested as surrogate measures when exercise testing is inapplicable. Already in 1973, a classical study by Bruce and colleagues indicated the feasibility of predicting  $VO_{2peak}$  from easily obtainable variables such as sex, age, weight and physical exercise habits in 295 healthy adults<sup>45</sup>. In the coming decades several studies attempted to examine the associations between CRF and anthropometrical or behavioral data, or a combination of both<sup>48-50</sup>.

The first study that was deliberately designed to develop and cross-validate a nonexercise model for assessment of VO<sub>2peak</sub> was probably that from Jackson et al in 1990<sup>51</sup>. Their cohort consisted of 2009, predominantly male (~90%), NASA employees who performed a graded maximal exercise test as part of their annual health examination. A multiple regression analysis revealed that age, sex, self-reported PA and body composition (BMI or percent body fat) were predictors of VO<sub>2peak</sub>. Together these variables explained 61% of the variance in VO<sub>2peak</sub> when BMI was included in the model and slightly more with percent body fat. The precision of the model was comparable or better (standard error of the estimate, SEE, was ~5.5 mL·kg<sup>-1</sup>·min<sup>-1</sup> for the two models, respectively) than the ÅstrandRhyming test, which is a well-established sub-maximal exercise tests widely used to estimate  $VO_{2peak}$ . Cross-validation in a sub-sample from the same cohort and in hypertensive individuals and persons with a positive electrocardiogram confirmed the accuracy of the model. The study contained a relatively low number of females (n=150 for the validation sample and n=43 for the cross-validation sample), but its applicability was later confirmed by a validation study in 165 females 18-45 years<sup>52</sup>. A limitation of the study was that the non-exercise model systematically underestimated CRF in well-trained participants with a VO<sub>2peak</sub> >55 mL·kg<sup>-1</sup>·min<sup>-1</sup>. This limitation was later confirmed by a validation study in well-trained college students with a mean age of 21 years<sup>53</sup>.

In 2005, an international group of experts expanded on the work by Jackson et al. by deriving and cross-validating non-exercise models in three large epidemiological databases  $(total n=38,137)^{54}$ . Similar variables as in the original study were used to develop new cohort-specific models in a larger group of NASA employees, participants in the ACLS Study at the Cooper Clinic, and the Allied Dunbar National Fitness Survey (ADNFS) in the UK. The NASA model was the most accurate and showed the highest cross-validity when applied to the other cohorts. The superior model fit is likely explained by the measurement method used for determining CRF, since in the NASA cohort CRF was measured directly as VO<sub>2peak</sub>, whereas it was estimated from maximal and sub-maximal exercise testing, respectively, in ACLS and ADNFS. Subsequent validation studies have confirmed its validity in healthy elderly<sup>55</sup>.

## Associations between physical activity and peak oxygen uptake

It is well established from randomized controlled trials that exercise training and  $VO_{2peak}$  is causally related, and structured PA is recognized as the main method to improve  $VO_{2peak}^{2,56}$ . Nevertheless, most population based studies including healthy participants indicate a weak to moderate relationship between self-reported habitual PA and  $VO_{2peak}^{57}$ . For example, a cross-sectional study from the Baltimore Longitudinal Study of Aging reported quite moderate correlations between overall self-reported PA and  $VO_{2peak}$  in 1116 healthy individuals over a wide age-range (*r*=0.28 and *r*=0.27 in men and women, respectively)<sup>57</sup>. After adjustment for age Lakka et al. reported a weak correlation (*r*=0.11) between  $VO_{2peak}$  and a wide range of conditioning PA in middle-aged men<sup>38</sup>. Similar associations have been reported in other populations with different age-ranges<sup>58-60</sup>.

The relatively weak association between PA levels and VO<sub>2peak</sub> at the population level, and stronger association with health outcomes for the latter, has generally been attributed to how PA has been measured<sup>61</sup>. Self-reported PA by questionnaires, the most widely used approach in population studies, are inherently prone to bias which threatens internal validity<sup>62</sup>. On the contrary, CRF levels can be measured directly with low measurement error and high reproducibility<sup>63</sup>. In recent years, however, objective measurement of PA by activity monitors has been introduced also in large-scale studies<sup>64,65</sup>. The correlation between objectively measured PA and VO<sub>2peak</sub>, however, is not very different from those obtained for self-reported PA with correlations generally ranging from 0.15-0.40<sup>66-68</sup>. Hence, the inherent bias of selfreport data does not seem to fully account for the weak association. Other influencing factors in the PA-VO<sub>2peak</sub> dose-response relationship are genetics, sex, age and individual fitness level<sup>69,70</sup>. The heritability of VO<sub>2peak</sub> have been estimated to be at least 50% and may hence be a primary contributor to the observed heterogeneity in VO<sub>2peak</sub> between subjects with similar exercise patterns<sup>71,72</sup>. Genetics have also been shown to play a major role in the observed responsiveness to a standardized exercise program<sup>73,74</sup>. Moreover, the separate domains of PA, including frequency, duration and intensity of activity, have seldom been taken into account in population studies. Talbot et al. reported markedly different associations with VO<sub>2peak</sub> for high-, moderate- and low-intensity activity, respectively in a heterogeneous population of community dwellers<sup>57</sup>. Activities requiring vigorous absolute intensity ( $\geq 6$ metabolic equivalents, METs) were moderately associated with VO<sub>2peak</sub> (r=0.33 and 0.27 in men and women, respectively), while a weak association was found for moderate intensity (r=0.12 and 0.17 for men and women, respectively) and no association was observed for light intensity (r=0.08 and 0.06 for men and women, respectively). Several other observational studies have reported stronger associations between VO<sub>2peak</sub> and self-reported vigorous intensity PA, compared to moderate intensity or total volume of PA<sup>60,75,76</sup>. Only a handful population based studies, however, have examined how different intensities during unsupervised, freely selected exercise are associated with VO<sub>2peak</sub> at the same or a higher total duration or volume performed.

# Current physical activity recommendations for apparently healthy adults

The WHO's global PA recommendations for healthy adults is to achieve a minimum of 150 minutes of *moderate* intensity PA throughout the week or at least 75 minutes of *vigorous* intensity PA per week<sup>13</sup>. The recommended total duration could be obtained by accumulating bouts of at least 10 minutes and should preferably be spread throughout the week.

Conceptually similar recommendations were first launched in 1995, almost simultaneously as the first public health guidelines for PA in the U.S. were published by the ACSM and Centers for Disease Control and Prevention, which set the stage for a governmental report from the U.S. Surgeon General<sup>16</sup>. The primary recommendations were highly consistent across the different expert panels and represented a paradigm shift from an *exercise for fitness* approach to *PA for health promotion*. These guidelines were cornerstone publications that were soon adopted, with no or minor modifications, by a number of countries worldwide, including Norway<sup>77</sup>.

The ACSM and the American Heart Association have extended on the primary recommendations and developed group-specific recommendations for physical activity for elderly<sup>78,79</sup>, heart disease patients<sup>80</sup>, diabetes patients and more<sup>81</sup>. Additionally, the ACSM have developed specific recommendations for the purpose of exercise prescription in primary care, with special emphasis on the quantity and quality of exercise needed for developing and maintaining CRF<sup>2</sup>. Basically, these recommendations coincide with the general guidelines for health promotion and disease prevention, but are extended to include musculoskeletal and neuromotor fitness.

The primary recommendation before 1995 was to undertake vigorous intensity activity in bouts of at least 20 minutes with the aim of increasing physical fitness<sup>82</sup>. The highlighting of moderate intensity activity, such as brisk walking, was a somewhat controversial topic when the recommendations were first published<sup>83</sup>. Apparently, the new recommendations were based on a tentative conclusion that recommending moderate intensity activity, and allowing for accumulating bouts throughout the day, was the best-buy approach for promoting PA in an increasingly sedentary population. However, a large number of studies, although mostly published after the shift in recommendations, have confirmed the benefit of moderate intensity activity to reduce morbidity and premature mortality<sup>37,84</sup>. Notably, the recommendations can now be reached by either moderate or vigorous intensity activity, or a combination of both, provided a certain total volume of energy expenditure is satisfied. An inherent implication is that there is a 2:1 ratio between time spent at vigorous and moderate intensity activity with concern to health outcomes. This seems to be based on an assumption that it is the total amount of work that matters and that energy expenditure will be equal by doubling the total duration of moderate as compared to vigorous intensity activity. In this case, the benefits of recommending and undertaking vigorous intensity PA are solely

restricted to being a time efficient alternative. What has been less clear, however, is whether higher intensities confers benefits compared to moderate intensities for the same amount of energy expenditure. Although this has been proposed by small scale randomized trials<sup>85</sup>, most epidemiological studies that have proposed larger benefits of higher intensity have not taken into account that PA undertaken at higher intensity also confers a higher total volume of exercise. Moreover, some recent large-scale studies have reported risk reductions for both cardiovascular disease and all-cause mortality at PA volumes as low as half of that expressed in current recommendations<sup>86</sup>. The recommended amount and intensity of exercise have also never been validated against directly measured VO<sub>2peak</sub> at the population level.

# AIMS AND HYPOTHESES

The main aim of the current thesis was to further examine the correlates of  $VO_{2peak}$  in a large, healthy population and explore the possibility of accurately estimating  $VO_{2peak}$  without exercise testing. Furthermore we wanted to examine how freely selected, self-reported exercise patterns were associated with  $VO_{2peak}$  in a large sample of healthy, community dwelling men and women.

# SPECIFIC AIMS

## Prediction of VO<sub>2peak</sub> from non-exercise variables

To derive and cross-validate a simple, non-exercise based prediction model of  $VO_{2peak}$  that could potentially be incorporated in healthcare settings.

We hypothesized that age and a set of modifiable clinical and self-reported variables could explain a large proportion of the variance in  $VO_{2peak}$  and thus be used to predict  $VO_{2peak}$  without exercise testing.

# The association between self-reported exercise patterns and VO<sub>2peak</sub>

To cross-sectionally examine how different combinations of intensity and total time spent at habitual exercise were associated with  $VO_{2peak}$  in an apparently healthy, free-living population.

We hypothesized that vigorous intensity of exercise was associated with higher  $VO_{2peak}$  than low and moderate intensity for the same time spent and total volume performed on habitual exercise.

#### Estimated VO<sub>2peak</sub> and long-term mortality

To evaluate the predictive value of estimated  $VO_{2peak}$  from a non-exercise model for long-term (~24 years) mortality in men and women who were healthy at baseline.

We hypothesized that estimated  $VO_{2peak}$  at baseline were inversely associated with the risk of premature CVD and all-cause mortality.

# MATERIAL AND METHODS

# The Nord-Trøndelag Health Study (HUNT)

The Nord-Trøndelag Health Study (Norwegian spelling: "Helseundersøkelsen i Nord-*Trøndelag*», abbreviated HUNT) is a longitudinal, population-based health survey in Norway. Nord-Trøndelag County is located in the middle of the country, covers both inland and coastal areas and consists of 24 smaller municipalities (Figure 2). Briefly, the county is regarded demographically similar to Norway as a whole, except from an education level and income slightly below the national average<sup>87</sup>. The population is stable and homogenous regarding ethnicity (mostly Caucasians) and socio-economic status and has a low net migration. The HUNT Study is regarded as one of the most comprehensive population-based health surveys in the world and invites all residents above 20 years of age to participate. The survey has been carried out at three occasions, the first in 1984-86 (HUNT 1), the second in 1995-97 (HUNT 2) and the third in 2006-08 (HUNT 3). From the first survey in the mid-eighties, the study has been consecutively expanded to include a large number of sub-studies which examines different aspects relevant to the major public health issues of the time. The main strength of the HUNT Study is the wide range of information, excellent data quality, involvement of a whole unselected population, easy linkage to other health registries and a generally high participation rate. In HUNT 1 ~89% of those invited chose to participate, while the corresponding rates for HUNT 2 and 3 were ~69% and ~54%, respectively (Figure 1). The HUNT Study is collaboration between the HUNT Research Centre (at Department of Public Health, The Faculty of Medicine, NTNU), Nord-Trøndelag County Council and the Norwegian Institute of Public Health. The current thesis contains data from HUNT 1 and HUNT 3.

HUNT 1 (1984-86) Invited: 86,404 Participated: 77.212 HUNT 2 (1995-97) Invited: 93,898 Participated: 65,237

**HUNT 3 (2006-08)** Invited: 93,860 Participated: 50,807

HUNT Fitness Study Invited: 12,609 Appeared: 5,633 Measured VO<sub>2neak</sub>: 4,631

Figure 1: Flow-chart of invited and participated adults (≥20 years) in the three HUNT surveys including the HUNT Fitness Study.




Figure 2: Nord-Trøndelag County with its 24 municipalities. Courtesy: Krokstad et al. 2012.

# The HUNT Fitness Study

The HUNT Fitness Study was a sub-study in HUNT 3 designed to obtain normal values of  $VO_{2peak}$  in a healthy population. The study was carried out between June 2007 and June 2008. Four municipalities within the county (Stjørdal, Verdal, Levanger and Namsos) were chosen in advance and the VO<sub>2peak</sub> testing was performed in connection with the basic HUNT examination. Exclusion criteria for participation in the HUNT Fitness Study were known cardiovascular disease, cancer, obstructive lung disease and use of blood pressure medication. Further exclusions were done for blindness, pregnancy and any physical impairment preventing intense treadmill walking. Before exercise testing all participants also had to pass a brief medical interview involving the abovementioned exclusion criteria. A total of 12,609 persons were offered participation in the HUNT Fitness Study and at study closure 4631 individuals (2,368 women and 2,263 men, age: 19-90 years) had their VO<sub>2peak</sub> tested. At present, these data provides one of the largest reference materials of objectively measured VO<sub>2peak</sub> over a wide age range. A detailed description of the enrollment procedure and a participation flow-chart is presented elsewhere<sup>88</sup>. In addition to measurement of VO<sub>2peak</sub> the HUNT Fitness Study also involved measurement of endothelial function from flow-mediated dilatation (FMD) of the brachial artery using ultrasound technology (Vivid-I, GE Healthcare, USA), and apprehension of questionnaire-based information about pain and health-related quality of life. These data, however, were not used in the thesis.

#### **Clinical measurements**

All clinical measurements were performed by trained nurses at the local HUNT examination facility. Height and body weight was read to the nearest centimeter (cm) and 0.5 kilogram (kg), respectively, using internally standardized measures (Model DS-102, Arctic Heating AS, Nøtterøy, Norway). Body mass index (BMI) was calculated by dividing body weight by the squared value of height in meters. Waist circumference (WC) was only measured in HUNT 3 and read to the nearest centimeter using a steel band horizontally at the height of the umbilicus. Blood pressure was measured three times by an automatic oscillometry (Dinamap 845XT, Critikon) and the mean of the second and third reading was used for analysis. Resting heart rate in HUNT 1 was measured by palpating the radial pulse over 15 seconds after at least four minutes of seated rest. In the case of irregular pulse or difficulties counting heart beats, the test was extended to 30 seconds, if necessary with a stethoscope placed over the heart. In The HUNT Fitness Study, the lowest heart rate was registered by 3-point electrocardiogram during FMD measurement with the participants lying in supine position on a bench for 10 minutes in a dim lit and quiet room. Blood samples were drawn from the participants in HUNT 3 and non-fasting glucose, triglycerides, total cholesterol and HDL cholesterol was analyzed in addition to some biomarkers not relevant for the present thesis.

#### Peak oxygen uptake measurements

Prior to the maximal exercise test, all participants carried out a 10 minute warm-up period. After a brief introduction to treadmill walking or running, preferably without hand-rail grasp, the speed was individually adjusted to a work-load causing slightly increased breathing and hart rate. Before entering the test treadmill (DK7830; DK City, Taichung, Taiwan) all participants were equipped with a face-mask (Hans Rudolph, Shawnee, KS) and heart rate monitor (Polar S610 or RS400; Polar Electro Oy, Kempele, Finland) and instructed in detail about test procedures. Oxygen uptake (VO<sub>2</sub>) and heart rate were then measured continuously during an incremental, individualized treadmill protocol until exhaustion. VO<sub>2</sub> kinetics was measured directly by a portable mixing chamber gas analyzer (MetaMax II; Cortex, Leipzig, Germany). The initial workload was chosen from the warm-up pace, and speed and/or inclination was then increased whenever the participant reached an oxygen uptake that was stable over 30 seconds. As a prolongation of the warm-up period, and before exhaustion was reached, most participants had their steady-state VO<sub>2</sub> measured during one (*n*=2773) or two (*n*=2543) submaximal levels. For each level, speed (km/h), inclination (%), heart rate and subjective level of exertion on the Borg 6-20 scale was registered in addition to VO<sub>2</sub>. A test

was considered maximal (VO<sub>2max</sub>) if the VO<sub>2</sub> did not increase more than 2 mL·kg<sup>-1</sup>·min<sup>-1</sup> despite increased workload, combined with a respiratory exchange ratio at or above 1.05. Since 12.6% of the participants did not reach both the VO<sub>2max</sub> criteria, the term VO<sub>2peak</sub> are used throughout this thesis and in the corresponding papers. An individual's VO<sub>2peak</sub> was registered as the mean of the three successively highest 10 seconds VO<sub>2</sub> registrations. A detailed description of the test protocol is previously published by our group<sup>89</sup>. The test equipment was calibrated with volume calibration repeated every third test and two point gas calibration every fifth. Before and after each test the ambient room air was routinely checked. Before the start of the study the validity of the MetaMax II apparatus were tested by comparison against Douglas bag and iron lung (Cortex Biophysik). Direct measurements of VO<sub>2peak</sub> are preferable to indirect estimation due to higher precision and reliability<sup>62</sup>. However, the methods are more complicated and warrants trained personnel.

## Self-reported information

Some essential information was questionnaire-based in both HUNT 1 and HUNT 3. In all three papers all data on leisure time PA (exercise) were collected through a self-administered questionnaire included with the invitation letter. The questions covered the three essential domains of PA; frequency, intensity and duration. The frequency question was stated as "How often do you exercise?" with the response options "Never", "Less than once a week", "Once a week", "2-3 times a week" and "Almost every day". The intensity question was stated as "If you exercise as frequently as once or more a week: How hard do you push yourself?", with the response options "I take it easy without breaking a sweat or losing my breath", "I push myself so hard that I lose my breath and break into sweat" and "I push myself near exhaustion". The duration question was stated as "How long does each session last?", with the response options "Less than 15 minutes", "15-29 minutes", "30 minutes to one hour" and "More than one hour". In Paper I and III the individual responses to each question was weighted to form a physical activity index score (PA-Index). The individual weighting was chosen on the basis of each variables association with VO<sub>2peak</sub> in a multiple linear regression model. The new index was compared to two previously published PA indexes used in the HUNT cohort, but preferred on the basis of a stronger total association with VO<sub>2peak</sub>. In Paper II, the response options were collapsed into categories which roughly corresponded to current recommendations for PA for the general population. Inactive people were defined as those reporting none or less than once a week of regular PA. The questionnaire applied was the same in all three papers, with the exception for the intensity questions used in Paper II. This

question was taken from a questionnaire handed out in connection with the  $VO_{2peak}$  testing and was chosen because it gave more detailed information on relative exercise intensity. Participants were asked to assess their usual intensity of exercise on the well-known Borg 6to 20-point scale which is frequently validated against objective measures such as heart rate and  $VO_2^{90,91}$ . Other self-reported variables include smoking status ("Never smoked", "Former smoker" and "Current smoker"), alcohol consumption last 14 days ("None", "1-4 times", "5-10 times" and "More than 10 times"), marital status ("Married", "Unmarried", "Widow/widower" and "Divorced/separated"), family history of disease and attained education ("9 years or less", "10-12 years" and "More than 12 years").

# Other register data

The unique 11-digit identification number allocated to all Norwegian citizens make it possible to link data from the HUNT database and other health registries. In Norway, it is mandatory for physicians or public health officers to report deaths to the National Cause of Death Registry. The underlying cause of death is registered using the International Classification of Disease (ICD) coding system. In Paper III, the primary end-point was deaths caused by cardiovascular disease (ICD: 9<sup>th</sup> Revision: 390-459, 10<sup>th</sup> Revision: 100-199) and all causes. The information on causes of death was complete through December 31<sup>st</sup>, 2010.

#### **Ethics**

The data collections in all HUNT surveys, including The HUNT Fitness Study and the specific studies included in the thesis are approved by the Regional committee for medical research ethics, The Norwegian Data Inspectorate and Health Directorate and are performed in conformity with Norwegian law and the Declaration of Helsinki. In HUNT 2 and 3 all participants signed a document of informed consent, while in HUNT 1 attendance and participation in the medical examination was considered as approval of informed consent. The mortality follow-up in Paper III was approved by HUNT Research Centre and Statistics Norway which is the responsible unity for collection and organization of the data.

# METHODOLOGICAL CONSIDERATIONS

The validity of a study is concerning the degree to which a study reaches a correct conclusion and can be broadly separated into internal and external validity. Internal validity is the validity of the inferences made as they pertain to the members of the study population while external validity is the extent to which the inferences can be generalized to people outside the study population (*generalizability*). In the following the internal and external validity of the studies included in the thesis will be discussed. The precision of the specific results (control of random errors) are discussed in the Results and discussion section.

#### Internal validity (control of systematic error)

Systematic errors in estimates are often referred to as biases, as opposite to validity. Potential bias are commonly sub-classified into three different types; *selection bias, information bias* and *confounding*.

# Selection bias

Selection bias refers to systematic error introduced by procedures used for selection of participants into the study or factors that influence study participation. Such bias appears if the relation of the exposure to the outcome is different for those who participate in a study and those who theoretically would be eligible for the study<sup>92</sup>. The HUNT studies in general invite the total adult population of a county and have a high participation rate and these factors may reduce bias due to selection. The participation rate, however, declined somewhat from being exceptionally high (89%) in HUNT 1 to a considerably lower, but acceptable in most age groups, in HUNT 3 (54%). However, a recent study of attendants and non-attendants in HUNT 3 proposed that there is generally no reason to be concerned about biased associations, although it depends on the given research question<sup>93</sup>. Moreover, the most pronounced difference between attendants and non-attendants were a higher prevalence of cardiovascular disease and diabetes among the latter, and these groups were not included in our studies.

The relatively low participation rate in The HUNT Fitness Study (44.7% of those invited) may also make Paper I and II subject to self-selection bias. Accordingly, it may be possible that those volunteering for exercise testing were also more fit than the corresponding healthy sample of non-attendants. However, almost all of those who were invited to testing from the basic HUNT study agreed to participate in the VO<sub>2peak</sub> test. Yet, many potential participants chose to withdraw their participation in the study, partly because of long waiting

lines due to limited capacity at the test facilities. Nevertheless, a comparison of participants in the HUNT Fitness Study and the overall healthy population in HUNT 3 revealed only minor mean differences for several important health indicators<sup>88</sup>. For example, in female Fitness Study participants systolic blood pressure was 123.5 mmHg compared to 124.3 mmHg in the total healthy population, diastolic blood pressure was 69.7 mmHg compared to 69.8 mmHg and waist circumference were 0.86 m compared to 0.88 m, respectively. In men, systolic blood pressure was 132 mmHg in the Fitness Study sample compared to 131 mmHg in the healthy HUNT population and diastolic blood pressure 76 mmHg compared to 75 mmHg. BMI were slightly lower in The Fitness Study participants (25.4 compared to 26.1 in women and 26.6 compared to 27.0 in men) and a lower proportion reported to be inactive defined as exercising less than once per week (14.1% compared to 20.6%). The HUNT Fitness Study participants are therefore considered to be fairly representative of the general population of apparently healthy, free-living men and women in Nord-Trøndelag County.

#### Information bias

Information bias is commonly arising because of errors or inconsistency in the measurement of the exposure or outcome variables. Misclassification is a common source of information bias for categorical variables collected from self-report. Misclassification can be differential or non-differential depending on the variables relationship to the other variables. Differential misclassification occurs when the value of a variable depends on the actual value of another variable, while non-differential misclassification implies that the value of a variable is not dependent on the actual value of another variable<sup>92</sup>.

All clinical variables measured in HUNT are collected by trained nurses using standardized equipment and procedures which consolidates high construct validity. The main outcome variable, VO<sub>2peak</sub>, was measured by ventilatory gas analysis which is considered as the gold standard measurement of cardiorespiratory fitness<sup>62</sup>. The non-exercise predicted VO<sub>2peak</sub>, however, are prone to misclassification bias when categorized as in Paper III. The misclassification, however, is probably non-differential (i.e. random) which typically leads to more conservative or underestimated associations. Another obvious source of information bias in the current thesis is the use of self-reported measures of PA.

#### Assessment of physical activity (PA)

Several different methods for assessment of PA are available and the preferred method depends largely on the degree of accuracy needed as opposed to the feasibility and cost of the

method of choice. For example, the doubly labeled water method are recognized as the gold standard method of assessing energy expenditure in free-living individuals, but its expense and complicated procedure limits the usefulness in epidemiological settings<sup>62</sup>. This method is therefore mostly used to validate less accurate measurement methods such as self-report questionnaires. In recent years, however, the introduction of accelerometers and pedometers that individuals wear on their hip or arms during daily living has made it possible to measure PA quite accurately also in population studies<sup>94</sup>. Self-report measures of PA, as opposed to objective measurement, may induce misclassification bias due to a tendency to over- or underreporting of a certain behavior due to social desirability or simply because recalling specific behaviors is a complex cognitive task. The misclassification caused by incorrect recall of PA may be differential (i.e. non-random) if more active people, especially those taking part in vigorous PA and sports, are more likely to accurately recall their activity<sup>95</sup>. Indeed, the questionnaire applied in Papers I-III was more accurate in measuring vigorous than low- and moderate intensity activity in a previous validation study<sup>96</sup>. Furthermore, selfreported PA has consistently been shown to overestimate the objective level of PA<sup>94</sup>. This may indicate bias due to social desirability, suggesting that people tend to over-rate their actual PA level. This assumption is reflected in recent studies showing that compliance to PA recommendations, as measured by objective methods (accelerometers or pedometers), are considerably lower than previous prevalence estimates based on self-report<sup>94</sup>. The estimated compliance to the PA recommendations in the general population therefore varies greatly depending on how PA is measured. Nonetheless, simple self-report questionnaires have been the method of choice in the field of PA epidemiology over several decades. Indeed, most of the evidence that form the basis of today's PA recommendations are based on self-report and we can thus conclude that PA questionnaires certainly have contributed to the field of PA and health<sup>97</sup>.

However, one must keep in minds that self-report questionnaires and accelerometers in essence measures different things. While most questionnaires in general asks the participant about a certain behavior, accelerometers merely measures movements. Hence, the disagreement between the measurement methods may not just be a question about accuracy. The difference may also be attributed to the fact that self-report measurement takes into account the interpretation of people about what they really do. For instance, an hour at the gym or playing football may not equal an hour of dynamic movement, still the total time period engaged in the activity may be the maximum accuracy people are able to recall and

17

interpret. Furthermore, there is at present no consensus about how to translate certain accelerometer counts into certain intensities, particularly relative intensity, for different groups such as elderly populations. Accordingly, we may speculate that self-report data are more easily translated into comprehensible public health guidelines. Moreover, the association between objectively measured PA by accelerometers and health outcomes and premature mortality is yet to be established. Hence, we might expect that the introduction of objective PA measurement in population studies ultimately leads to a shift in the recommended amount and intensity of PA for health promotion.

# Confounding

Confounding is an important issue in observational studies because confounding factors can potentially obscure the true association between exposure and outcome. Confounding may bias any association observed if one or more variables are associated with the exposure and also causally related to the outcome variable<sup>92</sup>. Thus, the effect of the exposure is mixed together with the effect of another variable. Confounding therefore introduces bias in studies examining cause-effect issues (Paper II and III), but is not of particular concern in pure prediction models (Paper I). The error introduced by confounding factors in non-randomized studies can be dealt with by statistically controlling for these variables in multivariable models (*adjustment*), by excluding participants at specific levels of the confounder (*stratification*).

The HUNT studies include a wide range of variables that allows for statistical adjustment for several potential confounders. Selection of potential confounders and how to deal with them is, however, a careful process that should be based on prior knowledge and not merely statistical grounds. Age and sex were the most obvious confounders in our studies since both are strong determinants of VO<sub>2peak</sub> and may causally affect both PA levels and risk of mortality. Women have systematically lower VO<sub>2peak</sub> than men across all adult age-groups and for the ease of interpretation we chose to stratify our analysis by sex in all studies, instead of including sex as a covariate in the linear models. All analyses were adjusted for age. Another important confounding factor in most observational studies with recourse to hard-endpoints (i.e. mortality or cardiovascular disease) is the existence of undetected subclinical disease which may lead to biased interpretation of the cause-effect relationship (*reverse causation*). For instance, low VO<sub>2peak</sub> may be caused by an underlying disease that

concurrently increases risk of premature mortality. We cannot fully exclude the possibility of this in Paper III. However, the large sample size and broad range of information on baseline health status allowed us exclude a large number of participants anticipated to have a subclinical disease at baseline (i.e. self-reported long-term functional impairment, motion impairment and angina pectoris). Moreover, excluding the first 5 years of follow-up in a sub-analysis did not change the results appreciably which might have been the case if low-fit subjects had the specific diseases already at baseline.

Importantly, a variable that is associated with both the exposure and the outcome might be on the causal pathway between exposure and outcome (a *mediator*) and should then not be regarded as a confounder. PA and  $VO_{2peak}$  (exposure variables in Paper II and III, respectively) positively affects a broad range of factors that may be on the causal pathway to the outcome (i.e.  $VO_{2peak}$  or cardiovascular mortality) and adjusting for these intermediate variables may lead to overly conservative estimates. For instance, we chose not to adjust for blood pressure in Paper III since it is well known that PA can reduce blood pressure in a causal manner and that blood pressure is causally related to mortality risk<sup>98</sup>. However, we excluded participants on blood pressure medication (*restriction*) although the need for pharmacological reduction in blood pressure may be caused by low PA or  $VO_{2peak}$  and also is known to causally reduce mortality, because medication use might be associated with underlying subclinical disease or a genetic vulnerability that increases risk<sup>99</sup>.

## External validity (generalizability)

Generalizability refers to whether the results apply to people outside the population under study. The homogenous nature of the HUNT population, including the HUNT Fitness Study sample, may limit generalizability of the results to other populations. Nord-Trøndelag county, however, is geographical and demographically representative of Norway as a whole, also regarding health<sup>100</sup>. A limitation, however, may be lack of larger cities and a low proportion of immigrants of non-European background. However, this non-representativeness is assumed to be unrelated to the associations we studied. The association between CRF and cardiovascular or all-cause mortality is well-established, and similarly strong, for a wide range of population samples and is therefore probably not confounded by race, ethnicity, socio-economic status or geographic residence<sup>33,34,101</sup>. Participants invited to the HUNT Fitness Study were apparently healthy, and hence not representative of unselected populations normally containing a large proportion of people with cardiovascular or pulmonary diseases.

Nevertheless, as compared to previously published data on VO<sub>2peak</sub> from comparable populations, the participants in HUNT had a somewhat higher VO<sub>2peak</sub><sup>102-104</sup>. Therefore, the lack of an external validation sample is a limitation of Paper I. However, previous studies have shown that similar models derived in healthy samples can be applied to groups receiving anti-hypertensive medication and people with a positive exercise electrocardiogram<sup>51</sup>. Moreover, cross-validation analysis in individuals from the HUNT Fitness Study with clustered cardiovascular risk factors (n=224) or hypertension (n=938) indicated that the model was valid also when applied to these subgroups. In the hypertensive group of men and women the mean difference between measured and predicted VO<sub>2peak</sub> was negligible and the correlation was similar to that observed in the total sample (men, r=0.77, SD 5.58 mL·kg<sup>-1</sup>·min<sup>-1</sup> , women, r=0.68, SD 4.84). In the group with a clustering of cardiovascular risk factors, as previously defined by Aspenes et al.<sup>27</sup>, the mean difference were 0.5 mL·kg<sup>-1</sup>·min<sup>-1</sup> (r=0.77, SD 4.87 mL·kg<sup>-1</sup>·min<sup>-1</sup>) Hence, the non-exercise model may be applicable also to high-risk subjects although derivation of population specific models may be preferable.

#### Statistical analyses

Paper I and II were designed as cross-sectional studies and included participants from the HUNT Fitness Study. Paper III was a prospective follow-up study of apparently healthy participants in HUNT 1. Analyses were done separately for men and women in all three papers. Precision of estimated means and hazard ratios were indicated by 95% confidence intervals. All statistical p-values were two-sided and the statistical procedures were conducted using PASW Statistics version 18.0 (Copyright 1993-2007 Polar Engineering and Consulting) or STATA for Windows version 12.1 (StataCorp LP, 1985-2007).

In *Paper I*, multiple linear regression analyses with  $VO_{2peak}$  as the dependent variable were used to develop the non-exercise models. Inclusion of potential predictor variables were done hierarchically, meaning they were entered one by one or in blocks of two or more variables based on a priori assumptions of the variables` association with  $VO_{2peak}$ . This method is preferable because the investigator easily can control the entry of predictor variables based on theoretical considerations<sup>105</sup>. An alternative regression method could be stepwise or backward regression which allows the computer program to select a set of the "best" predictors based on correlation coefficients. This approach, however, has several pitfalls because it is entirely data driven and the obtained model may not be the optimal regarding both internal and external validity<sup>106</sup>. Two important statistical measures were used

to evaluate the accuracy of the models, namely the standard error of estimate (SEE) and the squared multiple regression coefficient  $(R^2)^{107}$ . SEE refers to the random error of prediction for a regression line and are equal to a standard error score of 1 in terms of the units of the dependent variable. SEE is calculated as the sum of squared differences between actual and predicted values, divided by the total number of subjects. On the other hand, R<sup>2</sup>, also called the coefficient of determination, is a measure of the strength of association and tells us what proportion of the variation of a variable (i.e. VO<sub>2peak</sub>) that can be explained by a set of predictor variables. The models were further examined for accuracy by examining subgroups of age, PA-level and VO<sub>2peak</sub> for constant errors (CE) and total errors (TE). CE are a measure of systematic over- or under-prediction and were calculated as the mean difference between measured and predicted VO<sub>2peak</sub> (mean residuals) within the subgroups. A negative CE value indicates that the model, at average, tended to overestimate VO<sub>2peak</sub> in that particular subgroup, while a positive value indicates a potential under-prediction. In contrast, TE combines the systematic error and the random error (SEE) and represents the total error of the model when applied to the particular subgroup. Any systematic over- or under-prediction among subgroups could be corrected by adding or subtracting the appropriate CE value from a cross-validation statistics for a particular sub-group, to the y-intercept of the original equation. Theoretically, this method would result in a constant error of zero for the modified equation when used in the intended population<sup>108</sup>. To test this hypothesis a cross-validation study in an independent sample would be necessary. The final model was, however, internally cross-validated by splitting the data-set into a derivation and a cross-validation sample. The regression analysis was performed on the derivation sample and the obtained model used to predict VO<sub>2peak</sub> for each individual in the cross-validation sample. The correlation between observed scores and the predicted scores constitute the cross-validity coefficient which were squared and compared to the original  $R^2$  of the validation sample. CE and TE values were estimated for the cross-validation sample when the model obtained from the derivation sample was used. Here, CE and TE represent the systematic and total error values of a model derived in one sample and validated in another sample. PRESS-statistics (Predicted Residual Sum of Squares) represents an alternative to simple-data splitting as an internal crossvalidation procedure. This method may be preferable to data-splitting in smaller samples because it allows all observations to be included in both derivation and cross-validation. When the PRESS procedure was applied to the data material in Paper I we observed a R<sup>2</sup> of 0.61 and 0.55 and a SEE of 5.71 and 5.15, in men and women, respectively. Hence, this method did not add anything to simple data-splitting in the present cohort.

In Paper II, a general linear model (GLM) was used, with VO<sub>2peak</sub> as the dependent variable, to determine the association between different groups of self-reported exercise patterns and VO<sub>2peak</sub>. Adjustment was made for age only or age, BMI, smoking status and occupational PA. From the sub-maximal steady-state VO2-measures and the VO2peak-test, the test-subject's individual perceived exertion on the Borg scale association with VO<sub>2</sub> was calculated ( $Y = a \cdot X + b$ , where Y is VO<sub>2</sub> and X is Borg). For a given Borg scale rating a corresponding VO<sub>2</sub> value as a percentage of VO<sub>2peak</sub> was established based on the individual treadmill test. The individual energy expenditure during self-reported exercise was calculated by multiplying the VO<sub>2</sub> (L·min<sup>-1</sup>) corresponding to the self-reported Borg scale rating by 5 kcal·min<sup>-1</sup> (equivalent to ~1 L VO<sub>2</sub> for 1 minute). Furthermore, average energy expenditure was multiplied by the self-reported weekly duration of exercise to estimate total energy expenditure. Estimated resting energy expenditure was subtracted to obtain an estimate of net energy expenditure caused by exercise. In order to assess the independent effect of relative intensity within groups with different net energy expenditure, VO<sub>2peak</sub> was entered as a dependent variable and intensity groups as independent variable with estimated weekly energy expenditure (kcal/week) and age as continuous variables as covariates. The analyses were then done separately for quartiles of weekly energy expenditure. Hence, we could separate the effect of intensity independent of its contribution to total energy expenditure. An implicit limitation of this cross-sectional study is that it cannot suggest causal pathways, but merely indicate associations and this limitation has to be acknowledged when interpreting the results<sup>109</sup>.

In *Paper III*, Cox-proportional hazard models were used to assess the association of mortality with estimated  $VO_{2peak}$ . The Cox-model offers the opportunity to include numerous covariates and hence efficiently control for confounding. The outcome variables were death from cardiovascular disease and death from all-causes. We adjusted for age by entering age as the time-scale. Using age as the time-scale instead of time-on-study limits the introduction of bias than can occur when age is highly correlated with the predictor variable of interest, which is the case with estimated  $VO_{2peak}$ . We also did stratified analysis for younger and older subjects due to a moderate effect modification by age 60. Effect modification may appear when the influence of two variables on the outcome variable are not additive in their respective effects (i.e. the association between estimated  $VO_{2peak}$  and mortality were different for younger and older subjects). The validity of the prediction models were assessed by

examining measures of discrimination and calibration<sup>110</sup>. Discrimination was assessed by calculating the area under the receiver operating curves (AUC, also known as Harrell's *c*-statistic) and its 95% confidence intervals for estimated CRF and each modifiable constituent component, respectively. The AUC describes the probability that a classifier will assign a higher risk to a randomly chosen participant who died than a randomly chosen participant who survived until end of follow-up. Hence, a risk prediction by pure chance yields a *c*-statistic of 0.50, and higher values reflect better discrimination. The calibration refers to the degree of similarity between the observed and predicted risk (i.e. low-fit participants with a given predicted risk will actually experience events at the same rate). The Cox-regression model was calibrated by comparing the mean incidence proportion of events (CVD and all-cause, respectively) for each quintile of predicted risk and each estimated VO<sub>2peak</sub>-group, with the multi-adjusted predicted risk obtained by the Cox-models.

#### **RESULTS AND DISCUSSION**

The current thesis shows that peak oxygen uptake  $(VO_{2peak})$  can be predicted with reasonable accuracy from easily available clinical and self-reported variables. The final multiple regression model (non-exercise model) could predict long-term cardiovascular and all-cause mortality in people who were apparently healthy and below 60 years at baseline. Furthermore, we demonstrate that habitual exercise patterns of moderate relative intensity for a long total duration or vigorous intensity for a relatively short duration, adding up to the total volume as recommended by the health authorities, both were associated with a beneficial  $VO_{2peak}$  –level.

# Non-exercise models of peak oxygen uptake

To our knowledge, the non-exercise models in Paper I are the first developed in a Scandinavian population and among the few derived from a large sample that included similar amounts of men and women with directly measured VO<sub>2peak</sub> as the outcome variable. The accuracy of these models, as judged by  $R^2$  (0.61 and 0.56 for men and women, respectively) and SEE (5.7 and 5.1 for men and women, respectively), are comparable to previously published models containing similar, large samples and a wide age range (Table 1)<sup>51,54,104,111</sup>. Non-exercise models that report considerably lower SEE and higher R<sup>2</sup> were generally based on smaller and more selected samples and may therefore have limited generalizability<sup>112,113</sup>. A large sample size is crucial for obtaining a useful prediction equation<sup>114</sup>. More predictor variables applied to smaller samples may spuriously increase the explanatory power<sup>107</sup>. The vast majority of previous non-exercise models include the variables sex, age, PA level and body composition, while some also include smoking, resting heart rate or height<sup>51,54,115</sup>. The non-exercise model in Paper I differ from most previous studies in that we made sex-specific models instead of including a dummy-coded sex variable. Sex differences in body composition are well-documented and may support sex-specific models as long as the sample size is large. Moreover, inclusion of product terms revealed interactions with sex for age, BMI and WC, respectively, which further support the preference of sex-specific models. Although WC/BMI was the strongest modifiable predictor in our sample, habitual PA levels are a key determinant of CRF and should therefore be measured with precision. In an attempt to improve the accuracy of prediction, Japanese researchers have included objective assessment of PA in their prediction models<sup>116,117</sup>. Hence, they would possibly overcome the accompanying bias associated with self-report measures of PA. When including time spent in moderate-to-vigorous PA or limited to vigorous PA as measured by accelerometers together

with age and BMI or waist circumference, respectively, they observed a considerably higher  $R^2$  and lower SEE compared to previous models ( $R^2$ , 0.71-0.86, SEE, 3.0-4.2). However, to obtain an objective measure of PA, it is required that the individual wears an activity monitor for up to 7 consecutive days, which may not be feasible in most healthcare settings<sup>118</sup>.

In Paper I, we instead attempted to make a PA index from self-reported data that correlated well with VO<sub>2peak</sub>. Hence, we examined the independent contributions of frequency, duration and intensity of PA and weighted each PA dimension differently according to the obtained  $\beta$ -coefficients in a multiple regression analysis. It is proposed from several large-scale studies that intensity of PA are more strongly associated with VO<sub>2peak</sub> than frequency or duration<sup>60,75</sup>. The index takes this into account by weighting higher relative intensity more than higher frequency and duration of PA, respectively (see Table 4 in Paper I). The correlation between the PA-Index and  $VO_{2peak}$  were 0.39 and 0.44 in women and men, respectively. We might, however, speculate that questionnaires making use of absolute intensity (activities assumed to require a certain energy expenditure), are more suitable in predicting VO<sub>2peak</sub> since the absolute intensity during exercise are inherently limited by the maximal exercise capacity. For example, the Duke Activity Status Index (DASI) asks participants about their ability to perform 12 common daily activities that requires different levels of functional capacity. This index has been shown to correlate moderately well (r=0.58) with directly measured VO<sub>2peak</sub> in an independent sample of healthy subjects<sup>119</sup>. Similarly, the Veterans Specific Activity Questionnaire (VSAQ) lists 13 activities with a corresponding MET-value and was shown to correlate moderately well with  $VO_{2peak}$  (r=0.42) in people referred for exercise testing for clinical reasons<sup>120</sup>.

Authors	Participants	Age	Z	% female	Predictor variables	R'	SEE	SEE (%)
Tackson et al (1990) <sup>51</sup>	Healthy NASA	18-70	2009	0 7%	Ane sev DA RMI or % RF RHR	0.61	5.70 (BMI)	14.4%
	employees	01-01	1007	0/ 1.7	1150, 500, 111, DMI 01 /0 D1 , 1111	0.66	5.35 (%BF)	13.5%
	NASA		1863	21.6%		0.65	5.08 (NASA)	13.2%
Jurca et al.(2005) <sup>54</sup>	ACLS	20-70	46,190	22.4%	Age, sex, BMI, RHR, PA	0.60	5.25 (ACSL)	13.0%
	ADNFS		1706	50.0%		0.58	6.90 (ADNFS)	15.6%
Motthoms of al (1000) <sup>104</sup>	Ucolthy voluntoore	10.70	700	21 702	Age, age <sup>2</sup> , sex, PA, height, weight	0.74	5.64 (H,W)	15.2%
Maurews et al. (1999)	nealiny volumens	19-19	661	0/7.10	or BMI	0.73	5.76 (BMI)	15.5%
	Former exercise		0300	20.00/	Age, sex, PA, %BF	0.70	5.61	14.5%
VIIAICY EL AL. (1227)	study particpants		0007	0/0.60	Above+RHR, smoking status	0.85	5.38	14.0%
	II and the NTA C A					0.66	4.80 (WC)	13.4%
Wier et al. (2006) <sup>115</sup>	nealuly INADA	19-82	2801	13.7%	Age, sex, FA allu DIVII, WC 01 %	0.67	4.72 (%BF)	13.2%
	emproyees				Br, respectively	0.64	4.90 (BMI)	13.7%
Bruce et al. (1973) <sup>45</sup>	Healthy volunteers	48	295	53.2%	Age, sex, PA, weight	0.65	4.84	13.0%
						0.77	4.90	12.7%
Heil et al. (1995) <sup>112</sup>	Healthy volunteers	20-79	439	52.2%	Age, age <sup>2</sup> , %BF, PA, sex	0.72	4.64 (皇)	13.8%
						0.72	5.02~(3)	11.4%
-	Healthy wellness							
Bradshaw et al. (2005) <sup>113</sup>	program participants	18-65	100	50.0%	Age, sex, BMI, PFA, PA	0.86	3.45	8.6%
	LI <sub>0.0</sub> 14h LII INT					0.67	5.47	13.7%
Nes et al. (2011)	nealuiy num i nartioinante	19-90	4260	51.6%	Age, PA-I, WC, RHR	0.61	5.70~(3)	12.8%
	participatitis					0.56	5.14 (皇)	14.3%

In the model used for prospective mortality follow-up (Paper III), BMI was used instead of WC as a measure of body composition since WC was not measured in HUNT 1. However, both variables were examined extensively during the derivation of the model and yielded only small differences in R<sup>2</sup> and SEE as shown in Table 2. Previous studies have shown that inclusion of waist or BMI in multivariable models did not change model characteristics substantially<sup>115,121</sup>. Noteworthy, BMI was a strong predictor of VO<sub>2peak</sub>, despite that VO<sub>2peak</sub> were defined as the amount of oxygen consumption per kilo body mass (mL·kg<sup>-1</sup>·min<sup>-1</sup>). The finding that BMI were highly associated with VO<sub>2peak</sub> may indicate that simply dividing VO<sub>2</sub> by body mass do not fully account for the influence of body mass on VO<sub>2peak</sub> as intended. Some studies have also examined the predictive ability of percent body fat in non-exercise models and found similar or slightly better model fit<sup>112,115,122</sup>. However, percent body fat is estimated by measuring thickness of a minimum of three skinfolds and a possibly higher precision may not justify the time requirement needed to measure it properly.

Variable	Μ	len	Women			
	WC-model	BMI-model	WC-model	BMI-model		
Intercept	100.27	92.05	74.74	70.77		
Age	-0.296	-0.327	-0.247	-0.244		
PA-Index	0.226	0.257	0.198	0.213		
WC/BMI	-0.369	-0.933	-0.259	-0.749		
RHR	-0.155	-0.167	-0.114	-0.107		
R	0.782	0.770	0.745	0.753		
$\mathbb{R}^2$	0.612	0.593	0.555	0.568		
SEE	5.70	5.84	5.14	5.06		

**Table 2:** Multiple regression coefficients for predicting  $VO_{2peak}$  (mL·kg<sup>-1</sup>·min<sup>-1</sup>) in the total sample with waist or BMI included in the model

PA-Index, physical activity index, WC, waist circumference, BMI, body mass index RHR, resting heart rate, R, multiple regression coefficient, R<sup>2</sup>, squared multiple regression coefficient, SEE, standard error of estimate

The accuracy of the present models, in terms of SEE and  $R^2$ , are comparable to submaximal exercise testing of VO<sub>2peak</sub>. For example the Multistage shuttle run test<sup>123,124</sup>, the Rockport 1-mile walk test<sup>125</sup>, the modified Bruce protocol<sup>45,126</sup>, the single-stage submaximal treadmill test<sup>127,128</sup>, the Åstrand-Rhyming test<sup>46,129</sup> and the ACSM prediction equation<sup>130</sup> all report SEE within the range of 3.5 to 6.5 mL·kg<sup>-1</sup>·min<sup>-1</sup>. However, most submaximal tests are population-specific and direct comparison may be limited without thorough cross-validation of both methods in an independent sample. We are aware of two other studies that validated non-

exercise testing models and submaximal testing methods in the same sample. Jackson et al. (1990) reported similar correlations with directly measured VO<sub>2peak</sub> for their non-exercise model (r=0.79), compared to the Åstrand-Rhyming submaximal test (r=0.78), in a healthy cross-validation sample<sup>51</sup>. However, the submaximal exercise test considerably overestimated VO<sub>2peak</sub> for the whole range of fitness levels, while the non-exercise model underestimated VO<sub>2peak</sub> among high-fit subjects. Mailey et al. (2010) validated the non-exercise model from Jurca et al. (2005) in elderly subjects, and found fairly similar cross-validity correlations between VO<sub>2peak</sub> and maximal METs estimated from the non-exercise model (r=0.66) and the Rockport 1-mile walk test (r=0.68), respectively<sup>55</sup>. Moreover, the non-exercise model was more closely related to cardiovascular risk factor clustering compared to the Rockport test<sup>55</sup>.

One reason why non-exercise models, as well as submaximal testing methods, fail to fully account for the variance in directly measured VO<sub>2peak</sub> may be that the individual variability attributed to genetics are high. Several lines of evidence suggest that heritability may be responsible for more than 50% of the variability of VO<sub>2peak</sub> in heterogeneous populations<sup>72</sup>. This is congruent with the results in Paper I, and others<sup>45,51,54</sup>, showing that ~40% of the variance are left unexplained after including a wide range of modifiable and non-modifiable predictor variables. CRF are, however, frequently measured by maximal treadmill tests that, in comparison to sub-maximal and non-exercise tests, may better capture the heterogeneity in VO<sub>2peak</sub><sup>45,131</sup>. These protocols have been used in epidemiological studies and yield fairly accurate estimates of VO<sub>2peak</sub> (*r*~0.90, SEE~3-4.0 mL·kg<sup>-1</sup>·min<sup>-1</sup>)<sup>132</sup>. However, these protocols suffer from many of the same limitations as direct measurement in terms of time-use, personnel requirement, equipment and participant efforts.

A possible limitation of most established non-exercise models is that they were derived from cross-sectional data. Therefore the accuracy of these models to estimate temporal changes in VO<sub>2peak</sub> is not known. Accordingly, one does not know whether changes in the modifiable predictor variables over time, by training or detraining, may be detected by non-exercise prediction of VO<sub>2peak</sub>. Furthermore, most cross-sectional models, including ours, found that VO<sub>2peak</sub> was linearly related to age and hence included age as a linear term. However, longitudinal VO<sub>2peak</sub> data suggest a non-linear decline with increasing age<sup>133,134</sup>. A recent study from the ACLS cohort attempted to overcome these problems by developing models from longitudinal exercise test data using linear mixed models<sup>122</sup>. These models are promising for capturing temporal changes in VO<sub>2peak</sub> and warrants further attention.

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	W	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5
and (mL kg <sup>1</sup> min <sup>1</sup> ) $28.2\pm4.6$ $32.4\pm4.6$ $35.4\pm5.2$ $38.8\pm5.2$ $m(kg^2)$ $62.1\pm9.8$ $55.0\pm8.9$ $47.8\pm9.3$ $42.1\pm9.0$ $m(kg^2)$ $28.8\pm4.1$ $26.2\pm3.3$ $55.5\pm8.0$ $82.3\pm7.4$ $m(kg^2)$ $96.8\pm10.1$ $82.1\pm8.3$ $85.5\pm8.0$ $82.3\pm7.4$ $m(kg^2)$ $65\pm10.1$ $82.2\pm3.3$ $85.3\pm8.0$ $82.3\pm7.4$ $m(kg)$ $76.24$ $787.2$ $71/29$ $79.21$ $m(kg)$ $75\pm10$ $71\pm10$ $69\pm9$ $68\pm9$ $m(kg)$ $75\pm10$ $71\pm10$ $69\pm9$ $68\pm9$ $m(kg)$ $75\pm10$ $71\pm10$ $69\pm9$ $68\pm9$ $m(kg)$ $75\pm10$ $71\pm10$ $61\pm0.3$ $11.1\pm0.3$ $m(kg)$ $53\pm1.10$ $54\pm1.101$ $498.460$ $98\pm0.68$ $m(kg)$ $53\pm1.10$ $54\pm1.101$ $48.645$ $11.51\pm0.33$ $m(kg)$ $1.51\pm0.33$ $1.51\pm0.33$ $1.51\pm0.33$ $1.51\pm0.33$ $m(kg)$ $1.58\pm0.6$	мощеп	<31.0 mL·kg <sup>-1</sup> ·min <sup>-1</sup>	31.1-34.4 mL·kg <sup>-1</sup> ·min <sup>-1</sup>	34.5-37.3 mL·kg <sup>-1</sup> ·min <sup>-1</sup>	37.4-40.7 mL·kg <sup>-1</sup> ·min <sup>-1</sup>	>40.7 mL·kg <sup>-1</sup> ·min <sup>-1</sup>
years) $62.1\pm 9.8$ $550\pm 8.9$ $47.8\pm 9.3$ $42.1\pm 9.0$ $(mkg^2)$ $28.8\pm 1.1$ $26.2\pm 3.3$ $25.3\pm 4.0\pm 2.9$ $24.0\pm 9.2$ $(mkg^2)$ $65\pm 10.1$ $87.3\pm 3.2$ $25.3\pm 4.0\pm 2.9$ $24.0\pm 9.2$ $(m)$ $65\pm 10.1$ $87.2$ $76.2\pm 3.3$ $25.3\pm 4.0\pm 2.9$ $24.0\pm 9.2$ $(m)$ $55\pm 1.0$ $57\pm 1.7$ $76.2\pm 7.7$ $792.1$ $792.1$ $(m)$ $137\pm 1.7$ $127\pm 1.5$ $121\pm 1.3$ $118\pm 1.1$ $(m)$ $5.5\pm 1.0$ $782.2$ $712.9$ $792.1$ $(m)$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.6\pm 0.9$ $(m)$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.9\pm 0.6$ $(m)$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.9\pm 0.6$ $(m)$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.9\pm 0.6$ $(m)$ $5.5\pm 1.0$ $5.5\pm 1.0$ $5.5\pm 0.6$ $5.9\pm 0.6$ $(m)$ $5.5\pm 1.0$ $5.5\pm 0.6$ $5.5\pm 0.6$ $5.8\pm 0.6$ $(m)$ $5.5\pm 0.6$ $1.58\pm 0.6$ $1.58\pm 0.6$ $1.51\pm 0.3$ $(m)$ $5.5\pm 0.6$ $1.5\pm 0.6$ $4.2\pm 5.4$ $0.98\pm 0.41$ $(m)$ $(mkg^3)$ $5.5\pm 0.9$ $4.2\pm 5.4$ $0.98\pm 0.41$ $(mkg^3)$ $61.2\pm 0.3$ $1.5\pm 0.6$ $4.2\pm 5.4$ $0.98\pm 0.41$ $(mkg^3)$ $61.2\pm 0.3$ $1.5\pm 0.2$ $5.5\pm 0.2$ $4.2\pm 5.4$ $(mkg^3)$ $61.2\pm 0.3$ $5.5\pm 0.9$ $4.2\pm 5.4$ $0.98\pm 0.6$ $(mkg^3)$ $61.2\pm 0.3$ $5.5\pm 0.9$ $5.5\pm 0.2$ </td <td><math>VO_{2peak} (mL \cdot kg^{-1} \cdot min^{-1})</math></td> <td><math>28.2 \pm 4.6</math></td> <td>32.4±4.6</td> <td><math>35.4\pm 5.2</math></td> <td><math>38.8\pm5.2</math></td> <td><math>44.4\pm 6.8</math></td>	$VO_{2peak} (mL \cdot kg^{-1} \cdot min^{-1})$	$28.2 \pm 4.6$	32.4±4.6	$35.4\pm 5.2$	$38.8\pm5.2$	$44.4\pm 6.8$
	Age (years)	$62.1 \pm 9.8$	$55.0\pm 8.9$	$47.8 \pm 9.3$	$42.1 \pm 9.0$	$33.9\pm 8.4$
(cm) $96.8\pm10.1$ $88.7\pm8.3$ $85.5\pm8.0$ $82.3\pm7.4$ $gg HR$ (beatsmin') $65\pm10$ $62\pm9$ $60\pm8$ $82\pm8.8$ $58\pm8.8$ sing staus (% no/ves) $76/24$ $78/22$ $71/29$ $79/21$ $79/21$ sing staus (% no/ves) $75\pm10$ $71\pm17$ $127\pm17$ $127\pm16$ $71\pm10$ $99\pm9$ dis BP (mmHg) $55\pm1.0$ $5.3\pm1.0$ $6.31\pm10$ $6.31\pm10$ $69\pm9$ $68\pm9$ fasting glucos (mldl) $5.5\pm1.0$ $5.1\pm10$ $5.1\pm0.9$ $5.0\pm0.9$ $5.0\pm0.9$ fasting glucos (mldl) $5.5\pm1.0$ $5.1\pm10$ $5.1\pm10.3$ $5.9\pm0.3$ $68\pm9.3$ cholesterol $1.51\pm0.37$ $1.51\pm0.34$ $1.51\pm0.35$ $0.08\pm0.41$ distribution $6.21\pm1.0$ $5.5\pm1.0$ $5.1\pm0.34$ $0.98\pm0.41$ cholesterol $1.58\pm0.69$ $1.8\pm0.34$ $0.08\pm0.41$ $0.08\pm0.41$ distribution $0.21\pm1.4$ $0.28\pm0.41$ $0.08\pm0.41$ cholesterol $1.51\pm0.35$ $0.01\pm0.6$ <	BMI (m/kg <sup>2</sup> )	$28.8 \pm 4.1$	$26.2\pm3.3$	$25.3\pm3.4$	$24.0\pm 2.9$	$22.5\pm 2.1$
ng HR (beatsmin <sup>1</sup> )         65±10         62±9         60±8         58±8           ning status (% no/yes)         7624         78/22         71/29         79/21           nic BP (mmHg)         137±17         127±15         121±13         118±11           nic BP (mmHg)         55±1.0         5.3±1.0         5.1±0.9         5.6±0.9           nic BP (mmHg)         5.5±1.0         5.3±1.0         5.1±0.9         5.0±0.9           noisesterol         6.21±1.0         5.3±1.0         5.1±0.9         5.0±0.9           cholesterol         1.520.37         1.51±0.33         113±4.1         151±0.33           cholesterol         1.58±0.69         1.8±0.54         0.8±0.41         151±0.33           serides         1.58±0.69         1.8±0.59         1.17±0.54         0.8±0.41           serides         1.58±0.69         1.8±0.59         1.17±0.54         0.8±0.41           denstrol         1.58±0.69         1.8±0.72         0.40±5.5         0.98±0.41           denstrol         1.58±0.69         1.8±0.54         0.8±0.41         0.8±0.41           endetstrol         1.58±0.69         1.8±0.72         0.40±5.5         0.95±0.4           denstrol         0.11±0.3         3.4.6±5.2	Waist (cm)	$96.8 \pm 10.1$	$88.7\pm 8.3$	$85.5\pm 8.0$	82.3±7.4	$76.1\pm6.4$
cing status (% no/yes) $76/24$ $78/22$ $71/29$ $79/21$ die BP (mmHg) $137\pm17$ $127\pm15$ $121\pm13$ $118\pm11$ die BP (mmHg) $5.5\pm1.0$ $5.3\pm1.0$ $6.9\pm9$ $6.8\pm9$ fasting glucose (m/dl) $5.5\pm1.0$ $5.3\pm1.0$ $5.1\pm0.9$ $5.6\pm0.9$ fasting glucose (m/dl) $5.5\pm1.0$ $5.3\pm1.0$ $5.1\pm0.9$ $5.8\pm9.6$ fasting glucose (m/dl) $5.5\pm1.0$ $5.3\pm1.0$ $5.1\pm0.9$ $5.8\pm0.9$ cholesterol $1.55\pm0.60$ $1.51\pm0.33$ $1.51\pm0.33$ $9.8\pm0.8$ cholesterol $1.55\pm0.60$ $1.51\pm0.34$ $1.51\pm0.33$ $1.51\pm0.33$ scholesterol $1.53\pm0.60$ $1.51\pm0.34$ $1.51\pm0.33$ $1.51\pm0.33$ scholesterol $1.53\pm0.60$ $1.51\pm0.33$ $1.51\pm0.33$ $1.51\pm0.33$ scholesterol $3.8\pm0.65$ $1.33\pm0.34$ $1.51\pm0.33$ $1.51\pm0.33$ scholesterol $3.8\pm0.66$ $1.33\pm0.64$ $1.51\pm0.33$ $1.51\pm0.33$ scholesterol $0.17\pm0.34$ $2.55\pm0.94$	Resting HR (beats min <sup>-1</sup> )	$65{\pm}10$	62±9	60±8	$58\pm 8$	$56\pm 8$
dic BP (mmHg) $137\pm17$ $127\pm15$ $121\pm13$ $118\pm11$ olic BP (mmHg) $75\pm10$ $71\pm10$ $69\pm9$ $68\pm9$ fasting glucose (m/dl) $5.5\pm1.0$ $5.3\pm1.0$ $5.1\pm0.9$ $5.0\pm0.9$ fasting glucose (m/dl) $5.5\pm1.0$ $5.3\pm1.0$ $5.1\pm0.9$ $5.0\pm0.3$ cholesterol $6.21\pm1.0$ $5.90\pm1.11$ $5.1\pm0.35$ $5.0\pm0.3$ cholesterol $1.50\pm0.37$ $1.51\pm0.33$ $1.51\pm0.33$ $1.51\pm0.33$ cholesterol $1.58\pm0.69$ $1.38\pm0.81$ $1.51\pm0.33$ $1.51\pm0.33$ cholesterol $3.45\pm0.81$ $1.17\pm0.54$ $0.98\pm0.41$ $0.58\pm0.41$ actorl $1.92$ $2.52\pm0.99$ $41.2\pm5.4$	Smoking status (% no/yes)	76/24	78/22	71/29	79/21	77/23
olic BP (mmHg) $75\pm10$ $71\pm10$ $71\pm10$ $69\pm9$ $68\pm9$ fasting glucose (m/dl) $5.5\pm1.0$ $5.3\pm1.0$ $5.1\pm0.9$ $5.0\pm0.9$ cholesterol $5.5\pm1.0$ $5.3\pm1.0$ $5.3\pm1.0$ $5.1\pm0.9$ $5.0\pm0.9$ cholesterol $1.50\pm0.37$ $1.51\pm0.34$ $1.51\pm0.35$ $1.51\pm0.33$ cholesterol $1.58\pm0.69$ $1.38\pm0.81$ $1.51\pm0.35$ $1.51\pm0.33$ verides $1.58\pm0.69$ $1.38\pm0.69$ $1.38\pm0.81$ $1.51\pm0.35$ $1.51\pm0.33$ $\sqrt{20intile 1}$ $0.98\pm0.41$ $0.98\pm0.41$ $-38.2 mL+g^{1}-min^{-1}$ $38.3-42.2 mL+g^{-1}-min^{-1}$ $42.3-45.8 mL+g^{1}-min^{-1}$ $45.8-50.3 mL+g^{1}-min^{-1}$ $= (mL+g^{3}^{-}-min^{-1})$ $34.6\pm5.2$ $40.0\pm5.9$ $44.2\pm5.4$ $0.98\pm0.61$ $91.1\pm5.9$ $\sqrt{20}$ $\sqrt{2}$ $29.1\pm3.4$ $27.3\pm3.0$ $26.7\pm2.4$ $48.6\pm0.2$ $\sqrt{2}$ $\sqrt{2}$	Systolic BP (mmHg)	$137\pm 17$	$127\pm 15$	$121\pm 13$	$118\pm 11$	$115\pm10$
fasting glucose (m/dl)5.5±1.05.3±1.05.1±0.95.0±0.9cholesterol $6.21\pm1.0$ $5.90\pm1.11$ $5.41\pm1.01$ $4.98\pm0.89$ cholesterol $1.50\pm0.37$ $1.51\pm0.34$ $1.51\pm0.35$ $1.51\pm0.33$ cholesterol $1.58\pm0.69$ $1.58\pm0.69$ $1.58\pm0.69$ $1.58\pm0.69$ $1.51\pm0.34$ cholesterol $1.58\pm0.69$ $1.58\pm0.69$ $1.58\pm0.69$ $1.51\pm0.34$ $1.51\pm0.35$ verrides $1.58\pm0.69$ $1.58\pm0.69$ $1.38\pm0.81$ $1.17\pm0.54$ $0.98\pm0.41$ $ask$ (mL/kg <sup>-1</sup> min <sup>-1</sup> ) $34.6\pm5.2$ $40.0\pm5.9$ $44.2\pm5.4$ $0.98\pm0.41$ $ask$ (mL/kg <sup>-1</sup> min <sup>-1</sup> ) $34.6\pm5.2$ $40.0\pm5.9$ $48.7\pm9.7$ $44.0\pm8.3$ $ank$ (mL/kg <sup>-1</sup> min <sup>-1</sup> ) $34.6\pm5.2$ $40.0\pm5.9$ $48.7\pm9.7$ $41.0\pm8.3$ $ank$ (mL/kg <sup>-1</sup> min <sup>-1</sup> ) $34.6\pm5.2$ $40.0\pm5.9$ $48.7\pm9.7$ $41.0\pm8.3$ $ank$ (mL/kg <sup>-1</sup> min <sup>-1</sup> ) $34.6\pm5.2$ $40.0\pm5.9$ $48.7\pm9.7$ $41.0\pm8.3$ $ank$ (mL/kg <sup>-1</sup> min <sup>-1</sup> ) $34.6\pm5.2$ $40.0\pm5.9$ $48.7\pm9.7$ $41.0\pm8.3$ $ank$ (mL/kg <sup>-1</sup> min <sup>-1</sup> ) $55.2\pm9.9$ $48.7\pm9.7$ $41.0\pm8.3$ $ank$ (mV/g <sup>2</sup> ) $29.1\pm3.4$ $27.3\pm3.6$ $81.7\pm9.7$ $41.0\pm8.3$ $ank$ (mH/g <sup>2</sup> ) $61.7\pm10.3$ $55.2\pm9.9$ $57\pm8$ $55\pm7.4$ $ank$ (betarmin <sup>-1</sup> ) $62\pm9$ $57\pm8$ $55\pm7.4$ $41.0\pm8.3$ $ank$ (betarmin <sup>-1</sup> ) $62\pm9$ $57\pm8$ $57\pm8$ $55\pm7.4$ $ank$ (mH/g) $80\times10$ $72\pm9$ $77\pm9$ $77\pm9$ $ank$ (m	Diastolic BP (mmHg)	$75\pm10$	$71 \pm 10$	6776	$68 \pm 9$	66±8
cholesterol $6.21\pm1.0$ $5.90\pm1.11$ $5.41\pm1.01$ $4.98\pm0.89$ cholesterol $1.50\pm0.37$ $1.51\pm0.34$ $1.51\pm0.35$ $1.51\pm0.33$ cholesterol $1.56\pm0.37$ $1.51\pm0.34$ $1.51\pm0.35$ $1.51\pm0.33$ vertiles $1.58\pm0.69$ $1.38\pm0.81$ $1.17\pm0.54$ $0.98\pm0.41$ vertiles $2.82\pm0.69$ $1.38\pm0.81$ $1.17\pm0.54$ $0.98\pm0.41$ vertiles $2.38.2  \text{mL·kg}^1  \text{min}^1$ $38.3-42.2  \text{mL·kg}^1  \text{min}^1$ $42.3-45.8  \text{mL·kg}^1  \text{min}^1$ $45.8-50.3  \text{mL/kg}^1  \text{min}^1$ $^{auk} (mL·kg^1  min^{-1})$ $34.6\pm5.2$ $40.0\pm5.9$ $44.2\pm5.4$ $48.6\pm6.2$ $vertiles$ $2.31\pm3.4$ $2.73\pm3.0$ $26.7\pm2.4$ $44.0\pm8.3$ $(m/k_3^2)$ $29.1\pm3.4$ $2.73\pm3.0$ $26.7\pm2.4$ $44.0\pm8.3$ $(m/k_3^2)$ $29.1\pm3.4$ $27.3\pm3.0$ $26.7\pm2.4$ $44.0\pm8.3$ $(m/k_3^2)$ $29.1\pm3.4$ $27.5\pm0.7$ $44.0\pm8.3$ $55\pm1.4$ $(m/k_3^2)$ $10.4$ $131\pm0.7$ $772.2$ $772.4$ $25.6\pm2.4$	Non-fasting glucose (ml/dl)	$5.5 \pm 1.0$	$5.3 \pm 1.0$	$5.1 \pm 0.9$	$5.0 \pm 0.9$	$4.8\pm0.8$
	Total cholesterol	$6.21 \pm 1.0$	$5.90 \pm 1.11$	$5.41\pm1.01$	$4.98 \pm 0.89$	$4.60\pm0.70$
yccrides $1.58\pm0.69$ $1.38\pm0.81$ $1.17\pm0.54$ $0.98\pm0.41$ yccrides $1.58\pm0.69$ $1.38\pm0.69$ $1.38\pm0.81$ $1.17\pm0.54$ $0.98\pm0.41$ Active the the the the the the the the the th	HDL cholesterol	$1.50\pm0.37$	$1.51\pm0.34$	$1.51 \pm 0.35$	$1.51\pm0.33$	$1.54\pm0.30$
Quintile 1Quintile 2Quintile 3Quintile 4 $<38.2 \mathrm{mL}.\mathrm{kg}^{-1}.\mathrm{min}^{-1}$ $38.3.422 \mathrm{mL}.\mathrm{kg}^{-1}.\mathrm{min}^{-1}$ $45.8.50.3 \mathrm{mL}.\mathrm{kg}^{-1}.\mathrm{min}^{-1}$ $<38.2 \mathrm{mL}.\mathrm{kg}^{-1}.\mathrm{min}^{-1}$ $38.3.422 \mathrm{mL}.\mathrm{kg}^{-1}.\mathrm{min}^{-1}$ $42.3.45.8 \mathrm{mL}.\mathrm{kg}^{-1}.\mathrm{min}^{-1}$ $48.66.2$ $\mathrm{var}$ $34.6\pm5.2$ $40.0\pm5.9$ $44.2\pm5.4$ $48.6\pm6.2$ $\mathrm{var}$ $51.7\pm10.3$ $55.2\pm9.9$ $44.2\pm5.4$ $48.6\pm6.2$ $\mathrm{var}$ $29.1\pm3.4$ $27.3\pm3.0$ $26.7\pm2.4$ $48.6\pm6.2$ $\mathrm{var}$ $104.0\pm8.1$ $98.4\pm6.9$ $94.9\pm6.0$ $91.1\pm5.9$ $\mathrm{r}$ $104.0\pm8.1$ $98.4\pm6.9$ $94.9\pm6.0$ $91.1\pm5.9$ $\mathrm{r}$ $104.0\pm8.1$ $98.4\pm6.9$ $57\pm2$ $79.26+2.4$ $\mathrm{r}$ $104.0\pm8.1$ $98.4\pm6.9$ $57\pm2$ $79.26-2.4$ $\mathrm{r}$ $104.0\pm8.1$ $98.4\pm6.9$ $57\pm2$ $77\pm2.9$ $\mathrm{r}$ $80/20$ $78/22$ $77\pm2.4$ $75/25$ $79/21$ $\mathrm{r}$ $139\pm15$ $134\pm14$ $131\pm13$ $129\pm12$ $\mathrm{r}$ $80/20$ $78/22$ $75/25$ $79/21$ $\mathrm{r}$ $80/20$ $79\pm9$ $57\pm40.9$ $77\pm9$ $\mathrm{r}$ $80+10$ $79\pm9$ $77\pm9$ $75\pm9$ $\mathrm{r}$ $5.69\pm1.00$ $5.7\pm20.28$ $1.25\pm0.29$ $\mathrm{r}$ $1.18\pm0.27$ $1.22\pm0.29$ $1.25\pm0.29$ $\mathrm{r}$ $1.25\pm0.29$ $1.25\pm0.29$ $1.25\pm10.09$ $\mathrm{r}$ $1.25\pm0.29$ $1.25\pm0.29$ $1.25\pm10.09$ $\mathrm{r}$ $1.25$	Triglycerides	$1.58 \pm 0.69$	$1.38\pm0.81$	$1.17 \pm 0.54$	$0.98{\pm}0.41$	$0.91 \pm 0.43$
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5
$34.6\pm5.2$ $40.0\pm5.9$ $44.2\pm5.4$ $48.6\pm6.2$ $61.7\pm10.3$ $55.2\pm9.9$ $48.7\pm9.7$ $44.0\pm8.3$ $61.7\pm10.3$ $55.2\pm9.9$ $48.7\pm9.7$ $44.0\pm8.3$ $29.1\pm3.4$ $27.3\pm3.0$ $26.7\pm2.4$ $25.6\pm2.4$ $104.0\pm8.1$ $98.4\pm6.9$ $94.9\pm6.0$ $91.1\pm5.9$ $62\pm9$ $59\pm9$ $57\pm8$ $55\pm7$ $62\pm9$ $59\pm9$ $57\pm8$ $55\pm7$ $80/20$ $78/22$ $75/25$ $79/21$ $139\pm15$ $134\pm14$ $131\pm13$ $129\pm12$ $80\pm10$ $79\pm9$ $77\pm9$ $75\pm9$ $80\pm10$ $79\pm9$ $5.7\pm1.3$ $5.2\pm0.9$ $5.69\pm1.00$ $5.7\pm40.90$ $5.4\pm1.3$ $5.2\pm0.9$ $5.69\pm1.00$ $5.7\pm0.90$ $5.4\pm1.3$ $5.2\pm0.9$ $7.118\pm0.27$ $1.22\pm0.28$ $1.25\pm0.29$ $1.25\pm0.28$	Men	<38.2 mL·kg <sup>-1</sup> ·min <sup>-1</sup>	38.3-42.2 mL·kg <sup>-1</sup> ·min <sup>-1</sup>	42.3-45.8 mL·kg <sup>-1</sup> ·min <sup>-1</sup>	45.8-50.3 mL·kg <sup>-1</sup> ·min <sup>-1</sup>	>50.3 mL·kg <sup>-1</sup> ·min
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	VO <sub>2peak</sub> (mL·kg <sup>-1</sup> ·min <sup>-1</sup> )	34.6±5.2	40.0±5.9	44.2±5.4	48.6±6.2	54.7±6.9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Age (years)	$61.7\pm10.3$	$55.2\pm9.9$	$48.7\pm9.7$	$44.0\pm 8.3$	$34.2\pm10.0$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	BMI (m/kg <sup>2</sup> )	$29.1 \pm 3.4$	$27.3\pm3.0$	$26.7\pm 2.4$	$25.6 \pm 2.4$	$24.1\pm 2.4$
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Waist (cm)	$104.0\pm 8.1$	$98.4\pm 6.9$	$94.9\pm6.0$	$91.1\pm 5.9$	85.3±6.2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Resting HR (beats min <sup>-1</sup> )	$62 \pm 9$	59±9	57±8	55±7	53±8
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Smoking status (% no/yes)	80/20	78/22	75/25	79/21	82/18
(mmHg) $80\pm10$ $79\pm9$ $77\pm9$ $75\pm9$ lucose (m/dl) $6.0\pm2.2$ $5.7\pm2.0$ $5.4\pm1.3$ $5.2\pm0.9$ srol $5.69\pm1.00$ $5.74\pm0.90$ $5.59\pm0.98$ $5.44\pm0.97$ rol $1.18\pm0.27$ $1.22\pm0.28$ $1.25\pm0.29$ $1.25\pm0.28$ rol $2.07\pm1.2$ $2.02\pm1.28$ $1.25\pm0.28$ $1.25\pm0.28$	Systolic BP (mmHg)	$139\pm 15$	$134\pm 14$	$131\pm 13$	$129{\pm}12$	$125 \pm 11$
lucose (ml/dl) $6.0\pm2.2$ $5.7\pm2.0$ $5.4\pm1.3$ $5.2\pm0.9$ srol $5.69\pm1.00$ $5.74\pm0.90$ $5.59\pm0.98$ $5.44\pm0.97$ srol $1.18\pm0.27$ $1.22\pm0.28$ $1.25\pm0.29$ $1.25\pm0.28$ $2.07\pm1.12$ $2.02\pm1.28$ $1.25\pm0.29$ $1.25\pm0.28$	Diastolic BP (mmHg)	$80{\pm}10$	79 <u>+</u> 9	$77\pm9$	75±9	6769
trol $5.69\pm1.00$ $5.74\pm0.90$ $5.59\pm0.98$ $5.44\pm0.97$ trol $1.18\pm0.27$ $1.22\pm0.28$ $1.25\pm0.29$ $1.25\pm0.28$ trol $2.07\pm1.12$ $2.02\pm1.28$ $1.25\pm0.28$	Non-fasting glucose (ml/dl)	$6.0\pm 2.2$	$5.7\pm 2.0$	$5.4\pm 1.3$	$5.2 \pm 0.9$	$5.0 \pm 1.2$
rol         1.18±0.27         1.22±0.28         1.25±0.29         1.25±0.28 $2,07\pm1.12$ $2,02\pm1.28$ $1,02\pm1.00$ $1,25\pm0.28$	Total cholesterol	$5.69{\pm}1.00$	$5.74\pm0.90$	$5.59\pm0.98$	$5.44{\pm}0.97$	$4.74\pm0.93$
2 07±1 12 2 03±1 36 1 82±1 10 1 72±1 00	HDL cholesterol	$1.18 \pm 0.27$	$1.22\pm0.28$	$1.25\pm0.29$	$1.25 \pm 0.28$	$1.28 \pm 0.27$
	Triglycerides	$2.07{\pm}1.12$	$2.03\pm1.38$	$1.82 \pm 1.16$	$1.75\pm 1.00$	$1.26 \pm 0.60$

#### Cross-validity of the model

Given the SEE of the current models (5.7 and 5.1 mL·kg<sup>-1</sup>·min<sup>-1</sup> for men and women, respectively) there is a relatively wide scatter around the line of identity for measured and predicted values. Implicitly, a predicted  $VO_{2peak}$  for an individual will be lower or higher than the true value in most participants. Moreover, the degree of inaccuracy may further increase when a model derived from a given population are applied to a different population. Therefore, different cross-validation techniques are commonly used to estimate how accurately a predictive model will perform in an independent data set. Such methods are important in guarding against a spuriously high model-fit that may appear when multiple predictors are included in a regression model. The problem of over-fitting a model can be detected by simple data-splitting procedures as presented in Paper I. Here, the regression model was developed on a randomly drawn part of the sample and tested on the other half of the sample.

Overall, the cross-validation statistics revealed high model stability as evidenced by small differences between measured and predicted values and relatively stable total error, across subgroups of age and PA levels in both sexes (see Table 5 in Paper I). The model seems to be most accurate among those with a medium fitness level reporting none or mostly low-intensity PA and those who were above 35 years for men and 50 years for women. However, in accordance with previous studies<sup>51,104</sup>, the model tended to overestimate  $VO_{2peak}$  in low-fit subjects and subsequently, underestimate  $VO_{2peak}$  in high-fit subjects. When the model was applied to the cross-validation sample it tended to underestimate and overestimate  $VO_{2peak}$ , respectively, by at average ~4-5 mL·kg<sup>-1</sup>·min<sup>-1</sup> in low- and high-fit men and women.

	Total sample	<60 years	≥60 years
Men			
$Q_1$	<36.1	<38.9	<31.6
$Q_2$	36.1-41.5	38.9-44.2	31.6-34.8
Q3	41.5-46.5	44.3-48.5	34.9-39.1
$Q_4$	46.6-52.0	48.6-53.5	39.2-43.4
Q5	>52.0	>53.5	>43.4
Women			
$Q_1$	<29.1	<31.2	<25.0
$Q_2$	29.1-33.3	31.2-34.9	25.0-27.9
Q3	33.4-37.2	35.0-39.1	28.0-30.7
$Q_4$	37.3-42.0	39.2-43.2	30.8-33.8
Q5	>42.0	>43.2	>33.8

**Table 4:** Age and sex-specific quintile cut-off values for measured  $VO_{2peak}$  (mL·kg<sup>-1</sup>·min<sup>-1</sup>)

Q1-5, quintiles of measured VO2peak

#### Cross-classification

In a health perspective the systematic under-prediction among high-fit subjects may not sustain a pressing problem, because moderate and high fitness is not associated with high disease risk. At the extremes of CRF, such as among heart disease patients or top level endurance athletes, VO<sub>2peak</sub> should be directly measured with regularity because relatively small increments/decrements may have great impact on prognosis or performance<sup>135</sup>. The ability to easily and correctly classify low-fit apparently healthy subjects, however, is of crucial importance since several dose-response studies suggest that the largest increase in risk are between low-fit and medium-fit persons $^{28,39}$ . We evaluated the ability of the non-exercise models to classify an individual's VO<sub>2peak</sub> by cross-classification procedures. In Paper I we show that the model was quite accurate in classifying high- and low-fit subjects since ~90% of the participants were correctly classified into the same or adjacent quartile of measured  $VO_{2peak}$  (see Table 6, Paper I). In practice this implies, given that the quartile cut-points are used, that a woman with a predicted VO<sub>2peak</sub> below 32 mL·kg<sup>-1</sup>·min<sup>-1</sup> probably has a measured VO<sub>2peak</sub> at least below 35 mL·kg<sup>-1</sup>·min<sup>-1</sup> and a man with a predicted value below 40 mL·kg<sup>-1</sup> <sup>1</sup>·min<sup>-1</sup> is very likely to have a measured VO<sub>2peak</sub> below 44 mL·kg<sup>-1</sup>·min<sup>-1</sup>. In a previous study from the HUNT Fitness Study, Aspenes et al. showed that men and women with a measured VO<sub>2peak</sub> below 44 mL·kg<sup>-1</sup>·min<sup>-1</sup> and 35 mL·kg<sup>-1</sup>·min<sup>-1</sup>, respectively, had an increased prevalence of cardiovascular risk factor clustering<sup>27</sup>. Hence, we might be able to capture highrisk subjects by using the right cut-offs. The distribution of some cardiovascular risk factors stratified by quintiles of estimated  $VO_{2peak}$  in the HUNT Fitness Study participants is shown in Table 3. Several clinical cardiovascular risk factors differ in a dose-response manner across estimated  $VO_{2peak}$  categories. In the following we show that the model was reasonably accurate in cross-classifying low-fit subjects into the correct tail of the measured  $VO_{2peak}$  distribution (i.e. 1<sup>st</sup> and 2<sup>nd</sup> quintile). The age- and sex-specific cut-off values for measured  $VO_{2peak}$  in the total sample and men and women above and below 60 years are presented in Table 4.

Table 5 shows cross-classification of low-fit participants (1<sup>st</sup> quintile of measured VO<sub>2neak</sub>) across quintiles of predicted VO<sub>2peak</sub> based on the BMI-model. Hence, the percentages represent the sensitivity of the model to capture those with a low measured VO<sub>2peak</sub>. In the total sample slightly above 40% were correctly classified into the lowest quintile. However, more than 80% were correctly classified within one quintile. Hence, a predicted VO<sub>2peak</sub> below 41.5 and 33.3 mL·kg<sup>-1</sup>·min<sup>-1</sup> in men and women, respectively, would capture most participants with a measured VO<sub>2peak</sub> below 36.1 and 29.1 mL·kg<sup>-1</sup>·min<sup>-1</sup>. Extreme misclassification occurred very rarely as only 2.2 and 3.6% of the low-fit men and women, respectively, were predicted to be in the two highest categories of VO<sub>2peak</sub>. In subgroups the non-exercise model were, as expected, less accurate in classifying low-fit subjects of normal weight and those reporting a high PA level. However, a relatively few subjects fell into these categories (n=63 and n=111 for normal weight men and women, respectively and n=25 and n=23 for highly active men and women in 1<sup>st</sup> quintile of VO<sub>2peak</sub>). On the other hand, the majority of subjects who were predicted to be in the lowest quintile actually had a measured VO<sub>2peak</sub> in the 1<sup>st</sup> (~70% in both men and women) or 2<sup>nd</sup> quintile (>90% in men and women). Only 1-2% of those predicted to have low fitness did actually have a VO<sub>2peak</sub> in the two highest quintiles. Therefore, we can be relatively confident that those with a low predicted VO<sub>2peak</sub> actually has a low VO<sub>2peak</sub> (high positive predictive value). These numbers are in accordance with two previous studies that evaluated the classification accuracy of nonexercise testing<sup>104,136</sup>. Hence, we considered the model as accurate enough to correctly identify low-fit and high-fit subjects in an epidemiological study (Paper III).

		Classification into predicted quintiles (%)						
		Μ	en			Wo	men	
Low measured $VO_{2peak}(Q_1)$	$N^{a}$	$Q_1$	Q <sub>1-2</sub>	Q <sub>4-5</sub>	$N^{a}$	<b>Q</b> <sub>1</sub>	Q <sub>1-2</sub>	Q <sub>4-5</sub>
Total sample	414/2067	41.5	84.0	2.2	439/2193	42.8	80.4	3.6
<60 years <sup>b</sup>	321/1601	45.5	86.0	2.8	349/1745	36.1	73.6	5.5
≥60 years <sup>b</sup>	94/466	50.0	72.3	5.7	90/448	43.3	66.6	15.5
Low activity <sup>c</sup>	247/759	51.8	89.0	1.6	254/795	56.3	87.4	2.0
Moderate activity <sup>c</sup>	142/954	28.2	81.9	2.1	162/1038	26.5	72.2	6.2
High activity <sup>c</sup>	25/354	16.0	48.0	8.0	23/360	8.7	60.9	4.3
Normal weight <sup>d</sup>	63/644	12.7	63.5	4.8	111/1182	13.5	62.1	12.6
Overweight <sup>d</sup>	222/1143	36.5	85.1	2.7	182/733	37.4	78.6	1.1
Obese <sup>d</sup>	129/280	64.3	92.2	0.0	146/278	71.9	96.6	0.0

Table 5: Cross-classification of participants with low measured VO<sub>2peak</sub> into categories of predicted VO<sub>2peak</sub>

 $Q_{1.5}$ , quintiles of predicted  $VO_{2peak}$ <sup>a</sup>number in lowest quintile of  $VO_{2peak}$  and total number in subgroup <sup>b</sup>age-specific quintile from Table 4 <sup>c</sup>Tertiles of PA-Index

<sup>d</sup>BMI <25 (normal), 25-30 (overweight), >30 (obese)

#### Estimated VO<sub>2peak</sub> and mortality

In Paper III we used the non-exercise model of Paper I to estimate VO<sub>2peak</sub> in a large sample of healthy men and women who took part in the first HUNT Study in 1984-85. Furthermore, we assessed the association with all-cause and cardiovascular mortality after ~24 years of follow-up. Previous population-based studies have confirmed that exercise tested CRF is a powerful and independent predictor of premature mortality in asymptomatic populations<sup>24,28,137</sup> and in people with cardiovascular disease<sup>24,34,36,138</sup>. Assuming that the nonexercise model were able to correctly classify VO<sub>2peak</sub> in an independent sample from the HUNT population, we hypothesized an increased risk of mortality among those estimated to have low VO<sub>2peak</sub> at baseline and an overall inverse association between mortality and estimated VO<sub>2peak</sub>.

Indeed, the observed risk reductions associated with higher estimated VO<sub>2peak</sub> in participants below 60 years at baseline, were comparable to those obtained in population based studies that estimated CRF from maximal treadmill tests<sup>24,31</sup>. A meta-analysis by Kodama and co-workers reported a summarized risk reduction for all-cause mortality of 13% per MET (~3.5 mL·kg<sup>-1</sup>·min<sup>-1</sup>) higher CRF<sup>31</sup>. Among the 19 studies that were included, the reported risk reductions ranged from 4 to 26% per MET higher CRF. Hence, our findings of 8-14% reduction in all-cause mortality and 21% reduction in cardiovascular mortality per estimated MET seem to be well within the expected range. In participants below 60 years, we observed a 12 and 17% lower risk of all-cause mortality and ~25% lower risk of cardiovascular mortality in men and women, respectively, with medium CRF compared to those in the lowest quintile. It could be argued, however, that prediction of mortality from a non-exercise model does not provide more information than what is already available from the respective variables included in the model (i.e. age, BMI, PA and RHR). In Paper III, however, we show that estimated VO<sub>2peak</sub> had a better discriminative ability than each of its constituent components separately, also when age was statistically controlled for. This may not be surprising since BMI, PA, RHR are all independent predictors of premature mortality<sup>139-141</sup>. However, estimated VO<sub>2peak</sub> was also a better predictor than a composite score derived from the sum of z-scores for each variable. Consequently, we might propose that the non-exercise model were able to discriminate participants by  $VO_{2peak}$  and therefore might add to the prognostic utility of each separate risk factor.

Only one other study has examined the association between estimated CRF from a non-exercise model and premature mortality. Stamatakis and co-workers used one of the models from Jurca et al. to estimate CRF in 32.319 healthy men and women<sup>142</sup>. In general, their findings of a 12-15% decrease in all-cause and 25-27% decrease in cardiovascular mortality per SD increase in estimated METs (SD was ~1.6-1.7 METs) are close to those obtained in Paper III. That study pooled data from eight different cohorts and had a shorter follow-up time (~9 years). The prognostic utility of non-exercise testing of CRF should be evaluated further in other populations. A few other studies have, however, attempted to predict premature mortality from more simple CRF estimates without performing exercise testing. Among 906 women referred for coronary angiography, maximal METs estimated from the DASI questionnaire predicted adverse cardiovascular events and all-cause mortality<sup>143</sup>. Each estimated MET was associated with an 8% decrease in risk of adverse cardiovascular events and 7% decrease in risk of all-cause mortality. Similarly, a study that estimated METs from the VSAQ questionnaire during a mean follow-up of 4.5 years, reported a 10% survival benefit during per each MET in 1185 men referred for exercise testing for clinical reasons<sup>144</sup>. Moreover, a prospective cohort study including 858 middleaged participants from Scotland found that self-rated fitness were an independent and similarly strong predictor of all-cause mortality as self-rated overall health status<sup>145</sup>. Although the risk reductions reported in these studies were generally lower compared to Paper III and that from Stamatakis et al., and may vary according to baseline hazards, the findings at least suggest that including self-rated fitness levels may increase the accuracy of future nonexercise models and their association with hard endpoints.

### Intensity and volume of physical activity in relation to health outcomes

Today's recommendations for PA allows for shorter total duration of PA spend at vigorous intensities or longer total duration of moderate intensity as long as the total volume exceeds ~500 MET/min per week (minutes per week  $\cdot$  intensity in METs, corresponds to ~1000 kcal). An implication of this statement is that the benefits of higher intensity, as opposed to low or moderate, are attributed essentially to the higher energy expenditure per time unit. However, accumulating evidence from randomized trials indicate that high intensity training may yield health benefits independent of its contribution to the total energy expenditure<sup>85,146</sup>. Some epidemiological evidence are also emerging, including a large prospective cohort study involving 416,175 individuals that were followed for  $\sim 8$  years<sup>86</sup>. In that study, self-reported PA was separated into moderate and vigorous intensity for five different categories of total weekly energy expenditure. For a similar or lower estimated energy expenditure, reporting vigorous intensity activities was associated with lower risk of death from cardiovascular disease, diabetes and all-causes. Moreover, a study of men in the Health Professionals` Follow-up Study found a significantly lower risk of coronary heart disease for vigorous compared to low and moderate intensity after statistically controlling for total energy expenditure<sup>147</sup>. Also, a previous HUNT study showed that a single weekly exercise session of high intensity considerably reduced the risk of cardiovascular mortality compared to no activity, while no additional benefit was observed by increasing the duration or frequency of exercise sessions<sup>148</sup>.

However, it is suggested that self-reported PA by questionnaires are more imprecise in measuring low and moderate intensity exercise (misclassification bias) and we might suspect that most people who are doing vigorous intensity activity also do considerable amounts of moderate intensity activity<sup>95</sup>. Hence, the inability to separate the effects of high and moderate intensity activity in relation to health outcomes has been a problem of observational studies. The incorporation of objective measurement of PA by accelerometers in population based studies, however, may be superior to self-report measures concerning the independent effects of moderate and vigorous intensity PA. Recently, Jansen and Ross showed that vigorous intensity PA measured by accelerometers had a considerably larger influence on metabolic syndrome prevalence compared to moderate intensity PA after controlling for total energy expenditure dose<sup>149</sup>. Intriguingly, ~75 min of vigorous PA had double the benefit of ~150 min of moderate PA when energy expenditure was kept constant.

## Intensity and volume of exercise in relation to peak oxygen uptake (VO<sub>2peak</sub>)


Several short-term randomized controlled trials have indicated that vigorous intensity exercise, relative to the individual's VO<sub>2peak</sub> or maximal heart rate, yield larger improvements in VO<sub>2peak</sub> than moderate intensity exercise for a similar amount of total work performed<sup>150-</sup> <sup>153</sup>. For practical reasons randomized trials generally mimic only two or three out of an infinitely number of possible exercise patterns (i.e. combinations of frequency, duration and intensity) in free-living individuals. Furthermore, such trials are hampered by relatively short follow-up time (solely <1 year, usually 8-12 weeks) and small and/or selected samples. Whether these benefits are maintained over a longer time frame, i.e. over the course of a lifetime, and hence relevant for public health guidelines, is therefore a matter of controversy. On the contrary, observational studies may better capture more permanent PA behavior and provide complementary information on dose-response issues. In Paper II, we cross-sectionally examined how self-reported, freely selected exercise patterns of longer total duration at moderate intensity and shorter durations at vigorous intensity were associated with VO<sub>2peak</sub> in healthy adults. Briefly, similar VO<sub>2peak</sub> was observed in groups approximating those patterns, but considerably higher net estimated energy expenditure were found among the longer duration-moderate intensity groups. Interestingly, however, groups reporting shorter exercise time than recommended (i.e. less than 75 minutes per week, mean ~45-50 minutes) at vigorous intensity, had comparable VO<sub>2peak</sub> values to those in the moderate intensity-long duration groups. Despite this, the energy expenditure was considerably lower than the total recommended volume. Possible dose-response relationships between PA at low, moderate and vigorous intensity and VO<sub>2peak</sub> from these data are shown in Figure 3 and 4. Our observation of substantially higher VO<sub>2peak</sub> levels among those reporting vigorous-intensity, as compared to moderate and low intensity at similar total duration, is in accordance with data from randomized controlled trials<sup>57,76</sup> (Figure 3, see also Figure 1 in Paper II). Although not essentially novel, this information is important since lack of time is one of the most stated barriers to habitual exercise<sup>154,155</sup>. The intensity-dependent associations were, however, attenuated after adjusting for weekly net energy expenditure (Figure 4, see also Figure 2 in Paper II). In men, VO<sub>2peak</sub> was still slightly higher for vigorous intensity PA, as compared to moderate intensity at all total volumes performed. Among women, however, at least the recommended total volume of 1000 kcal·week<sup>-1</sup> seemed to be necessary to achieve benefits from vigorous intensity PA when net energy expenditure was constant between the two intensity groups.

In Paper II we assessed the intensity of exercise using the Borg 6-20 scale. The Borg scale is considered as a valid measure of relative intensity and correlated well with relative VO<sub>2</sub> and heart rate at different stages of incremental treadmill walking or running in the present population. Contrary to the majority of observational studies, intensity of exercise was therefore assessed relative to the individuals` exercise capacity not in absolute MET values<sup>124,125</sup>. This may be more appropriate when the age-span is large and CRF levels differ widely among participants. For example, an absolute intensity of 7 METs (VO<sub>2</sub>~25 mL·kg<sup>-</sup> <sup>1</sup>·min<sup>-1</sup>) corresponded to 82% of VO<sub>2peak</sub>, and 14-15 on the Borg scale (*vigorous* intensity) for an average 60-year-old woman, while it corresponded to only 45% of VO<sub>2peak</sub> and Borg scale 8-9 (low intensity) for a 20-year-old man among the participants in Paper II. Hence, undertaking PA requiring 7 MET may yield a substantially different exercise stimulus at different tails of the CRF distribution. Hence, the perceived exertion of activities requiring a certain absolute intensity may be negatively associated with the individuals` level of CRF<sup>156</sup>. Moreover, it is practically important because current guidelines support perceived exertion as the primary method in exercise prescription<sup>2,140,157</sup>. Paper II was also novel in that we estimated self-reported PA energy expenditure on the basis of the concurrent VO<sub>2</sub> associated with each individual's Borg scale ratings at the incremental treadmill test. Previous studies have provided crude estimates of energy expenditure from self-report data by assigning certain MET values to specific activities based on the compendium by Ainsworth et al<sup>158,159</sup>. Hence, we used a more direct approach in determining individual energy expenditure. However, we acknowledge that people may rate the exertion different in a test setting as compared to recalling usual exercise intensity in daily life. Hence, the estimated energy expenditure may be subject to bias when translating perceived exertion on the treadmill to habitual exercise. However, reporting a shorter total duration and/or lower intensity than recommended was consistently associated with estimated net energy expenditure below 1000 kcal·week<sup>-1</sup>. Moreover, a doubling of total time spent within the different intensity groups was associated with an approximately doubling of net energy expenditure (see Table 4 in Paper II).


The findings in Paper II in no way negate current PA recommendations, but suggest that vigorous relative intensity certainly compensates for lower total exercise time and may also be beneficial to moderate intensity PA at similar net energy expenditure, at least in men and active women. Indeed, the observed differences in VO<sub>2peak</sub> may seem small, but as previously mentioned, a difference of 1 MET (~3.5 mL·kg<sup>-1</sup>·min<sup>-1</sup>) may provide a reduced

38

relative risk of premature mortality in the order of 10-25% which must be considered as a clinically relevant difference<sup>31</sup>. Broadly recommending sporadic vigorous intensity exercise may, however, be controversial due to possible increased risk of musculoskeletal injury and triggering of heart attacks in subgroups with underlying disease<sup>160,161</sup>. Furthermore, the modest estimated energy expenditure in the low volume-vigorous intensity groups may not be sufficient for preventing weight gain<sup>162</sup>. Hence, reducing sedentary time and, accordingly, accumulating low intensity activity through daily life activities should be highly encouraged in addition to exercise training and may yield health benefits independent of increased  $VO_{2peak}$ <sup>163,164</sup>. Furthermore, the results herein may be explained by relatively fit people being more likely to engage in more frequent and/or more vigorous PA. Hence, causality can only be determined by large-scale randomized trials with careful control of exercise behavior and drop-outs.



**Figure 3:** Weekly exercise time and  $VO_{2peak}$  in men and women at different intensities. Low intensity (Borg scale 6-11, ~40-65% of  $VO_{2peak}$ ), moderate intensity (Borg scale 12-13, ~70-72% of  $VO_{2peak}$ ) and vigorous intensity (Borg scale 14-20, >80% of  $VO_{2peak}$ ). The curves were smoothed through the mean  $VO_{2peak}$  for groups reporting different total exercise time at low-, moderate and vigorous intensity, respectively.



**Figure 4:** Total kcal per week spent at exercise and  $VO_{2peak}$  in men and women at different intensities. Moderate intensity (Borg scale 12-13, ~70-72% of  $VO_{2peak}$ ) and vigorous intensity (Borg scale 14-20, >80% of  $VO_{2peak}$ ). The curves were smoothed through the mean  $VO_{2peak}$  for groups with different energy expenditure at moderate and vigorous intensity, respectively.

#### Practical application of the results

The current thesis may provide an opportunity for physicians and other health personnel to put focus also on the individual level of CRF in clinical consultations. The non-exercise model from Paper I can easily be incorporated in computer programs that estimates the CRF level (see <u>www.ntnu.no/cerg/vo2max</u>) or in prediction charts (see Appendix). When a low level of CRF is identified a maximal exercise test using ventilatory gas analysis could be considered to objectively determine VO<sub>2peak</sub> and provide an accurate baseline level before eventually entering a structured exercise program. However, one should be aware that the estimation are limited in capturing individuals who are low-fit despite of being highly active

and of normal weight etc. (potentially so-called non-responders). A conversation about the agreement between self-rated fitness and self-reported exercise patterns may help in detecting these relatively rare cases. Furthermore, focus should be set on the major modifiable determinant of CRF, namely the habitual PA pattern. The current PA recommendations provide a good starting point for such a discussion. The accumulation of 150 minutes of moderate-intensity exercise per week, preferably spread throughout the week, might be sufficient to improve fitness, but at least 75 minutes of vigorous intensity exercise is also satisfactory if time is limited. Precise definitions of frequency, duration and intensity should be provided. Moreover, exercise prescription should be tailored to the individuals` characteristics by taking into account age and baseline CRF, preferably by prescribing exercise intensity on a relative scale and also by considering the accompanying risks of certain activities in high risk groups.

#### Future research

We recognize that the non-exercise models may need further refinement to be applicable for broad implementation in clinical practice. Firstly, it should be externally validated in a different cohort, preferably containing a larger number of high-risk subjects. Secondly, future studies should elucidate whether precision could be increased, without compromising simplicity, by further refinement of the PA variable and potentially including measures of self-rated CRF. Thirdly, longitudinal studies should also examine whether changes in estimated  $VO_{2peak}$  are associated with different health outcomes. The HUNT database may be applicable for such a study if  $VO_{2peak}$  could be estimated with the same model at minimum two time points (i.e. HUNT 1 and 2).

The issue of dose-response between PA and  $VO_{2peak}$  and their relation to different health outcomes also warrants further consideration. Paper II introduces a novel approach to estimate energy expenditure of exercise from the Borg scale in community-dwelling populations that could be used in prospective analysis of PA and future health. Planned follow-up studies of the HUNT Fitness Study population may also unveil how different exercise patterns and  $VO_{2peak}$  interact as prognostic factors for cardiovascular and all-cause mortality as well as more rare outcomes such as specific types of cancers.

41

### **Conclusions**

The current thesis provides an internally well-validated prediction model that could estimate  $VO_{2peak}$  reasonably well without exercise testing on the basis of age, an index of habitual PA, body composition and resting heart rate. Furthermore, we demonstrated that the non-exercise test could predict long-term cardiovascular and all-cause mortality, at least in men and women below 60 years at baseline. Notably, the relative risk reductions were similar to those reported by studies utilizing direct measurement of  $VO_{2peak}$ . Lastly, we provide evidence that exercise patterns in accordance with current recommendations were associated with a beneficial  $VO_{2peak}$  both among participants preferring a high amount at a moderate relative intensity and a lower amount at a vigorous intensity.

# REFERENCES

- **1.** ACSM. *ACSM's guidelines for exercise testing and prescription*. 7 ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2005.
- 2. Garber CE, Blissmer B, Deschenes MR, et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. *Med Sci Sports Exerc.* 2011;43(7):1334-1359.
- **3.** Caspersen C, Powell K, Christenson G. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. *Public Health Rep.* 1985;100(2):126-131.
- **4.** Bassett DR, Howley ET. Limiting factors for maximum oxygen uptake and determinants of endurance performance. *Med Sci Sports Exerc.* 2000;32(1):70.
- 5. Jettè M, Sidney K, Blümchen G. Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. *Clin Cardiol.* 1990;13(8):555-565.
- 6. Beaglehole R, Bonita R, Alleyne G, et al. UN high-level meeting on non-communicable diseases: addressing four questions. *The Lancet.* 2011;378(9789):449-455.
- Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*. 2012;380(9859):2224-2260.
- **8.** Lee I-M, Shiroma E, Lobelo F, Puska P, Blair S, Katzmarzyk P. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *The Lancet*. 2012;380(9838):219-229.
- **9.** Blair S, Sallis R, Hutber A, Archer E. Exercise therapy the public health message. *Scand J Med Sci Sports*. 2012;22(4):24-28.
- **10.** Lee D-C, Sui X, Ortega FB, et al. Comparisons of leisure-time physical activity and cardiorespiratory fitness as predictors of all-cause mortality in men and women. *Br J Sports Med.* 2011;45(6):504-510.
- **11.** Talbot LA, Morrell CH, Metter EJ, Fleg JL. Comparison of cardiorespiratory fitness versus leisure time physical activity as predictors of coronary events in men aged <=65 years and >65 years. *Am J Cardiol.* 2002;89(10):1187-1192.
- **12.** Action plan for the global strategy for the prevention and control of noncommunicable dieseases 2008-2013 Geneva, Switzerland: World Health Organization;2009.
- **13.** *Global recommendations on physical activity for health.* Geneva, Switzerland: World Health Organization;2010.
- 14. EU Physical activity guidelines. Brussels, Belgium: European Union;2008.
- **15.** *Prevention and control of non-communicable diseases: Report of the Secretary-General.* New York, U.S.: United Nations;2011.

- **16.** *Physical Activity and Health: A Report of the Surgeon General.* Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion;1996.
- **17.** Sallis RE. Exercise is medicine and physicians need to prescribe it! *Br J Sports Med.* 2009;43(1):3-4.
- **18.** D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. *Circulation*. 2008;117(6):743-753.
- **19.** Conroy R, Pyorala K, Fitzgerald A, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J.* 2003;24(11):987 1003.
- **20.** Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. *BMJ*. 2007;335(7611):136.
- **21.** Balady GJ, Larson MG, Vasan RS, Leip EP, O'Donnell CJ, Levy D. Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham Risk Score. *Circulation.* 2004;110(14):1920-1925.
- 22. Gulati M, Black HR, Shaw LJ, et al. The prognostic value of a nomogram for exercise capacity in women. *N Engl J Med.* 2005;353(5):468-475.
- **23.** Laukkanen J, Kurl S, Salonen R, Rauramaa R, Salonen J. The predictive value of cardiorespiratory fitness for cardiovascular events in men with various risk profiles: a prospective population-based cohort study. *Eur Heart J*. 2004;25(16):1428-1437.
- 24. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. *N Engl J Med.* 2002;346(11):793-801.
- **25.** Blair S, Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: Current evidence and research issues. *Med Sci Sports Exerc.* 1999;31(11):646-642.
- 26. Coleman KJ, Ngor E, Reynolds K, et al. Initial validation of an exercise "Vital sign" in electronic medical records. *Med Sci Sports Exerc*. 2012;44(11):2071-2076.
- 27. Aspenes S, Nilsen T, Skaug E, et al. Peak oxygen uptake and cardiovascular risk factors in 4631 healthy women and men. *Med Sci Sports Exerc.* 2011;43(8):1465-1473.
- **28.** Blair S, Kohl 3rd H, Paffenbarger Jr R, Clark D, Cooper K, Gibbons L. Physical fitness and allcause mortality. A prospective study of healthy men and women. *JAMA*. 1989;262(17):2395-2402.
- **29.** Church T, Cheng Y, Earnest C, et al. Exercise capacity and body composition as predictors of mortality among men with diabetes. *Diabetes Care*. 2004;27:83 88.
- **30.** Myers J, Kaykha A, George S, et al. Fitness versus physical activity patterns in predicting mortality in men. *Am J Med.* 2004;117(12):912-918.
- **31.** Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of allcause mortality and cardiovascular events in healthy men and women: A meta-analysis. *JAMA*. 2009;301(19):2024-2035.

- **32.** Kaminsky LA, Arena R, Beckie TM, et al. The importance of cardiorespiratory fitness in the United States: The need for a national registry: A policy statement from the American Heart Association. *Circulation*. 2013;127(5):652-662.
- **33.** Laukkanen J, Lakka T, Rauramaa R, et al. Cardiovascular fitness as a predictor of mortality in men. *Arch Intern Med.* 2001;161(6):825-831.
- **34.** Kokkinos P, Myers J, Kokkinos JP, et al. Exercise capacity and mortality in black and white men. *Circulation*. 2008;117(5):614-622.
- **35.** Lee I-M, Sesso H, Oguma Y, Paffenbarger R, Jr. Relative intensity of physical activity and risk of coronary heart disease. *Circulation*. 2003;107(8):1110-1116.
- **36.** Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in women: The St James Women Take Heart Project. *Circulation*. 2003;108(13):1554-1559.
- **37.** Manson J, Greenland P, LaCroix A, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. *N Engl J Med.* 2002;347:716 725.
- **38.** Lakka TA, Venalainen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men. *N Engl J Med.* 1994;330(22):1549-1554.
- **39.** Williams PT. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. *Med Sci Sports Exerc*. 2001;33(5):754-761.
- **40.** Kokkinos P, Myers J, Faselis C, et al. Exercise capacity and mortality in older men: A 20-Year follow-up study. *Circulation*. 2010;122(8):790-797.
- **41.** Church T, Kampert J, Gibbons L, Barlow C, Blair S. Usefulness of cardiorespiratory fitness as a predictor of all-cause and cardiovascular disease mortality in men with systemic hypertension. *Am J Cardiol.* 2001;88(6):651-656.
- **42.** Sassen B, Cornelissen VA, Kiers H, Wittink H, Kok G, Vanhees L. Physical fitness matters more than physical activity in controlling cardiovascular disease risk factors. *Eur J Cardiovasc Prev Rehabil.* 2009;16(6):677-683.
- **43.** Balady GJ, Arena R, Sietsema K, et al. Clinician's guide to cardiopulmonary exercise testing in adults: A scientific statement from the American Heart Association. *Circulation*. 2010;122(2):191-225.
- 44. Howley ET, Bassett DR, Welch HG. Criteria for maximal oxygen uptake: review and commentary. *Med Sci Sports Exerc.* 1995;27(9):1292-1301.
- **45.** Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. *Am Heart J.* 1973;85(4):546-562.
- **46.** Åstrand P-O, Ryhming I. A nomogram for calculation of aerobic capacity (physical fitness) from pulse rate during submaximal work. *J Appl Physiol*. 1954;7(2):218-221.
- 47. Siconolfi SF, Garber CE, Lasater TM, Carleton RA. A simple, valid step test for estimating maximal oxygen uptake in epidemiologic studies. *Am J Epidemiol*. 1985;121(3):382-390.
- **48.** Leon AS, Jacobs DR, Debacker G, Taylor HL. Relationship of physical characteristics and life habits to treadmill exercise capacity. *Am J Epidemiol*. 1981;113(6):653-660.

- **49.** Siconolfi SF, Lasater TM, Snow RC, Carleton RA. Self-reported physical activity compared with maximal oxygen uptake. *Am J Epidemiol.* 1985;122:101 105.
- **50.** Blair S, Kannel W, Kohl H, Goodyear N, Wilson P. Surrogate measures of physical activity and physical fitness: evidence for sedentary traits of resting tachycardia, obesity and low vital capacity. *Am J Epidemiol.* 1989;129(6):1145-1156.
- **51.** Jackson AS, Blair SN, Mahar MT, Wier LT, Ross RM, Stuteville JE. Prediction of functional aerobic capacity without exercise testing. *Med Sci Sports Exerc.* 1990;22(6):863-870.
- Williford HN, Scharff-Olson M, Wang N, Blessing DL, Smith FH, Duey WJ. Cross-validation of non-exercise predictions of VO<sub>2peak</sub> in women. *Med Sci Sports Exerc.* 1996;28(7):926-930.
- **53.** Kolkhorst FW, Dolgener FA. Nonexercise model fails to predict aerobic capacity in college students with high VO<sub>2peak</sub>. *Res Q Exerc Sport.* 1994;65(1):78-83.
- 54. Jurca R, Jackson AS, LaMonte MJ, et al. Assessing cardiorespiratory fitness without performing exercise testing. *Am J Prev Med.* 2005;29(3):185-193.
- **55.** Mailey E, White S, Wojcicki T, Szabo A, Kramer A, McAuley E. Construct validation of a nonexercise measure of cardiorespiratory fitness in older adults. *BMC Public Health*. 2010;10(1):59.
- 56. Oja P. Dose response between total volume of physical activity and health and fitness. *Med Sci Sports Exerc.* 2001;33(6):S428-S437.
- **57.** Talbot LA, Metter EJ, Fleg JL. Leisure-time physical activities and their relationship to cardiorespiratory fitness in healthy men and women 18-95 years old. *Med Sci Sports Exerc*. 2000;32(2):417-425.
- **58.** Tager IB, Hollenberg M, Satariano WA. Association between self-reported leisure-time physical activity and measures of cardiorespiratory fitness in an elderly population. *Am J Epidemiol.* 1998;147(10):921-931.
- 59. Jackson AS, Wier LT, Ayers GW, Beard EF, Stuteville JE, Blair SN. Changes in aerobic power of women, ages 20-64 yr. *Med Sci Sports Exerc.* 1996;28(7):884-891.
- **60.** Laukkanen J, Laaksonen D, Lakka T, et al. Determinants of cardiorespiratory fitness in men aged 42 to 60 years with and without cardiovascular disease. *Am J Cardiol.* 2009;103(11):1598-1604.
- **61.** Blair S, Cheng Y, Holder J. Is physical activity or physical fitness more important in defining health benefits? *Med Sci Sports Exerc.* 2001;33:S379 S399.
- **62.** Vanhees L, Lefevre J, Philippaerts R, et al. How to assess physical activity? How to assess physical fitness? *Eur J Cardiovasc Prev Rehabil.* 2005;12(2):102-114.
- **63.** Arena R, Myers J, Williams MA, et al. Assessment of functional capacity in clinical and research settings: A scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. *Circulation.* 2007;116(3):329-343.
- **64.** Troiano R, Berrigan D, Dodd K, Masse L, Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. *Med Sci Sports Exerc.* 2008;40:181 188.

- **65.** Hansen BH, Kolle E, Dyrstad SM, Holme I, Anderssen SA. Accelerometer-determined physical activity in adults and older people. *Med Sci Sports Exerc.* 2012;44(2):266-272.
- **66.** Schmidt MD, Cleland VJ, Thomson RJ, Dwyer T, Venn AJ. A comparison of subjective and objective measures of physical activity and fitness in identifying associations with cardiometabolic risk factors. *Ann Epidemiol.* 2008;18(5):378-386.
- **67.** Nokes N. Relationship between physical activity and aerobic fitness. *J Sports Med Phys Fitness*. 2009;49(2):136-141.
- **68.** Dvorak RV, Tchernof A, Starling RD, Ades PA, DiPietro L, Poehlman ET. Respiratory fitness, free living physical activity, and cardiovascular disease risk in older individuals: A doubly labeled water study. *J Clin Endocrinol Metab.* 2000;85(3):957-963.
- **69.** Swain DP, Franklin BA. VO<sub>2</sub> reserve and the minimal intensity for improving cardiorespiratory fitness. *Med Sci Sports Exerc.* 2002;34(1):152-157.
- **70.** Earnest C, Blair S, Church T. Age attenuated response to aerobic conditioning in postmenopausal women. *Eur J Appl Physiol.* 2010;110(1):75-82.
- **71.** Skinner JS, Jaskolski A, Jaskolska A, et al. Age, sex, race, initial fitness, and response to training: the HERITAGE Family Study. *J Appl Physiol*. 2001;90(5):1770-1776.
- **72.** Bouchard C, Daw E, Rice T, et al. Familial resemblance for VO<sub>2max</sub> in the sedentary state: the HERITAGE family study. *Med Sci Sports Exerc.* 1998;30:252 258.
- **73.** Bouchard C, Rankinen T. Individual differences in response to regular physical activity. *Med Sci Sports Exerc.* 2001;33(6):S446-S451.
- **74.** Bouchard C, Sarzynski MA, Rice TK, et al. Genomic predictors of the maximal O<sub>2</sub> uptake response to standardized exercise training programs. *J Appl Physiol.* 2011;110(5):1160-1170.
- **75.** Siconolfi SF, Lasater TM, Snow RCK, Carleton RA. Self-reported physical activity compared with maximal oxygen uptake. *Am J Epidemiol.* 1985;122(1):101-105.
- **76.** Aadahl M, Kjaer M, Kristensen JH, Mollerup B, Jorgensen T. Self-reported physical activity compared with maximal oxygen uptake in adults. *Eur J Cardiovasc Prev Rehabil.* 2007;14(3):422-428.
- 77. *Norske anbefalinger for ernæring og fysisk aktivitet*. Oslo, Norway: Helsedirektoratet (Norwegian Directorate of Health);2005.
- **78.** Mazzeo RS, Cavanagh P, Evans WJ, et al. ACSM Position Stand: Exercise and Physical Activity for Older Adults. *Med Sci Sports Exerc.* 1998;30(6):992-1008.
- **79.** Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in older adults: Recommendation from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc.* 2007;39(8):1435-1445.
- 80. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2012;126(25):354-471.

- **81.** Haskell WL, Lee I-M, Pate RR, et al. Physical activity and public health: Updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc.* 2007;39(8):1423-1434.
- **82.** ACSM. The recommended quantity and quality of exercise for developing and maintaining fitness in healthy adults. *Med Sci Sports*. 1978;10:vii-x.
- **83.** Lee I-M, Blair S, Manson J, Paffenbarger R. *Epidemiologic methods in physical activity studies*. Oxford New York: Oxford University Press; 2009.
- **84.** Lee I-M, Rexrode K, Cook N, Manson J, Buring J. Physical activity and coronary heart disease in women: Is "No pain, no gain" passe? *JAMA*. 2001;285(11):1447-1454.
- **85.** Tjonna AE, Lee SJ, Rognmo O, et al. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: A pilot study. *Circulation*. 2008;118(4):346-354.
- **86.** Wen CP, Wai JPM, Tsai MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. *The Lancet*. 2011;378(9798):1244-1253.
- **87.** Krokstad S, Knudtsen M. *Public health development. The HUNT Study, Norway:* HUNT Research Centre;2011.
- **88.** Aspenes S, Nilsen T, Skaug E, et al. Peak oxygen uptake and cardiovascular risk factors in 4,631 healthy women and men. *Med Sci Sports Exerc.* 2011;43(8):1465-1473.
- **89.** Rognmo Ø, Hetland E, Helgerud J, Hoff J, Slørdahl SA. High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. *Eur J Cardiovasc Prev Rehabil.* 2004;11(3):216-222.
- 90. Borg G. Perceived exertion. Exerc Sport Sci Rev. 1974;2:131-153.
- **91.** Whaley MH, Brubaker PH, Kaminsky LA, Miller CR. Validity of rating of perceived exertion during graded exercise testing in apparently healthy adults and cardiac patients. *J Cardiopulm Rehabil Prev.* 1997;17(4):261-267.
- 92. Rothman K, Greenland S, Lash T. *Modern Epidemiology*. 3 ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2008.
- **93.** Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. *BMC Med Res Methodol.* 2012;12(1):143.
- **94.** Tucker JM, Welk GJ, Beyler NK. Physical activity in U.S. adults: Compliance with the Physical Activity Guidelines for Americans. *Am J Prev Med.* 2011;40(4):454-461.
- **95.** Duncan GE, Sydeman SJ, Perri MG, Limacher MC, Martin AD. Can sedentary adults accurately recall the intensity of their physical activity? *Prev Med.* 2001;33(1):18-26.
- **96.** Kurtze N, Rangul V, Hustvedt B-E, Flanders WD. Reliability and validity of self-reported physical activity in the Nord-Trøndelag Health Study: HUNT 1. *Scand J Public Health*. 2008;36(1):52-61.

- **97.** Shiroma EJ, Lee IM. Physical activity and cardiovascular health: Lessons learned from epidemiological studies across age, gender, and race/ethnicity. *Circulation*. 2010;122(7):743-752.
- **98.** Kelley GA, Kelley KA, Tran ZV. Aerobic exercise and resting blood pressure: A meta-analytic review of randomized, controlled trials. *Prev Cardiol.* 2001;4(2):73-80.
- **99.** Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. *The Lancet*. 2000;356(9246):1955-1964.
- 100. Holmen J, Midthjell K, Kruger O, Langhammer A, Holmen T, Bratberg G. The Nord-Trondelag Health Study 1995-97 (HUNT2): objectives, contents, methods and participation. Nor J Epidemiol. 2003;13(1):19-32.
- **101.** Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. *N Engl J Med.* 1993;328(8):533-537.
- **102.** Fitzgerald MD, Tanaka H, Tran ZV, Seals DR. Age-related declines in maximal aerobic capacity in regularly exercising vs. sedentary women: A meta-analysis. *J Appl Physiol*. 1997;83(1):160-165.
- **103.** Zhang J-G, Ohta T, Ishikawa-Takata K, Tabata I, Miyashita M. Effects of daily activity recorded by pedometer on peak oxygen consumption (VO<sub>2peak</sub>), ventilatory threshold and leg extension power in 30- to 69-year-old Japanese without exercise habit. *Eur J Appl Physiol.* 2003;90(1-2):109-113.
- Matthews CE, Heil DP, Freedson PS, Pastides H. Classification of cardiorespiratory fitness without exercise testing. *Med Sci Sports Exerc.* 1999;31(3):486-493.
- **105.** Malek M, Berger D, Coburn J. On the inappropriateness of stepwise regression analysis for model building and testing. *Eur J Appl Physiol*. 2007;101(2):263-264.
- **106.** Slinker B, Glantz S. Multiple linear regression: Accounting for multiple simultaneous determinants of a continous dependent variable. *Circulation*. 2008;117(13):1732-1737.
- **107.** Pedhazur E. *Multiple Regression in Behavioural Research: Explanation and prediction.* 2 ed. New York: Holt, Rinehart and Winston; 1982.
- 108. Malek MH, Housh TJ, Berger DE, Coburn JW, Beck TW. A new non-exercise based VO<sub>2max</sub> prediction equation for aerobically trained men. J Strength Cond Res. 2005;19(3):559-565.
- 109. Rosner B. Fundamentals of Biostatistics. 6 ed. Belmont, CA: Thomson; 2006.
- 110. D'Agostino RB, Nam B-H. Evaluation of the performance of survival analysis models: Discrimination and calibration measures. In: Balakrishnan N, Rao CR, eds. *Handbook of Statistics*. Vol 23: Elsevier; 2003:1-25.
- Whaley MH, Kaminsky LA, Dwyer GB, Getchell LH. Failure of predicted VO<sub>2peak</sub> to discriminate physical fitness in epidemiological studies. *Med Sci Sports Exerc.* 1995;27(1):85-91.
- **112.** Heil DP, Freedson PS, Ahlquist LE, Price J, Rippe JM. Nonexercise regression models to estimate peak oxygen consumption. *Med Sci Sports Exerc.* 1995;27(4):599-606.

- 113. Bradshaw DID, George JDJ, Hyde AA, et al. An accurate VO<sub>2max</sub> nonexercise regression model for 18-65-year-old adults. *Res Q Exerc Sport*. 2005;76(4):426-432.
- **114.** Maxwell S. Sample size and multiple regression analysis. *Psychological Methods*. 2000;5:434-458.
- **115.** Wier LT, Jackson AS, Ayers GW, Arenare B. Nonexercise models for estimating VO<sub>2max</sub> with waist girth, percent fat, or BMI. *Med Sci Sports Exerc.* 2006;38(3):555-561.
- **116.** Cao Z-B, Miyatake N, Higuchi M, Miyachi M, Ishikawa-Takata K, Tabata I. Predicting VO<sub>2max</sub> with an objectively measured physical activity in Japanese women. *Med Sci Sports Exerc*. 2010;42(1):179-186.
- **117.** Cao Z-B, Miyatake N, Higuchi M, Miyachi M, Tabata I. Predicting VO<sub>2max</sub> with an objectively measured physical activity in Japanese men. *Eur J Appl Physiol.* 2010;109(3):465-472.
- **118.** Plasqui G, Bonomi AG, Westerterp KR. Daily physical activity assessment with accelerometers: new insights and validation studies. *Obesity Reviews*. 2013;14(6):451-462.
- **119.** Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status Index). *Am J Cardiol.* 1989;64(10):651-654.
- **120.** Myers J, Bader D, Madhavan R, Froelicher V. Validation of a specific activity questionnaire to estimate exercise tolerance in patients referred for exercise testing. *Am Heart J*. 2001;142(6):1041-1046.
- **121.** Lakoski SG, Barlow CE, Farrell SW, Berry JD, Morrow Jr JR, Haskell WL. Impact of body mass index, physical activity, and other clinical factors on cardiorespiratory fitness (from the Cooper Center Longitudinal Study). *Am J Cardiol.* 2011;108(1):34-39.
- **122.** Jackson AS, Sui X, O'Connor DP, et al. Longitudinal cardiorespiratory fitness algorithms for clinical settings. *Am J Prev Med.* 2012;43(5):512-519.
- **123.** Léger LA, Mercier D, Gadoury C, Lambert J. The multistage 20 metre shuttle run test for aerobic fitness. *J Sports Sci.* 1988;6(2):93-101.
- **124.** Léger LA, Lambert J. A maximal multistage 20-m shuttle run test to predict VO<sub>2max</sub>. *Eur J Appl Physiol Occup Physiol.* 1982;49(1):1-12.
- **125.** Kline G, Porcari J, Hintermeister R, et al. Estimation of VO<sub>2max</sub> from a one-mile track walk, gender, age, and body weight. *Med Sci Sports Exerc.* 1987;19:253 259.
- **126.** Foster C, Jackson AS, Pollock ML, et al. Generalized equations for predicting functional capacity from treadmill performance. *American Heart Journal*. 1984;107(6):1229-1234.
- 127. Ebbeling C, Ward A, Puleo E, Widrick J, Rippe J. Development of a single-stage submaximal treadmill walking test. *Med Sci Sports Exerc.* 1991;23(8):966-973.
- **128.** Waddoups L, Wagner D, Fallon J, Heath E. Validation of a single-stage submaximal treadmill walking test. *J Sports Sci.* 2008;26(5):491-497.
- **129.** Cink R, Thomas T. Validity of the Astrand-Ryhming nomogram for predicting maximal oxygen intake. *Br J Sports Med.* 1981;15(3):182-185.

- **130.** Greiwe J, Kaminsky L, Whaley M, Dwyer G. Evaluation of the ACSM submaximal ergometer test for estimating VO<sub>2max</sub>. *Med Sci Sports Exerc.* 1995;27(9):1315-1320.
- **131.** Balke B, Ware R. An experimental study of physical fitness of Air Force personnel. US Armed Forces Med J. 1959;10(6):675.
- **132.** Foster C, Jackson AS, Pollock ML, et al. Generalized equations for predicting functional capacity from treadmill performance. *Am Heart J.* 1984;107(6):1229 -1234.
- **133.** Fleg JL, Morrell CH, Bos AG, et al. Accelerated longitudinal decline of aerobic capacity in healthy older adults. *Circulation*. 2005;112(5):674-682.
- **134.** Jackson AS, Sui X, Hebert JR, Church TS, Blair SN. Role of lifestyle and aging on the longitudinal change in cardiorespiratory fitness. *Arch Intern Med.* 2009;169(19):1781-1787.
- **135.** Swank AM, Horton J, Fleg JL, et al. Modest increase in peak VO<sub>2</sub> is related to better clinical outcomes in chronic heart failure patients: Results from heart failure and a controlled trial to investigate outcomes of exercise training. *Circ Heart Fail*. 2012;5(5):579-585.
- **136.** Suminski RR, Wier LT, Poston W, Arenare B, Randles A, Jackson AS. The effect of habitual smoking on measured and predicted VO<sub>2max</sub>. *J Phys Act Health*. 2009;6(5):667-673.
- **137.** Sui X, LaMonte MJ, Blair SN. Cardiorespiratory fitness as a predictor of nonfatal cardiovascular events in asymptomatic women and men. *Am J Epidemiol.* 2007;165(12):1413-1423.
- **138.** Keteyian SJ, Brawner CA, Savage PD, et al. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. *Am Heart J.* 2008;156(2):292-300.
- **139.** Nauman J, Janszky I, Vatten LJ, Wisløff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. *JAMA*. 2011;306(23):2579-2587.
- **140.** Lee I-M, Hsieh C, Paffenbarger RS, Jr. Exercise intensity and longevity in men: The Harvard Alumni Health Study. *JAMA*. 1995;273(15):1179-1184.
- 141. Flegal K, Kit B, Orpana H, Graubard B. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis. *JAMA*. 2013;309(1):71-82.
- **142.** Stamatakis E, Hamer M, O'Donovan G, Batty GD, Kivimaki M. A non-exercise testing method for estimating cardiorespiratory fitness: associations with all-cause and cardiovascular mortality in a pooled analysis of eight population-based cohorts. *Eur Heart J.* 2012;34(10):750-758.
- **143.** Wessel T, Arant C, Olson M, et al. Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. *JAMA*. 2004;292(10):1179-1187.
- 144. McAuley P, Myers J, Abella J, Froelicher V. Evaluation of a specific activity questionnaire to predict mortality in men referred for exercise testing. *Am Heart J*. 2006;151(4):890.e891-890.e897.
- 145. Phillips AC, Der G, Carroll D. Self-reported health, self-reported fitness, and all-cause mortality: Prospective cohort study. *Br J Health Psychol.* 2010;15(2):337-346.
- **146.** Molmen-Hansen HE, Stolen T, Tjonna AE, et al. Aerobic interval training reduces blood pressure and improves myocardial function in hypertensive patients. *Eur J Prev Cardiol*. 2012;19(2):151-160.

- 147. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. *JAMA*. 2002;288(16):1994-2000.
- **148.** Wisløff U, Nilsen TI, Drøyvold WB, Mørkved S, Slørdahl SA, Vatten LJ. A single weekly bout of exercise may reduce cardiovascular mortality: how little pain for cardiac gain? 'The HUNT study, Norway'. *Eur J Cardiovasc Prev Rehabil.* 2006;13.
- **149.** Janssen I, Ross R. Vigorous intensity physical activity is related to the metabolic syndrome independent of the physical activity dose. *Int J Epidemiol.* 2012;41(4):1132-1140.
- 150. Gormley SE, Swain DP, High R, et al. Effect of intensity of aerobic training on VO<sub>2max</sub>. Med Sci Sports Exerc. 2008;40(7):1336-1343.
- **151.** Helgerud J, Høydal K, Wang E, et al. Aerobic high-intensity intervals improve VO<sub>2max</sub> more than moderate training. *Med Sci Sports Exerc*. 2007;39(4):665-671.
- **152.** Duncan GE, Anton SD, Sydeman SJ, et al. Prescribing exercise at varied levels of intensity and frequency: A randomized trial. *Arch Intern Med.* 2005;165(20):2362-2369.
- **153.** Duscha BD, Slentz CA, Johnson JL, et al. Effects of exercise training amount and intensity on peak oxygen consumption in middle-age men and women at risk for cardiovascular disease. *Chest.* 2005;128(4):2788-2793.
- **154.** Wolin K, Bennett G, McNeill L, Sorensen G, Emmons K. Low discretionary time as a barrier to physical activity and intervention uptake. *Am J Health Behav.* 2008;32(6):563-569.
- **155.** Sallis JF, Hovell MF. Determinants of exercise behaviour. *Exerc Sport Sci Rev.* 1990;18(1):307-330.
- **156.** Aadahl M, Kjær M, Jørgensen T. Perceived exertion of physical activity: Negative association with self-rated fitness. *Scand J Public Health.* 2007;35(4):403-409.
- **157.** Lee I-M, Paffenbarger R, Jr. Associations of light, moderate, and vigorous intensity physical activity with longevity: The Harvard Alumni Health Study. *Am J Epidemiol.* 2000;151(3):293-299.
- **158.** Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of physical activities: A second update of codes and MET values. *Med Sci Sports Exerc*. 2011;43(8):1575-1581.
- **159.** Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of Physical Activities: an update of activity codes and MET intensities. *Med Sci Sports Exerc*. 2000;32(9):S498-S516.
- 160. Hootman JM, Macera CA, Ainsworth BE, Addy CL, Martin M, Blair SN. Epidemiology of musculoskeletal injuries among sedentary and physically active adults. *Med Sci Sports Exerc*. 2002;34(5):838-844.
- **161.** Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion -- protection against triggering by regular exertion. *N Engl J Med.* 1993;329(23):1677-1683.
- **162.** Lee I-M, Djousse L, Sesso H, Wang L, Buring J. Physical activity and weight gain prevention. *JAMA*. 2010;303(12):1173-1179.
- **163.** Healy G, Dunstan D, Salmon J, et al. Breaks in sedentary time: beneficial associations with metabolic risk. *Diabetes Care*. 2008;31(4):661-666.

**164.** Swift DL, Johannsen NM, Tudor-Locke C, et al. Exercise training and habitual physical activity: A randomized controlled trial. *Am J Prev Med.* 2012;43(6):629-635.

# PAPER I

Nes, BM, Janszky, I, Vatten, LJ, Nilsen, TIL, Aspenes, ST & Wisløff, U. (2011) Estimating  $VO_{2peak}$  from a non-exercise prediction model: The HUNT Study, Norway. *Medicine & Science in Sports & Exercise*. **43**(11):2024-2030

Is not included due to copyright

# **PAPER II**

Nes, BM, Janszky, I, Bertheussen, GF, Aspenes, ST, Vatten, LJ, & Wisløff, U. (2012) Exercise patterns and peak oxygen uptake in a healthy population: The HUNT Study. *Medicine & Science in Sports & Exercise*. **44**(10):1881-1889

Is not included due to copyright

# PAPER III

Nes, BM, Vatten, LJ, Nauman, J, Janszky, I & Wisløff, U. (2013) Estimated cardiorespiratory fitness as a predictor of long-term all-cause and cardiovascular disease mortality: the HUNT study in Norway. *Medicine & Science in Sports & Exercise. Accepted for publication.* 

Is not included due to copyright

## **APPENDIX**

- 1. Prediction chart for estimation of  $VO_{2peak}$
- Questionnaire used in Paper I, HUNT 3 (2006-08)
   Questionnaire used in Paper II, The HUNT Fitness Study
- 4. Information used in Paper II, The HUNT Fitness Study
- 5. Questionnaire used in Paper III, HUNT 1 (1984-86)

## **STEP 1**


#### PHYSICAL ACTIVITY INDEX

Choose the option that best matches your usual exercise habits. Examples of exercise can be walking, skiing, cycling, swimming and indoor or outdoor sports.

#### How often do you exercise?

Never or less than once per week	0
Once a week	1
Two to three times a week	2
Almost every day	3
How hard do you usually push yourself?	*
I take it easy without losing my breath or breaking into sweat	0
I lose my breath and break into sweat	5
Almost to exhaustion	10
For how long do usually exercise?	*
Less than 30 minutes per session	1
More than 30 minutes per session	1.5
Your physical activity index score:	15

## STEP 2



# **Invitasjon til HUNT 3**

Viktig Enkelt Gratis

Du inviteres herved til å delta i den tredje store Helseundersøkelsen i Nord-Trøndelag (HUNT 3). Ved å delta får du en enkel undersøkelse av din egen helse, og du gir samtidig et viktig bidrag til medisinsk forskning.

Hver deltaker er like viktig, enten du er ung eller gammel, frisk eller syk, er HUNTveteran eller møter for første gang. Tilsvarende undersøkelse er tidligere gjennomført i 1984-86 (HUNT 1) og 1995-97 (HUNT 2 og Ung-HUNT). For å kunne studere årsaker til sykdom, er det viktig at også de som tidligere har deltatt møter fram.

#### Vennligst fyll ut spørreskjemaet, og ta det med når du møter til undersøkelse.

Undersøkelsen tar vanligvis ca 1/2 time. Du vil få brev med resultater fra dine prøver etter noen uker. Dersom noen av resultatene er utenom det normale, vil du bli anbefalt undersøkelse hos fastlegen din.

Du kan lese mer om HUNT 3 i den vedlagte brosjyren eller på www.hunt.ntnu.no. Har du spørsmål, kan du også ringe til HUNT forskningssenter, tlf 74075180.

## Vel møtt til undersøkelsen!

Vennlig hilsen

Steinar Krokstad

Steinar Krokstad Førsteamanuensis Prosjektleder HUNT 3

ð Muu Jostein Holmen Professor, daglig leder HUNT forskningssenter

A. Slardahl

Stig A. Slørdahl Professor, dekanus Det medisinske fakultet, NTNU

## Tid og sted for oppmøte

Dersom det foreslåtte tidspunktet ikke passer for deg, behøver du ikke bestille ny time. Du kan møte når det passer deg innenfor åpningstiden, men det kan da bli noe ventetid. Du kan også møte i en annen kommune, hvis det skulle passe bedre. Takk for at du deltar!

## Åpningstida:

hunt 3 Helseundersøkelsen i Nord-Trøndelag

# NTNU HUNT forskningssenter









# Slik fyller du ut skjemaet

- Skjemaet vil bli lest maskinelt.
- Det er derfor viktig at du krysser av riktig: Rett 🗵 🛛 Galt 💢 🗸
- Krysser du feil sted, retter du ved å fylle boksen slik:
- Skriv tydelige tall: 0 1 2 3 4 5 6 7 8 9
- Bruk bare svart eller blå penn. Ikke bruk blyant eller tusj.

Γ	HELSE OG DAGLIGLIV	ar	Æ
1	Hvordan er helsa di nå?		
	Dårlig Ikke helt god Go	d Sva	ært god
_			Lit god
2	Har du noen langvarig ( <u>minst 1 år)</u>		
	sykdom, skade eller lidelse av fysisk	Ja	Nei
	eller psykisk art som nedsetter dine funksjoner i ditt daglige liv?		
	,		
	Hvis ja:	r or node	o++2
	Hvor mye vil du si at dine funksjone	r er neas Middels	
	nedsatt	nedsatt	Mye nedsatt
	Er bevegelseshemmet		
	Har nedsatt syn		
	Har nedsatt hørsel		
	Hemmet pga. kroppslig sykdom. 📃	Ц	Ц
	Hemmet pga. psykisk sykdom 🛄		
8	Har du kroppslige smerter nå som	Ja	Nei
	har vart <u>mer enn 6 måneder?</u>		
4	Hvor sterke kroppslige smerter har av de siste 4 uker?	du hatt i	løpet
	Meget Mode-		Meget
	Ingen svake Svake rate	Sterke	sterke
6	I hvilken grad har din fysiske helse e	ller følels	es-
	messige problemer begrenset deg i		
	sosiale omgang med familie eller ve	nner i løp	et av
		Kunne ikke	
	Ikke i det hele tatt En del Litt Mye	ha sosial omgang	
	HELSETJENESTER		NE.
6	Har du i løpet av <u>de siste 12 måned</u>	er vært h	os:
		Ja	Nei
	Fastlege/allmennlege		
	Annen legespesialist utenfor sykehus		
	Konsultasjon uten innleggelse		_
	- ved psykiatrisk poliklinikk		
	- ved annen poliklinikk i sykehus		
	Kiropraktor		
	Homøopat, akupunktør, soneterapeut, hå	ands-	
	pålegger eller annen alternativ behandle	r 📘	
0	Har du vært innlagt i sykehus	Ja	Nei
	i løpet av <u>de siste 12 måneder?</u>	Ja	1461

 $\mathbf{F}$ 

•	SYKDOMMER OG PLAGER		٦
8	Har du hatt noe anfall med pipende eller tung pust de <u>siste 12 måneder?</u>	Ja	Nei
9	Har du noen gang de <u>siste 5 år</u> brukt medisiner for astma, kronisk bronkitt, emfysem eller KOLS?	Ja	Nei
10	Bruker du, eller har du brukt, medisin mot høyt blodtrykk?	Ja	Nei
1	Har du, eller har du noen gang hatt, noen av disse sykdommene/plagene: ( <i>Sett ett kryss pr. linje</i> ) Ja Nei	Hvis ja, hvo var du <b>først</b> <i>Eksempel:</i> <u>3</u> 4	
	Hjerteinfarkt		år gammel
	Angina pectoris (hjertekrampe) 🔲 🗌		år gammel
	Hjertesvikt		år gammel
	Annen hjertesykdom		år gammel
	Hjerneslag/hjerneblødning 🔲 🗌		år gammel
	Nyresykdom		år gammel
	Astma		år gammel
	Kronisk bronkitt, emfysem, KOLS 🔲 🗌		år gammel
	Diabetes (sukkersyke)		år gammel
	Psoriasis		år gammel
	Eksem på hendene		år gammel
	Kreftsykdom		år gammel
	Epilepsi		år gammel
	Leddgikt (reumatoid artritt) 🔲 🗌		år gammel
	Bechterews sykdom		år gammel
	Sarkoidose		år gammel
	Beinskjørhet (osteoporose)		år gammel
	Fibromyalgi		år gammel
	Slitasjegikt (artrose)		år gammel
	Psykiske plager som du har søkt hjelp for		år gammel
Ð	Har du noen gang fått påvist for høyt blodsukker?	Ja	Nei
	Hvis ja: I hvilken situasjon første gang		
	Ved helseundersøkelse Under syko Under svangerskap Annet		🖵 🔒

Т

HELSEUNDERSØKELSEN I NORD-TRØNDELAG

SKADER
--------

	Eksempel:	
	3 4 <sup>år</sup> gamme	-/
Ja Nei	t	
Lårhalsbrudd	år gamme	/
Brudd i handledd/underarm 🔲 🗌	år gamme	•/
	år	
Brudd/sammenfall av ryggvirvler 📃 📃	gamme	/
Nakkesleng (whiplash)	år gamme	•/

Hvis ja, hvor gammel

var du **første** gang?

#### 🙆 Har du foreldre, søsken eller barn som har, eller har hatt, følgende sykdommer? (Sett ett kryss pr. linje)

(Sett ett kryss pr. linje)			Vet
Hjerneslag eller hjerneblødning	Ja	Nei	ikke
før 60 års alder			
Hjerteinfarkt før 60-års alder			
Astma			
Allergi/høysnue/neseallergi			
Kronisk bronkitt/emfysem/KOLS			
Kreftsykdom			
Psykiske plager			
Beinskjørhet (osteoporose)			
Nyresykdom (ikke nyresten, urinveisinfeksjon, urinlekkasje) Diabetes (sukkersyke)			
	_	_	_

Har noen av dine besteforeldre, dine foreldres søsken eller dine Ja Nei søskenbarn fått diagnosen diabetes (type 1 eller type 2)?

#### HVORDAN FØLER DU DEG?

#### 10 Har du <u>de to siste uker</u> følt deg: (Sett ett krvss pr. linje)

1	Har du noen gang i livet opple noen over lengre tid har forsø kue, fornedre eller ydmyke de	kt å		Ja	Nei
	Ensom?				
	Nedfor/deprimert?				
	Irritabel?				
	Plaget av angst?				
	Nervøs og urolig?				
	Glad og optimistisk?				
	Trygg og rolig?				
		Nei	Litt	del	mye
	(Sett ett kryss pr. linje)	-	F	En god	Supprt

Γ		ТОВАКК		Ľ	10	5
	18	Røykte noen av de voksne <u>innendørs</u> da du vokste opp?		Ja		Nei
	19	Røykte mora di da du vokste opp?		Ja		Nei
(	20	Røyker du selv?				
		<b>Nei</b> , jeg har <u>aldri</u> røykt				
		Hvis du <u>aldri</u> har røykt, hopp til spørsmål 22.				
		<b>Nei</b> , jeg har sluttet å røyke				
		<b>Ja</b> , sigaretter <u>av og til</u> (fest/ferie, ikke da	iglig).			
		<b>Ja</b> , sigarer/sigarillos/pipe <u>av og ti</u> l				
		<b>Ja</b> , sigaretter <u>daglig</u>				
		<b>Ja</b> , sigarer/sigarillos/pipe <u>daglig</u>				
		Svar på dette hvis du <u>nå</u> røyker <b>dag</b> eller <u>tidligere</u> har røykt <b>daglig</b> :	lig			
		Hvor mange sigaretter røyker eller røykte du vanligvis <u>daglig</u> ?				aretter dag
		Hvor gammel var du da du begynte å røyke <u>daglig</u> ?			år ga	mmel
		Hvis du tidligere har røykt daglig, hvor gammel var du da du sluttet?			år ga	mmel
(	<b>2</b> ] B	Svar på dette hvis du røyker eller ha <b>av og til</b> , men <u>ikke daglig</u> :	ar røy	/kt		
		Hvor mange sigaretter røyker eller røykte du vanligvis <u>i måneden</u> ?				aretter mnd
		Hvor gammel var du da du begynte å røyke <u>av og til</u> ?			år ga	mmel
		Hvis du tidligere har røykt <u>av og til,</u> hvor gammel var du da du sluttet?		1	år ga	mmel
(	22	Bruker du, eller har du brukt, snus?				
		Nei, aldri Ja, av og Ja, men jeg har sluttet Ja, dagli				
		Hvis du <u>aldri</u> har brukt snus, hopp til spørsmå	23.			
		<b>Hvis ja:</b> Hvor gammel var du da du begynte med snus?			år gami	mel
		Hvor mange esker snus bruker/brukte du <u>pr. måned</u> ?				r snus nåned

Г	Hvis du bruker eller h snus, hva begynte du			le siga	retter	og
	Snus Omtrent samtidig (innenfor 3 måneder)	🔲	-	tter r ikke		
	Da du begynte å bru å slutte å røyke eller					ve
	Nei Ja, for å slutte å røyke		Ja, for reduse		inga	🔲
	MATVARER			2	Y-	Ê
3		0-3 ganger	<b>s disse</b> 1-3 ganger pr. uke	4-6 ganger	1 gang pr.	2 ggr el mer
	Frukt/bær Grønnsaker					pr. dag
	Sjokolade/smågodt Kokte poteter					
	Pasta/ris Pølser/hamburgere					
	Fet fisk (laks, ørret, sild, makrell, uer som pålegg/middag					
24	Bruker du følgende k (Sett ett kryss for hvert k			Ja, daglig	Av og til	Nei
	Tran				Ď	
	Omega-3-kapsler					
	Vitamin- og/eller minera	altilskud	d			
25	Hvor <u>mange glass</u> dr <sup>1</sup> /2 liter = 3 glass <i>(Sett</i> et			•	v følge	ende?
	S	Sjelden eller aldri	1-6 gl. pr uke	1 gl. pr. dag	2-3 gl. pr. dag	4 gl. eller mei pr. dag
	Vann, farris o.l					
	Helmelk (søt/sur)					
	Annen melk (søt/sur)					
	Brus/saft med sukker	Ц		Ц	Ц	
	Brus/saft uten sukker	Ц				
	Juice eller nektar					
26	Hvor mange kopper (Sett 0 dersom du ikke d					<u>gn</u> ?
		Koke kaffe		Annen kaffe	Т	ē
	Antall kopper					_
2	Hvor mange kopper drikker du <u>om kvelde</u> (etter kl 18)?			Anta koppe		

h

ALKOHOLBRUK

ca 1 gang pr. uke .....

2-3 ganger pr. måned.....

Omtrent hvor ofte har <u>måneder</u> drukket alkoh	du i løpet av de <u>siste 12</u> ol? (Regn ikke med lettøl)
4-7 ganger pr. uke	🗌 Ca 1 gang pr. måned
2-3 ganger pr. uke	📃 Noen få ganger pr. år . 🗌

Ingen ganger siste år

Aldri drukket alkohol...

29	Har du drukket alkohol i løpet av de <u>siste 4 uker</u> ?	Ja
	Hvie is:	

11110 jui		
Har du drukket så mye at	Nei	
du har kjent deg sterkt	Ja, 1-2 ganger	
beruset (full)?	Ja, 3 ganger eller mer	

Wron wange glass øl, vin eller brennevin drikker du vanligvis i løpet av 2 uker? (Regn ikke med lettøl) (Sett 0 hvis du ikke drikker alkohol)

	ØI	Vin	Brenne- vin
Antall glass			

4 Hvor ofte drikker du <u>5 glass eller mer</u> av øl, vin eller brennevin ved samme anledning?

Aldri	Ukentlig	
Månedlig	Daglig	

#### MOSJON/FYSISK AKTIVITET

Med mosjon mener vi at du f.eks går tur, går på ski, svømmer eller driver trening/idrett.

3 Hvor ofte driver du mosjon? (Ta et gjennomsnitt)

Aldri	
Sjeldnere enn en gang i uka	
En gang i uka	
2-3 ganger i uka	
Omtrent hver dag	

Bersom du driver slik mosjon, så ofte som en eller flere ganger i uka; hvor hardt mosjonerer du? (*Ta et gjennomsnitt*)

Tar det rolig uten å bli andpusten eller svett	
Tar det så hardt at jeg blir andpusten og svett	
Tar meg nesten helt ut	

Hvor lenge holder du på hver gang? (Ta et gjennomsnitt)

Mindre enn 15 minutter 🗌	30 minutter – 1 time
15-29 minutter	Mer enn 1 time

Nei


Г				
35	Har du vanligvis <u>minst 30 minutter</u> fysisk aktivitet daglig på arbeid og/eller i fritida?	eller i lengre sa		Ja Nei
30	Omtrent hvor mange timer sitter         du i ro på en vanlig hverdag?       Antall         (Regn med både jobb og fritid)       timer         ARBEID		t I moderat grad	<b>joner på</b> d
37	Hvis du er i lønnet eller ulønnet arbeid, hvordan vil du beskrive arbeidet ditt? <i>(Sett ett kryss)</i>	OPPVEKST - I	DA DU VAR <u>0-18 ÅR</u>	N G
	For det meste stillesittende arbeid (f.eks skrivebordsarbeid, montering) Arbeid som krever at du går mye (f.eks ekspeditørarbeid, lett industriarb.,undervisning).	Hvem vokste de Mor	AdoptivforeId	re
	Arbeid hvor du går og løfter mye (f.eks postbud, pleier, bygningsarbeid) Tungt kroppsarbeid (f.eks skogsarbeid, tungt jordbruksarbeid, tungt bygningsarbeid)	Ble dine foreldr flyttet de fra hv du var barn?	, , , , , , , , , , , , , , , , , , , ,	ar 7 år 🔲
33	HØYDE/VEKT Omtrent hva var din høyde da <u>du var 18 år</u> ?	Ø Døde noen av o foreldre da du		r 7 år 🗌
	Omtrent hva var din kroppsvekt da <u>du var 18 år</u> ?	<ul> <li>Vokste du opp</li> <li>Ja, katt</li> <li>Ja, hest</li> <li>Huar muo molk</li> </ul>	Nei Ja, hund Ja, annet leve	nde dyr . 🗌
	Ja Nei, for lett Nei, for tung Har du forsøkt å slanke deg i løpet av <u>de siste 10 år</u> ?	Sjelden/ 1-6 gl aldri pr. uk	. 1 glass 2-3 gl.	Mer enn 3 glass pr. dag
_	Nei 🔄 Ja, noen ganger 🔄 Ja, mange ganger 🗌	<ul><li>Vokste du opp</li></ul>	på gård med husdyr?	Ja Nei
42	Er din kroppsvekt minst 2 kg lavere nå Ja Nei enn for 1 år siden?	Når du tenker p vil du beskrive Svært god God	Vanskelig 	
•	ALVORLIGE LIVSHENDELSER SISTE 12 MÅNEDER	ALT I ALT		
_	Har det vært dødsfall i nær familie? (barn, ektefelle/samboer, søsken eller foreldre)       Ja       Nei         Har du vært i overhengende livsfare pga. alvorlig ulykke, katastrofe, voldssituasjon eller krig?       Ja       Nei	🚳 Når du tenker j	Nokså misforn	er du stort nøyd
ŀ		Både/og		

HELSEUNDERSØKELSEN I NORD-TRØNDELAG

٦

-





## Kjære HUNT-deltaker

Takk for at du møtte til Helseundersøkelsen. Vi vil også be deg om å fylle ut dette spørreskjemaet. Noen av spørsmålene likner de som du har svart på før, men det er viktig at du allikevel besvarer alt. Opplysningene blir brukt til forskning og forebyggende helsearbeid. Forskere vil kun ha tilgang til avidentifiserte data, det vil si at opplysningene ikke kan spores tilbake til en enkelt person.

## Slik fyller du ut skjemaet

Skjemaet vil bli lest maskinelt.	
Det er derfor viktig at du krysser av riktig: Rett 🗵 G	alt 🔀 🗸
Krysser du feil et sted, retter du ved å fylle boksen slik:	
Bruk svart eller blå penn. Ikke bruk blyant eller tusj.	
Dato for utfylling:	l.mm.åååå

## Mosjon/fysisk aktivitet

1. Under arbeid (lønnet eller ulønnet) eller vanlige daglige gjøremål-Hvordan vil du beskrive aktivitetsnivået ditt?



- Aktiviteter som krever at du går mye
- Aktiviteter hvor du går og løfter mye
- Tungt kroppsarbeid


Med mosjon mener vi at du f.eks går tur, går på ski, svømmer eller driver trening/idrett.

#### 2. Hvor ofte driver du mosjon? (ta et gjennomsnitt):

Aldri

- Sjeldnere enn en gang i uka
- En gang i uka
- 2-3 ganger i uka
- Omtrent hver dag





#### 3. Hvor lenge holder du på hver gang? (ta et gjennomsnitt)


- Mindre enn 15 minutter
- 15-29 minutter
- 30 minutter 1 time
- Mer enn 1 time
- 4. På en skala fra 6-20, hvor hard er aktivitetene du vanligvis utfører når du mosjonerer/trener?





	Smert	e										
		<b>du krop</b> nei, gå t	-		<u>nå</u> ? [	Ja	🗌 Nei					
	6. Ven akkı	nligst se urat nå. S	e <b>tt ring r</b> Skriv tyd	undt de elig ring	<b>et tallet</b> g rundt t	som b allet: (6	est ang	gir hvor	<sup>.</sup> sterke	smert	er du har	
	0	1	2	3	4	5	6	7	8	9	10	
In	gen smerf	er									Verst tenkelige smerter	

7. Vennligst sett kryss der du har smerte nå. Du kan krysse av flere steder.




### Generell helse

8. Hvordan vil du stort sett vurdere din helsetilstand i løpet av den siste uka?







9. I løpet av <u>den siste uka</u>, i hvilken grad begrenset fysiske helseproblemer dine vanlige fysiske aktiviteter (spasere, gå opp trapper)?

lkke i det hele tatt	Svært lite	En del	Муе	Kunne ikke utføre fysiske aktiviteter	
				deg å utføre ditt va n fysiske helse?	anlige
lkke i det hele tatt	Litt	Nokså	Meget	Kunne ikke utføre daglig arbeid	
11. Hvor ste	rke kroppslige s	merter har du	ı hatt i løpet	av <u>den siste uka</u> ?	
Ingen	Meget svake	Svake Mod	lerate Ste	rke Meget sterke	
12. I løpet av	v <u>den siste uka</u> ,	hvor mye ove	rskudd hadd	le du?	
Svært my	e Gansk	e mye E ]	En del	Litt Ikke noe	
				lin fysiske helse ell Igang med familie e	
Ikke i det hele tatt	Svært lite	En del	Mye	Kunne ikke ha sosial omgang	
				plaget av følelsesr t eller irritabel)?	nessige
Ikke i det	hele tatt Litt	En del	Mye	Svært mye	
				sonlige eller følelse legang eller andre g	
lkke i det hele tatt	Svært lite	En del	Mye	Kunne ikke utføre daglige gjøremå	
Vi vil gjerne	vite når du fylte	ut skjemaet i	forhold til k	ondisjonstesten.	
Var det:	] Før 🗌 Etter	🗌 Både fø	r og etter		



Kondisprosjektet       Kondisprosjektet     Image: State of the
Dato:
Personnummer:
Mann Kvinne Menopause: Før Under Etter Dag i MS-syklus:
Hormoner: 🗌 Ja 🗌 Nei 🛛 P-piller/spiral: 🗌 Ja 🔛 Nei
Kommentar:
Blodtrykk: / Vekt: kg Høyde: cm
Diabetes Nei Ja, type 1 2 Midjemål: cm
Find-risk Medisiner: Nei Ja, hvilke?
Spørsmål fra lege         Pipende eller tung pust siste 12 mnd, astma, kronisk bronkitt,         KOLS eller sarkoidose, hjertesykdom, angina eller medisin mot         høyt blodtrykk, hjerneslag/-blødning, kreftsykdom, gravid, blind:         Nei       Ja, eksl.         Medisinsk kontraindikasjon mot fysisk aktivitet:         Klarer du gå i motbakke eller trapper:
Info (for legen):
Fysisk arbeid og fysisk aktivitet "Hvor mange av de siste 7 dagene har du utført fysisk arbeide eller fysisk aktivitet som varte minst 10 minutter sammenhengende?" dager
"Hvor lenge holdt du gjennomsnittlig på med slike aktiviteter på de dagene du har nevnt?/Hvor lenge holdt du på med timer min slike aktiviteter denne dagen?"

"Jeg skal nå spørre deg om hvor hardt du har tatt i under aktiviteten eller arbeidet de siste 7 dagene. I den sammenheng har vi delt inn aktiviteten i følgende tidsintervaller: (1) 61 minutter eller mer, (2) 31-60 minutter, (3) 10-30 minutter." La gjennomsnittet bestemme hvilken varighet du spør om først. "For å beskrive intensiteten bruker vi Borg skala som du ser her. (Intervjuer peker på Borg skala). Du kan velge alle tallene. Da spør jeg: Hvor hardt tok du i under aktiviteten/arbeidet ...?" Spør om alle tidsintervallene.

10-30 minutter	31-60 minutter	61 r	ninutter eller mer
Hvilket tidsintervall har du tilbraki	t mest tid i den siste uka? 🔲 10-30	31-60	🗌 61 eller mer
			30/88

Kondisprosjektet
Endotelfunksjon
Stimulans i dag: 🗌 Nei 🗌 Røyketobakk 🗌 Snus/skrå 🗌 Alkohol Forrige: 📃 🗌 timer 🗌 min
Kaffe: Nei Ja, for min
Forrige næringsinntak (alt unntatt vann):
Har du trent i dag? 🗌 Nei 🛛 Ja, for 🔤 timer 🔄 min
Medisiner i dag? 🗌 Nei 🗌 Ja, hvilke?
Faste medisiner? Nei Ja, hvilke?
Baseline:     Image: Baseline:     Post:     Image: Baseline:       flow     diameter     laveste puls     Post:     Image: Baseline:       flow     diameter     laveste puls     flow(10 sek)     diameter(1 min)
Oksygenopptak         km/t       % stigning       hjertefrekvens       VO2 (L/min)       Borg         Startbelastning:       .       .       .       .       .       .         Trinn 2:       .       .       .       .       .       .       .       .       .       .         VO2max / VO2peak:       . <t< th=""></t<>
Kommentar endotel eller VO2:
Ikke gjennomført: 🗌 Kondis 🗌 Endotel 🗌 Spørreskjema 30488

Vi takker for frammøtet til undersøkelsen.					RØYKEVANER		
Vi vil også be deg være vennlig å fylle ut dette spørres				ŀ			JA NEI
Opplysninger vil bli brukt i et større forskningsarbeid om for har betydning for helsen.	nola s	som	1		Røyker du daglig for tiden?	17	
Svar etter beste skjønn. Kryss av for bare en av svar-mul						17	
(dersom det ikke stär nevnt noe annet). Det utfylte skjer neres i vedlagte svarkonvolutt. Porto er betalt.	ma re	etur-	-		Hvis du svarte «JA», røyker du DAGLIG for tiden:		
Alle opplysningene er underlagt streng taushetsplikt.					Sigaretter?		
Med hilsen					Pipe?		
Statens skjermbildefotografering Fylkeslegen ● Helserådet ● Statens Institutt For Folkehels						20	
Institutt for anvendt sosialvitenskapelig forskning/ Institutt for anvendt sosialvitenskapelig forskning/ Institutt for samfunnsforskning	se				Hvis du IKKE røyker SIGARETTER daglig for		JA NEI
instituti for samunisforskning					tiden: Har du røykt SIGARETTER daglig		╎└──┬──┐ ╎
Navn:					tidligere?	21	
					Ibie do comptenti da la borna la condeticida e		
Adr. :					Hvis du svarte «JA», hvor lenge er det siden du sluttet å røyke sigaretter daglig?		
Ti etikett							
F					Mindre enn 3 måneder	22	<b>1</b>
Postnr. Postkontor					3 måneder– 1 år 1–5 år		2
F.nr. :				Л	Mer enn 5 år		4
	·			1			
MOSJON					Hvis du røyker SIGARETTER daglig nå, eller har gjort det tidligere:		
					Hvor mange sigaretter røyker eller røykte du pr. dag? (Oppgi antall pr. dag medregnet håndrullede)		
Med mosjon mener vi at du f.eks. går tur, går på ski, svømmer eller driver trening/idrett.				•	dag: (Oppgi antali pr. dag medregnet handrullede)	23	Antall
			7.7 E	11. 11. 11.	Besvares av dem som røyker daglig nå		ه با که و د با در در مر د در
Hvor ofte driver du mosjon?		s 1	< 1.		eller har røykt daglig tidligere: (Gjelder både sigarett-, pipe- og sigar-røykere)		
(Ta et gjennomsnitt)	F				User commelses de la de bomme		신 출제 같이 ?
Aldri.	12	_	1 2		Hvor gammel var du da du begynte å røyke daglig?	25	år
Sjeldnere enn en gang i uka En gang i uka	Ē		2		Hvor mange år tilsammen har du røykt daglig?	27	år
2–3 ganger i uka		_	4				
Omtrent hver dag	╞		5				
		- 2.		and and a	ALKOHOLBRUK		
Dersom du driver slik mosjon så ofte som en eller flere ganger i uka:							
Hvor hardt mosjonerer du? (Ta et gjennomsnitt)					Hvor ofte har du drukket alkohol (øl, vin		
Tar det rolig uten å bli andpusten eller svett	13	Ĩ	4		eller brennevin) de SISTE 14 DAGENE?		
Tar det så hardt at jeg blir andpusten og svett	-	$\neg$	2				
Tar meg nesten helt ut	1		3		Jeg har ikke drukket alkohol, men er ikke totalavholdende	29	
Hvor lenge holder du på hver gang?					Jeg har drukket 1–4 ganger		2
(Ta et gjennomsnitt)					Jeg har drukket 5–10 ganger Jeg har drukket mer enn 10 ganger		3
Mindre enn 15 minutter	14		1		Jeg er totalavholdende, drikker aldri alkohol		5
16–30 minutter	-	_	2				
30 minutter-1 time Mer enn 1 time	-	-	3 4		Dersom du har drukket alkohol de siste 14		JA NEI
	22	121			dagene, har det ført til at du noen gang har følt deg beruset?		
SALT						30	البيسليسية ( محمد المحمد الم
	_	"	н 14 2		Har det vært perioder i livet ditt da du har drukket for mye, eller i hvert fall i meste laget?		이 같은 것이 있다. 전문에는 것이 같이 같이 같이 같이 같이 많이 했다.
Hvor ofte bruker du salt kjøtt eller salt fisk/sild til middag?					Nei	31	
Aldri, eller sjeldnere enn en gang i måneden	15	1			I tvil, kanskje		2
1–2 ganger i måneden			2	1.25	Ja		3
Opptil en gang i uka		_	3				
Opptil to ganger i uka	ŀ	-	4 5				
Mer enn to ganger i uka							
Hvor ofte pleier du å strø ekstra salt på middagsmaten?							
Sjelden eller aldri	16		1				
Av og til	┝	-	2				
Ofte Alltid eller nesten alltid	ŀ		3				
L							

BOSITUASJONEN		Hvis du er i`arbeid (gjelder også heltids husarbeid), ber vi deg fylle ut de neste spørsmålene:		
Bor du alene eller sammen med andre? Kryss av for de du bor sammen med. (Her kan du sette flere kryss.)		Er arbeidet ditt så fysisk anstrengende at du ofte er sliten i kroppen etter en arbeidsdag?		
	1.2 11-1-2-2-2-3	Ja, nesten alltid	45	
Bor alene		Ganske ofte	10	2
Foreldre eller svigerforeldre		Ganske sjelden		3
Andre voksne personer		Aldri, eller nesten aldri		4
Barn under 5 är				
Barn 6–15 år 37				
Barn over 15 är		Krever arbeidet ditt så mye konsentrasjon og oppmerksomhet at du ofte føler deg utslitt etter en arbeidsdag?		
	JA NEI	-		
Bor du fast i institusjon? (sykehjem, aldershjem eller liknende)		Ja, nesten alltid Ganske ofte		2
(sykenjem, aldersnjem eller liknende)		Ganske one		3
		Aldri, eller nesten aldri		4
UTDANNINGEN				
Hvilken utdanning har du fullført? Oppgi bare høyest fullførte utdanning.		Hvordan trives du alt i alt med arbeidet ditt?		
7 Avia fallvaskala allar kartara	日認認	Veldig godt	47	
7-årig folkeskole eller kortere 40 Exambalda, aller fortsettelsesskole		Ganske godt		2
Framhalds- eller fortsettelsesskole		Godt		
9-ang grunnskole Real- eller middelskole, grunnskolens 10. år		Ikke særlig godt		4
Ett- eller to-årig videregående skole		Dårlig		5
Artium, økonomisk gymnas eller almenfaglig retning i videregående skoler	6	Hvis du er gårdbruker eller annen selvstendig		
Høyskole eller universitet, mindre enn 4 år		næringsdrivende, har du noen		
Høyskole eller universitet, 4 år eller mer	<sub>8</sub>	ansatte som arbeider fast for deg?		
		Ingen fast ansatte	48	- QX
		1–2 fast ansatte		2
Har du fullført annen heldags utdanning, og i tilfelle i hvor mange år?	2999682	3-10 fast ansatte		3
Skriv antall år her 41	år	Mer enn 10 fast ansatte		4
SKIV altai a liei 4				
ARBEID		HVORDAN HAR DU DET?		
ANDLID	1. S. & & & & & & & & & & & & & & & & & &			1.8363233368
Hvis du er eller har vært i inntektsgivende arbeid, kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.)	-	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?		
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er		Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?	. 49	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er inntektsgivende arbeid nå, eller har vært det tid-		Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd? Svært fornøyd		
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn-	eg selv ktetellen	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?		
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.)	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd? Svært fornøyd		
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd? Svært fornøyd		3
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.)	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd? Svært fornøyd		3
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd		3
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nä, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nä, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd		3 4 5 6
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Meget misfornøyd		3 4 5 6
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd		3 4 5 6
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd		3 4 5 6 7 7
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd	. 50	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og         opplagt, eller trett og sliten?         Meget sterk og opplagt         Sterk og opplagt.		
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Både - og         Svært misfornøyd         Svært misfornøyd         Både - og         Meget stort sett sterk og         opplagt, eller trett og sliten?         Meget sterk og opplagt.         Sterk og opplagt.         Både - og	. 50	3 4 5 6 7 7 1 2 3 4
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten		
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt         Sterk og opplagt.         Både - og         Meget sterk og opplagt.         Sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten         Trett og sliten	- 50 - 50 	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten	- 50 - 50 	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt         Sterk og opplagt.         Både - og         Meget sterk og opplagt.         Sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten         Trett og sliten	- 50 - 50 	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt         Sterk og opplagt.         Både - og         Meget sterk og opplagt.         Sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten         Trett og sliten	- 50 - 50 	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt         Sterk og opplagt.         Både - og         Meget sterk og opplagt.         Sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten         Trett og sliten	- 50 - 50 	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt         Sterk og opplagt.         Både - og         Meget sterk og opplagt.         Sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten         Trett og sliten	- 50 - 50 	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt         Sterk og opplagt.         Både - og         Meget sterk og opplagt.         Sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten         Trett og sliten	- 50 - 50 	
kan du angi hvilken av disse yrkesgruppene ditt yrke faller innenfor? (Hvis du ikke er i arbeid nå, svarer du ut fra det yrket du hadde sist.) Hvis du har en ektefelle (eller samboer) som er i inntektsgivende arbeid nå, eller har vært det tid- ligere, angi tilsvarende hvilken yrkesgruppe han/ hun tilhører. (Evt. angi om han/hun <i>ikke</i> har hatt inn- tektsgivende arbeid.) Spesialarbeider, ufaglært arbeider	Deg se Ektefe	Når du tenker på hvordan du har det for tida, er du stort sett fornøyd med tilværelsen, eller er du stort sett misfornøyd?         Svært fornøyd         Meget fornøyd         Nokså fornøyd         Både - og         Nokså misfornøyd         Svært misfornøyd         Svært misfornøyd         Føler du deg stort sett sterk og opplagt, eller trett og sliten?         Meget sterk og opplagt         Sterk og opplagt.         Både - og         Meget sterk og opplagt.         Sterk og opplagt.         Både - og         Ganske sterk og opplagt.         Både - og         Ganske trett og sliten         Trett og sliten	- 50 - 50 	

			<ul> <li>HVORDAN ER DU?</li> </ul>		
<u> </u>	┥┌╶	A NE		-	
			→ Har du tendens til å ta dine oppgaver mer alvorlig		
51	.		enn folk flest?		
52			Ja, nettopp slik er jeg	60	
			Ja, stort sett	F	_
ı				⊢	-
		-		-	- :
53	-	i −	INEI, TVert imot	-	
	-	2			
	-	3		H	JA N
•••	-	4	Har du i løpet av det siste året ofte følt at du		A
			selv framover?	61	Ť
le					
		1 4 2	Egler du deg elltid under tiderress		
	-	1,:	også når det gjelder daglige gjøremål?		
	-	2		L	<u>.</u>
		3	Alltid, eller nesten alltid	52	
•••	-	4			
			Aldri	-	_
			м м	1.1	
			Er du vanligvis glad eller nedstemt?		
	$\vdash$	1		-	ТÅ,
		2		53 -	
	-	3			- 2
••	<u> </u>	4			-  '
	1.		Nokså dlad		
	Ŕ,				
	-				
	-	63333			二: / "人"。
	$\square$	Q			
		1.2.2			
••		4	HVA FB VIKTIG?		가다. 상태
	1.35			_	
			Synes du det er viktig at man prøver å være		
		1	fornøyd med det man har?	10	
	$\vdash$	2	Dette er særlig viktig		İ.
	$\vdash$		Dette er viktig	"  -	1
		4			3
		gan i			4
					5
					- •
			Synes du det er viktig at man kan		
e	1 d. d		slå av på kravene?		``
				5 🖵	1
			Dette er viktig		2
			Både - og		_ 3
	H	. 1			:4
			Dette er overhodet ikke viktig		5
	<u> </u>		Synes du det er viktig at man alltid		
•		5		-	י 'ר
			Dette er særlig viktig 66	÷ [	- 1
			Dette er viktig		2
	·		Bâde - og Dette er mindre viktig		3
					4
. 59		1	Lette er overbodet ikke viktig		_l⇒ 5
		2	Dette er overhodet ikke viktig		
			Dette er överhodet ikke viktig	1	
		2 3 4	Dette er överhodet ikke viktig		
		2 3	Dette er överhodet ikke viktig		
		2 3 4	Dette er överhodet ikke viktig		
		53  	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	32       Ja, nettopp slik er jeg	<pre>s1</pre>

TILLEGGS-SKJEMA OM BLODTRYKK			Hvis du har brukt medisin for blodtrykket før, men ikke nå: Når slutta du med medisiner?			
På skjemaet du leverte ved helseundersøkelsen, svarte du at du har, eller har brukt, medisin for høyt blodtrykk.			(Skriv årstallet i ruta)		1512337	
l Nord-Trøndelag har det siden 1980 pågått en undersøkelse om			-	19	100000	
blodtrykksbehandling. Formålet ved undersøkelsen er å gjøre be- handlingen bedre. En viktig del av undersøkelsen er å få opp- lysninger om hvordan du og alle andre med høyt blodtrykk har det, og hvilke erfaringer dere har gjort.			Vet ikke …	82		
Det er derfor meget viktig at du fyller ut dette skjernaet så nøye som mulig.			Hvorfor slutta du med medisinene? (Sett ett eller flere kryss)			
Enkelte spørsmål kan være vanskelig å svare på. Prøv like etter beste skjønn, og legg vekt på det som er vanlig eller snittlig for deg.			Legen bestemte det Jeg fikk plager av medisinene			
Alle opplysninger blir behandlet av oss med streng taush	• •			′86		
På forhånd takk!	•		Jeg var redd medisinene var skadelige Annen årsak (skriv hvilken nedenfor)			
					lkke skriv h	
Når ble det påvist at du hadde høyt blodtrykk første gang? (Skriv årstallet i ruta)			Skriv hvilken årsak det evt. var	89	1011074	
	_					
T Vet ikke …	9		Har legen gitt deg andre råd i forbindelse med at du har for høyt blodtrykk?			
Hvor ble det påvist?	67		(Sett kryss i bare <i>en</i> av rutene)			
(Sett kryss i bare en av rutene)			Nei		1	
Hos almenpraktiserende lege (distriktslege, privatpraktiserende lege, turnuskandidat)	69		Ja Husker ikke		2	
Hos militærlege	69	2			3	
På sykehus		3				
Vet ikke		4	Hvis «JA»; Hvilke råd?			
		JA NEI		92	lkke skriv h	
Bruker du medisin for blodtrykk nå? Hvis «NEI»: Gå til de to siste spm. nederst til venstre.	70			94		
Hvis «JA»: Når begynte du med medisiner for blodtrykket? (Skriv årstallet i ruta)	9		Hvordan opplever du behandlingen for blodtrykket? Gir det deg:			
	_		(Sett ett eller flere kryss)			
Vet ikke …	71		Lettelse, ro, trygghet			
		JA NEI	Anspenthet, engstelse, redsel, uro Dårlig humør, depresjon			
Bruker du doserings-eske for tabletter?	220		Ingen spesielle følelser			
Har du medisinkort som viser hva slags medisin du skal ta?						
	221		Synes du  at det er noen ulemper ved det			
Hender det at du glemmer å ta medisinene?			at du må ha behandling for høyt blodtrykk?			
(Sett kryss i bare en av rutene)			Noi ingon Homor			
Aldri	73		Nei, ingen ulemper Ja	100		
Sjelden (ca. en gang i mnd.) Oftere		2				
			Hvis «JA»: Hva synes du er mest plagsomt? (Sett ett eller flere kryss)			
Hvor viktig mener du at det er for deg at du tar	,					
blodtrykksmedisinen(e) akkurat som foreskrevet? (Sett kryss i bare <i>en</i> av rutene)			At du må bruke medisiner hver dag	101		
Ikke så viktig	74		At du må gå til legekontroll			
Viktig		2	At du må følge de råd som legen har gitt At du har ubehag av medisinene			
Meget viktig		3	At du er engstelig for at det er noe alvorlig	104		
Vet du hva blodtrykket ditt var ved siste kontroll? (Sett kryss i bare <i>en</i> rute)	?		som feiler deg	105		
Nei	75		At du synes det er leit å bli betraktet som «pasient»	100		
Ja	, o	2	«pasient» Annet			
Usikker		3				
Hvis «JA» eller «USIKKER», skriv hvor mye du tror det var:	76	lkke skriv hèr				
	79					
Skriv her						

			Om du bruker enrouter bya b	ator dan			
TILLEGGS-SKJEMA FOR SUKKER	Om du bruker sprøyter, hva heter den insulinen du bruker?						
Du har opplyst at du har sukkersyke. Et viktig mål for h	else	under-	(Skriv navnet som står på glasset,			18 398 1997 1997	
søkelsen er å finne ut hvordan sukkersyke best kan behandles for			begge dersom du bruker to sorter).				
å gi minst mulig plager.					128		<u></u>
Alle som har eller har hatt sukkersyke, bes derfor om å sva	are s	å godt			120	ikke	skriv h
som mulig på disse spørsmålene om sukkersyke.					130	19	
Noen har svart på et lignende skjema høsten 1982. Det e	r like	evel av			150		
stor betydning at disse fyller ut dette skjemaet.							
Alle opplysninger blir behandlet av oss med streng taush	etsp	likt.	Bruker du tabletter mot sukk	ersyken?	. 132		
På forhånd takk!						Salati Salati	
			Om du bruker tabletter mot sukk	ersyken skriv neden	-		
Ν			for hva de heter, antall mg. som	står på glasset/		1. 1999 1. 1999 1. 1999 1. 1999	
			pakningen og hvor mange slike t (Skriv om begge sorter dersom du b		ag:		
Når ble sukkersyken din oppdaget?			type tabletter mot sukkersyke)				
Når ble sukkersyken din oppdaget?	108			133 138			din
					139		
Hvordan ble sukkersyken din oppdaget?			Skriv navn på tabletten her	mg. pr. tabl. antall pr. da	9	1.16	ž Į
				140 145		1.52	, S S S S S S S S S S S S S S S S S S S
Jeg søkte lege på grunn av symptomer	110				146		₩ ₩ ₩
Ble oppdaget uten at jeg hadde symptomer		(110 (2010))? 산전감소의 25억	Skriv navn på tabletten her	mg. pr. tabl. antall pr. da	3		
(ved legeattest, bedriftskontroll, undersøkelse for annen sykdom i eller utenfor sykehus)		2				<u>200</u>	
			Hvor mange måltider spiser o	lu hver dag?	. 147		
Hva slags plager hadde du i tilfelle da			·····	jjjjj		1.0	Antall
sukkersyken ble oppdaget? (kryss evt. i flere ruter).		13-14-14-14-14 17-11-14-14-14-14 17-11-14-14-14-14-14-14-14-14-14-14-14-14-	Føler du at du vet nok om hva	2			ALL LAND
			slags mat du kan spise?		. 148	A REAL	
Ingen plager			Hvis du skal svare på hva du	virkelia spiser oa			
Unormal tørste		<b>- 333</b>	ikke hva legen din har sagt d	u bør spise, vil			
Stor vannlating			du da si at du: (Kryss av bare i d nærmest det du virkelig gjør)	len ruta som kommer			
Slapphet							1
Vekttap			Spiser stort sett det samme so ikke har sukkersyke		1.40		1
Underlivskløe					. 149		
Andre plager	117		Spiser hva jeg vil unntatt sukker og søtsaker				2
Hvis «ANDRE PLAGER», skriv hvilke:			-		•	C.G.M.	
			Bruker på øyemål bestemt mer potet, melk og frukt				3
			Veier/måler bestemt mengde b			5.89	p i i
	118	kke skriv her	evt. frukt en eller flere dager i u				4
						58	
	120						
		JA NEI	Kontrollerer du hjemme hvor			JA	A NE
Har noen av dine foreldre, søsken eller			du har i urinen? (Kryss av også o deg eller gjør det for deg)		150		
barn hatt sukkersyke?	122						
Hvis «JA», bruker eller brukte noen av			Hva heter den metoden du i t bruker til å måle sukker i urin				et.
disse insulinsprøyter?	123		bruker til å måle sukker i uni				
							lkke skriv
			Skriv navnet som står på pakningen her		151		12
						JA	
BEHANDLING			Kontrollerer du noen gang hje			1	강성
			sukker du har i blod (blodsuk (Kryss av også om noen hjelper deg		152		
		JA NEI					27.25
			Hva heter den metoden du i t bruker til å måle blodsukker?				
Bruker du insulinsprøyter mot sukkersyken?	124		bruker in a male blousukker:				skriv her
							¥š
Hvis «JA», bruker du sprøyter daglig?					153		¥ ₩
			Skriv navnet på pakningen og navn på evt. apparat du måler med.				
Sprøyte en gang daglig	125						
Sprøyte to eller flere ganger daglig			Hvis du selv kontrollerer suk	ker i urin eller blod,			
			hvor ofte gjør du det? (Kryss av også om noen hjelper deg	eller giør det for dea)			
Om du bruker sprøyter, hvor mye insulin		<u>1926) 26</u>	naryss av også om noen njelper deg	, oner gjør det for degj			1998. 1998. 1998.
tar du tilsammen hver dag?			Hver dag				
(Skriv antall ml i ruta – 1 «strek» svarer til 0,1 ml)	126		2-3 dager i uka			$\vdash$	2
		ml	En dag i uka				3
			En dag hver 14. dag				4
		19332A	En dag i måneden			$\vdash$	5
			Sjeldnere enn en dag i månede	n	•		6

VEND

			Har du selv hatt noen vedvarende (kroniske)		lkke skriv he
Hvis du selv kontrollerer sukker i urin		JA NEI	plager etter at du fikk sukkersyke? (Skriv hva slags sykdom/plager på linjene under).	191 193	
eller blod: måler du flere ganger om dagen de dagene du gjør det?	155			195	
				197 199	
Development de terrenin - eller blederstre estr				201	
Dersom du tar urin- eller blodprøve selv, tar du resultatene med til legen ved kontrol!? (kryss av i den ruta som passer best)					
Aldri	150		UNDERVISNING - STØTTE		
Aldri	156	2			JA NEI
Oftest Alltid		3 4	Er du medlem av Norges Landsforbund for Sukkersyke?	203	
		JA NEI	Har du noen gang deltatt på kurs eller møte om sukkersyke?	204	
Går du til regelmessig kontroll hos lege for sukkersyken din?	157		Får du grunnstønad gjennom trygdekontoret for sukkersyken?	205	
Hvis «JA», hvor lenge var det mellom de to siste gangene du var hos legen din til kontroll for sukkersyken?			Har du søkt om og fått særfradrag i skattelikninga fordi du har sukkersyke?	206	
Antall måneder (skriv i ruta)	158	mndr.	HVORDAN HAR DU DET?		
Hva slags lege går du til kontroll hos for sukkersyken? (Sett kryss i bare <i>en</i> rute)			Synes du det er vanskelig å ha sukkersyke? (kryss av i den ruta som passer best).		
Vanlig lege (distriktslege,			Ja, jeg føler det er som en plage hver dag		
almenpraktiserende lege, bedriftslege osv.) Sykehuslege (poliklinikk på sykehus)			Ja, jeg tenker ofte på det Ja, av og til		
Er innlagt i sykehjem eller annen institusjon			Nei, sjelden		4
og får kontroll der			Nei, jeg tenker nesten aldri på det		5
Andre		4	Føler meg akkurat som alle som ikke har sukkersyke		6
Hvis «andre», skriv hva slags lege på linja over	161	ikke skriv her	Dersom du synes det er vanskelig å ha sukker- syke, hva synes du er verst? (Skriv det du mener på linja nedenfor).		
ANNEN SYKDOM		-0.000		_	lkke skriv he
ANNEN STREEN		JA NEI	Skriv her		
Bruker du regelmessig medisin for annet enn sukkersyken?	. 162		Forteller du til andre at du har sukkersyke? (kryss av i den ruta som passer best).		
Deveen IA skylig hys diese medicinens beter			Ja, alltid når jeg mener de bør vite det	210	
Dersom «JA», skriv hva disse medisinene heter (Skriv det navnet som står på glasset eller pakningen.		ikke skriv her	Ja, men bare om de spør		2
Ta med alle sortene du bruker regelmessig. Skriv x bak navnet om du brukte dette også før du fikk sukkersyke).	163		Nei, helst ikke Jeg er redd for at andre skal få greie på det		3
	166				
	169 172				JA NEI
	172		Har du noen gang hatt for lavt blodsukker?		
	178 181		(«føling», «insulinsjokk»)	211	
Tror du man er mer utsatt for å få enkelte andre sykdommer dersom man har dårlig kontrollert sukkersyke?	184	JA NEI	Hvis «JA», hvor mange ganger har du hatt det den siste uka? (Skriv antall ganger i ruta)	212	
			Hvor mange ganger har du vært innlagt i syke- hus de siste 5 årene? (Skriv antall ganger i ruta)	213	
Hvis «JA», nevn navnet på 3 slike sykdommer: (Du behøver ikke å ha hatt disse sykdommene selv).		ikke skriv her	Dersom du har ligget i sykehus de siste 5 årene, hva har du ligget der for? (Skriv på linjene nedenfor)		likke skriv he
	185			214	
	187			216	
	189			218	